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MicroRNAs (miRNAs) are small non-protein coding RNA species involved in the 
regulation of gene expression. Bound to either protein or encapsulated in 
extracellular vesicles (EVs), miRNA are released from the cell and found within 
biological fluids. Following release, miRNAs have shown to play a role in cellular 
communication in vitro and to a lesser extent in vivo. The studies described in this 
thesis aimed to investigate the organ uptake of the hepatocyte enriched miRNA, miR-
122, in vivo during in the absence and presence of paracetamol-related drug induced 
liver injury (DILI). As it is known that kidney tubules can internalise EVs containing 
miRNA, it was hypothesised that miR-122 released from the liver during paracetamol-
related DILI, enters the kidney and has a protective role against subsequent injury. 
The production of miRNA is reliant on the activity of the cytoplasmic enzyme Dicer. 
To induced Dicer1 knockdown, Dicer1 flox/flox mice were treated with a hepatotropic 
Cre-AAV8 or its negative control Null-AAV8. In this model, investigation of Dicer 
expression via western blotting and RT-qPCR indicated a significant loss of Dicer in 
the liver one week following Cre-AAV8 treatment. Consequently, a time dependent 
loss of total hepatic miRNA was observed using RT-qPCR and in situ hybridisation. 
Cre-recombinase delivery was confirmed to be liver-specific with stable Dicer and 
organ-enriched miRNA expression in the spleen, kidney, heart, lung and brain. 
In the absence of DILI, It was found that the loss of total miRNA in the liver resulted 
in a significant reduction of miR-122 expression in the spleen and kidney. During 
paracetamol-induced liver injury, the well described increase of miR-122 in the 
circulation was not observed in the Cre-AAV8 treated mice. Subsequently, the 
increase of miR-122 expression in the spleen, kidney and heart was significantly 
diminished with the loss of hepatic miRNA production. Depletion of miR-122 resulted 
in an increase of CYP2E1 expression and activity in the liver and kidney following 
300mg/kg paracetamol. 
Therefore, these findings show that under normal physiological conditions, 
expression of miR-122 in the spleen and kidney is reliant on miRNA transfer from the 
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liver. During paracetamol induced hepatotoxicity, the mechanism of miR-122 
signalling is upregulated and extends to the heart. Lastly, the observed upregulation 
of CYP2E1 following a loss of miR-122 in the kidneys indicates hepatic miRNA plays a 




Liver injury is a disease which can develop into liver failure and can be life-
threatening. Paracetamol, also known as acetaminophen, is the leading cause of liver 
injury in the western world. To diagnose paracetamol toxicity, blood samples are 
taken and analysed for markers of liver injury. Previous studies have shown that 
molecules called microRNA are released from the injured liver into the bloodstream. 
MicroRNAs are important in the body because they block the conversion of DNA into 
a functional product, for example a protein. 
MicroRNA-122 (miR-122) is normally found in the liver at very high concentrations, 
with little-to-none found in other organs. Previous studies have shown that during a 
paracetamol overdose, patients have a 100 times greater concentration of miR-122 
in their bloodstream than a healthy patient. Due to this, miR-122 can be measured in 
patients to determine whether they require treatment for liver injury. However, it is 
unknown what happens to miR-122 after it is released into the bloodstream. Thus, 
this thesis explored which organs are responsible for the uptake of miR-122 from the 
bloodstream. Furthermore, it was investigated whether miR-122 impacts the gene 
function following its uptake into other organs.  
From the experiments described in this thesis, it was discovered that in health and 
during a paracetamol overdose, the kidney and spleen were responsible for the 
uptake of miR-122 from the bloodstream. In addition, once transferred from the liver 
to the kidney, miR-122 was found to decrease the concentration and activity of 
enzymes involved in the breakdown of drugs. This highlights that liver-derived miR-
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Chapter 1 Introduction 
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1.1 Liver function 
The liver performs a wide variety of vital functions for the maintenance of normal 
homeostasis. It plays a major role in the metabolism of key nutrients including 
carbohydrates (gluconeogenesis) and lipids (fatty acid oxidation) [1]. The liver also 
synthesises key proteins comprising of albumin and most clotting factors including 
prothrombin, fibrinogen and factors V, VII, VIII, IX, X, XI and XII [1, 2]. Bile acids are 
synthesised and secreted from the liver to aid digestion [3]. Furthermore, the liver is 
important for the modification (biotransformation) of endogenous and exogenous 
compounds into water soluble compounds for excretion in the bile and urine[1]. Thus, 
it is unsurprising that the disruption and decline of normal liver function is associated 
with high morbidity and mortality.
 
1.2 Acute liver failure 
Acute liver failure (ALF) is the severe clinical manifestation of acute hepatocyte injury, 
that has evolved over days or weeks, in the absence of chronic liver disease [4]. ALF is 
a rare event, with an incidence between 1 to 6 cases per million people each year in 
the western world [5, 6]. Historically, ALF had a fatality rate of around 80% [4]. However, 
with improvements in intensive care support and access to liver transplantation, 
short-term survival has increased to 67% [7].  
ALF is characterised by an unexpected and rapid loss of hepatic function (metabolic 
and immunological) that regularly progresses into hepatic encephalopathy, 
coagulopathy and multi-organ failure [8]. Hence, to help distinguish the cause of 
disease, potential complications and patient prognosis, ALF has been divided into 
three groups based on the onset of jaundice and encephalopathy. These groups are: 
hyperacute (0-7 days), acute (1-4 weeks) and subacute (4-12 weeks) [8, 9]. There are 
several important factors for the prognosis of patients with ALF. The most widely 
accepted criteria are the King’s College criteria which factors age, cause, duration of 
jaundice, INR and serum bilirubin levels [10, 11]. Hyperacute cases are identified by high 
aminotransferase and low bilirubin concentrations, whereas the acute and subacute 
have lower aminotransferase and higher bilirubin levels [4, 8, 9]. In general, hyperacute 
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patients have a greater chance of short-term survival than the patients with slower 
progressing liver injury [4, 8, 9].  
The onset of ALF has been linked to multiple causes including drug induced liver injury 
(DILI), viral hepatitis, ischemia and autoimmunity [4, 8]. However, the main causes of 
ALF varies between the developing and developed world. In the developing world, 
the main cause of ALF is believed to be viral hepatitis A, B and E [4, 8]. Whereas, in the 
developed world, including USA and UK, the main causes of ALF is paracetamol (also 
known as acetaminophen, APAP) toxicity and DILI [4, 8, 12, 13]. 
1.3 Drug-induced liver injury 
DILI describes the abnormalities in liver function tests associated with the intake of 
medication [14, 15]. The histological phenotypes of DILI are diverse and have been 
stratified into 12 patterns [16]. However, accounting for around 80% of observed cases 
in a large study, the most frequently observed phenotypes of DILI are presented as: 
acute and chronic hepatitis, acute and chronic cholestasis, and cholestatic hepatitis 
[17]. Hence, DILI frequently resembles acute and chronic liver disease. There are two 
forms of DILI based on their predictability and dose-dependency: idiosyncratic and 
intrinsic [14]. 
Idiosyncratic DILI is regularly described to be an unpredictable and unpreventable 
form of DILI [16, 18]. Its pathogenesis is not well understood as it has an unclear and 
complex dose-response relationship, with a variable latency period from weeks to 
months [19]. Additionally, it has been observed that the risk of developing idiosyncratic 
liver injury varies between individuals and is influenced by environmental (including 
lifestyle and alcohol consumption), host (such as age, race, genetics and sex) and drug 
factors (for example dosage and drug-drug interactions) [18]. However, some drugs 
cause idiosyncratic DILI more than often than others. Cases have been observed 
across an array of drugs with differing drug actions including antibiotics, 
anticonvulsants and analgesics in current use. These include: amoxicillin-clavulanic 
acid, valproic acid, isoniazid and minocycline [20, 21]. 
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In the UK, around 10% of DILI cases are due to idiosyncratic injury [20]. Nevertheless, 
the cases of idiosyncratic DILI are rare, occurring in 13.9-19.1 cases in 100,000 
patients per year [22, 23]. Due to this, it is infrequently detected in pre-clinical and 
clinical trials due to the limited number of subjects in the studies [18, 24]. Thus, this 
form of DILI has a major impact on the drug development industry, with it being a 
reason for implementing regulatory actions, such as black box warnings and drug 
withdrawals [25, 26].  
On the other hand, intrinsic DILI is predictable, reproducible in preclinical models and 
appears after a short latency period (hours to days) [16, 27]. Examples of drugs that can 
induce intrinsic DILI include aspirin, methotrexate and paracetamol at high doses[24]. 
However, paracetamol is the leading cause of DILI and ALF in the UK and USA [12, 21, 28-
30]. With it accounting for 38,000 hospital admissions in England alone (2010-2011), 
paracetamol surpasses cases of idiosyncratic DILI reaching ALF by four fold [31]. 
1.4 Mechanism of paracetamol-induced liver injury 
Paracetamol is the most commonly used antipyretic and analgesic in the western 
world [32]. It is widely available, found in more than 600 different prescriptions and 
over-the-counter medications including pain relievers, cough, cold and anti-allergy 
medication [33]. Although considered safe at therapeutic doses (4g/day), an 
unintentional (multiple moderate) or intentional (single severe) overdose can cause 
significant liver injury and in some cases progress to ALF [29]. 
Following therapeutic administration, around 25% of the dose undergoes “first pass” 
metabolism, predominantly in the liver [34]. Upon entering the liver, paracetamol 
enters the hepatocytes mainly via passive diffusion and subsequently forms 
conjugates with glucuronic acid (40-67%) and sulfate (20-46%)[35, 36] (Figure 1.1). This 
in turn leads to the formation of an inactive metabolite for excretion [32, 37]. However, 
a small percentage (<5%) is converted to a reactive metabolite, N-acetyl-p-
benzoquinone-imine (NAPQI) via cytochrome P450 (CYP450) oxidation [36]. 
Nonetheless, the small fraction of NAPQI produced is detoxified through glutathione 
conjugation and eliminated in the urine and bile [32].  
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The mechanism of paracetamol toxicity is well defined (Figure 1.1). In excess, 
paracetamol overwhelms the conjugation pathway and oxidisation by the CYP450 
enzymes becomes the leading route of metabolism [38, 39]. Subsequently, excessive 
NAPQI production leads to the depletion of glutathione stores [38, 39]. Hepatocyte 
injury occurs when glutathione stores are depleted to 30%, allowing the reactive 
metabolite to react with alternative targets [40]. NAPQI has been described to react 
with nucleophilic macromolecules, proteins, DNA and unsaturated lipids [40]. 
Additionally, these cellular events lead to mitochondrial dysfunction following NAPQI 
binding to mitochondrial proteins, production of reactive oxygen species (ROS), 
inhibition of mitochondrial respiration and a loss in ATP production [41, 42]. 
Furthermore, the reduction in mitochondrial function is associated with oxidative 
stress, resulting in necrosis and programmed cell death (apoptosis) [37, 43]. An 
inflammatory response then follows cell death which can determine the extent of 
tissue necrosis and risk of organ failure [43]. The CYP450 enzymes are concentrated in 
the centrilobular zone (zone III) of the liver [40, 44]. Hence, this is the most affected 
area of paracetamol-induced liver injury due to the greater oxidative capacity of 
hepatocytes in this zone. However, in extreme doses of paracetamol, necrosis can 
spread to the pericentral zone (zone I) and midlobular zone (zone II)[40].  
The antidote for paracetamol toxicity is N-acetylcysteine (NAC) which replenishes 
glutathione stores and neutralises NAPQI present in the liver [37, 40](Figure 1.1). When 
administered within around 8 hours of drug ingestion, NAC is highly effective at 






Figure 1.1 Mechanism of paracetamol metabolism and toxicity following a 
therapeutic dose and an overdose.  
Following therapeutic doses, the major pathways of paracetamol metabolism are 
glucoronidation and sulfation. The non-toxic products are then eliminated in the bile 
and urine. However, a small percentage is converted to the toxic metabolite NAPQI, 
which is detoxified by glutathione conjugation. During an overdose, the primary 
pathway of metabolism is saturated and the glutathione stores are depleted. 
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Furthermore, the accumulation of NAPQI leads to oxidative stress, liver injury and cell 
death. Diagram adapted from Vliegenthart et al. [46].  
1.5 Cytochrome P450 (CYP450) enzymes 
CYP450 enzymes are a superfamily of haem-containing enzymes classified by similar 
gene sequence, then assigned into family number (e.g. CYP2), subfamily letter (e.g. 
CYP2E) and differentiated by isoform number (e.g. CYP2E1) [47]. Different members of 
the CYP450 superfamily have distinct, but often overlapping substrate specificities 
[47]. CYP450 enzymes are predominantly found in the liver, but have been described 
to be expressed throughout the body, including the lung and kidney [48-52]. Here, they 
play an important role in the oxidation of endogenous compounds, environmental 
xenobiotics and pharmacological agents [53]. However, not all of the 57 human 
CYP450 enzymes are involved in drug metabolism [54]. In humans, it has been reported 
that six CYP450 enzymes: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4/5 account for around 
75% of drug metabolism [54, 55]. 
Intrinsic and extrinsic factors have been described to influence the expression and 
activity of the CYP450 enzymes. While genetic polymorphisms have been recognised 
to play a major role in the variability of a few CYP450 enzymes, most are controlled 
by sex, age, hormonal and diurnal factors [55]. Extrinsic factors such as xenobiotic 
exposure and environmental factors can inhibit and induce CYP450 activity [54]. 
Furthermore, it has been identified that xenobiotic receptors, AhR (aryl hydrocarbon 
receptor), PXR (pregnane X receptor) and CAR (constitutive androstane receptor) are 
activated in the presence of toxic compounds derived from endogenous and 
exogenous xenobiotics [56]. Once activated, they have been observed to regulate the 
expression of drug metabolising enzymes, including the CYP450 enzymes. AhR has 
been described to regulate CYP1A1 and CYP1B1, whilst CAR and PXR have been 




1.5.1 CYP450 enzymatic activity following paracetamol administration 
The CYP450 isoforms described to have a central role in the oxidation of paracetamol 
are: CYP2E1, CYP1A2, CYP3A4 and CYP2A6 [61, 62]. CYP2E1 is frequently described to 
have the greatest influence on the metabolism of paracetamol into NAPQI. Multiple 
studies have highlighted that changes in CYP2E1 expression and activity can 
significantly alter the rate of paracetamol oxidation [63, 64]. Additionally, the 
knockdown of CYP2E1 has been observed to induce resistance to paracetamol 
toxicity [65, 66]. Hence, it was hypothesised that inhibiting CYP2E1 could be a promising 
therapy in minimising NAPQI formation and liver toxicity following a paracetamol 
overdose. This hypothesis was tested in a study using fomepizole (4-methylpyrazole, 
4MP), a direct inhibitor of CYP2E1, alongside a treatment of 300mg/kg paracetamol 
in C57/BL6 mice [67]. Here, the inhibition of CYP2E1 was shown to prevent the 
depletion of GSH, reduce the formation of ROS and thus paracetamol toxicity [67]. In 
addition, these findings have been confirmed in humans, demonstrating that 
fomepizole treatment prevents the biotransformation of paracetamol to NAPQI [68]. 
However, fomepizole needs to be administered as early as possible to inhibit the drug 
metabolism phase and has limited benefits to patients presenting with significant 
liver injury [67]. 
Nonetheless, the importance of CYP1A2 during paracetamol toxicity has been 
demonstrated by CYP2E1 and CYP1A2 knockout mice displaying a significant 
resistance to paracetamol toxicity [38]. The contribution of CYP3A4 in paracetamol 
toxicity has also been indicated in alcohol-enhanced paracetamol toxicity studies[69]. 
Furthermore, it has been suggested that with increasing doses of paracetamol, the 
contribution of CYP2E1 in the formation of NAPQI decreases, indicating CYP1A2 and 
CYP3A4, significantly contributes to NAPQI production at higher doses [70].
1.6 ALT as a biomarker of paracetamol-induced liver injury 
During hepatocyte injury, alanine aminotransferase (ALT) is released into the 
circulation following the leakage and rupture of hepatocytes [71, 72]. Currently, serum 
ALT is the most commonly used diagnostic measure for suspected hepatotoxicity, 
including paracetamol toxicity [73, 74]. ALT has never been formally qualified as a 
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biomarker, however, it has been validated by decades of clinical use [75]. Despite this, 
ALT is unable to prognosticate early onset DILI due to its lack of specificity and 
sensitivity to hepatotoxicity [46, 74].  
The majority of patients (90%) present to the emergency department within 12 hours 
of drug overdose [76]. However, ALT on average takes 12-24 hours to significantly 
increase during paracetamol-induced hepatotoxicity [77]. Hence, to confidently 
exclude the development of hepatic injury using ALT, it is required to delay the 
measurement of ALT for at least 24 hours after the time of overdose [74]. As a 
consequence, there is an increase in the length of hospital stays and it limits patient 
stratification in an emergency care setting [74]. In addition, elevation of ALT is not 
limited to DILI. Circulating ALT rises in a range of acute and chronic liver diseases and 
in co-morbidities such as diabetes, heart failure and alcohol excess [46, 78]. Therefore, 
these limitations have highlighted the clinical need for new and improved biomarkers 
of DILI to be used in conjunction with or instead of the current biomarkers. Recently, 
new mechanistic and predictive biomarkers of DILI have been identified. These 
include keratin-18 (K18), high-mobility group box-1 (HMGB1) and microRNA-122 
(miR-122)(Table 1.1) [46]. 
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Table 1.1 Current and emerging biomarkers of paracetamol-induced liver injury 







 Reflects hepatocellular 
necrosis. 
 Abundant in the liver. 
 Prognostic value 
 Doesn’t provide mechanistic 
understanding of injury. 
 Increase occurs during 
myocardial infarction and exercise. 








 Reflects hepatocellular 
necrosis. 
 Prognostic value 
 Not liver specific. Abundant in 
the heart, kidneys and brain. 




Alpha-fetoprotein (AFP) Loss of circulating ALF 
is associated with poor 
prognosis 
 Highly enriched in liver 
progenitor cells. 
 Indicative of DILI 
prognosis. 
 Doesn’t provide mechanistic 








liver inflammation and 
their ratio could be 
used to assess extent 
of hepatocellular 
apoptosis and necrosis 
 Early detection during 
DILI 
 Indicative of DILI 
prognosis 
 Provides information on 
mechanism of cell death 
 Ubiquitously expressed-not 
liver specific 





Biomarker Biomarker utility  Advantages  Disadvantages Ref 
Glutamate 
dehydrogenase (GLDH) 
Elevations associated with 
mitochondrial dysfunction 
and hepatocellular injury.  
 Liver enriched 
 Early detection of DILI 
 Not influenced by age 
and gender (low intra- and 
inter- subject variation) 
 Elevated levels have been 




High mobility group box-
1 (HMGB1) 
Acts as a mediator of 
inflammation and its 
acetylated form acts as a 
biomarker of liver injury 
 Early detection of DILI 
 Indicative of DILI 
prognosis 
 Quick clearance 




Elevations associated with 
hepatocellular necrosis. 
 Liver enriched 
 Early detection of DILI 
 Quick clearance 
 Doesn’t increase 
following muscular injury 
 Doesn’t provide 








macrophages to sites of 
hepatic injury. 
 Indicative of DILI 
prognosis 
 Associated with the 
degree of liver necrosis 
 Broad localisation [88] 
Sorbitol dehydrogenase 
(SDH) 
Elevated during acute and 
mild liver injury. 
 Early recognition of DILI 
 Abundant in the liver 
 Short half-life 
 Not liver specific- high 
expression in the kidney and 
testis 
 Not indicative of DILI 
prognosis 
[89] 
Table adapted from Fu et al. [73]
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1.6.1 Biomarkers of paracetamol-induced kidney injury 
Injury induced by paracetamol toxicity is predominantly found in the liver [37]. 
Nevertheless, a paracetamol overdose can induce renal insufficiency in 1-2% of 
patients [43]. This has a significant clinical impact as it leads to a substantial increase 
in mortality in this subset of patients [90]. Hence, kidney function, determined by 
serum creatinine concentration, is included in the Kings College Criteria for liver 
transplantation [91]. Additionally, kidney injury marker-1 (KIM-1), a kidney specific 
biomarker with greater sensitivity than serum creatinine, has been newly proposed 
as a biomarker, enhancing prognosis studies in patients with paracetamol-induced 
liver injury [92].
1.7 MicroRNA 
MicroRNA’s (miRNA’s) are a class of small (∼22 nucleotides), non-protein coding RNA 
species conserved in their sequence across mammals, plants and viruses [93]. MiRNA’s 
role in the regulation of post-transcriptional gene expression is well recognised and 
estimated to modulate over half of human genes [94-96]. In addition to their role inside 
the cell, miRNA are found extracellularly, within the human circulation. 
1.7.1 MicroRNA biogenesis 
Within the genome, miRNA transcripts are primarily found in the exonic and intronic 
regions [97]. The remaining transcripts are intergenic, transcribed and regulated 
independently from a host gene [98]. The initial steps of miRNA processing occurs 
within the nucleus of the cell. Then, the precursors are exported into the cytoplasm 
for further processing into its mature functional form [97, 98](Figure 1.2). 
1.7.2 MicroRNA processing in the nucleus 
The transcription of miRNA has shown to be coordinated by transcription factors or 
upon the methylation of their promotor sequences [99, 100]. MiRNA biogenesis starts 
with the RNA polymerase II (Pol II) or RNA polymerase III (Pol III) mediated 
transcription of the miRNA gene into primary transcript (pri-miRNA), a long hairpin 
structure containing the mature sequence [95, 101, 102]. Next, the pri-miRNA is 
processed by the microprocessor complex composed of the ribonuclease, Drosha, 
and RNA-binding protein, DiGeorge Syndrome Critical Region 8 (DGCR8). DGCR8 
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recognises the N6-methyladenosine motif within the pri-miRNA, while Drosha is 
responsible for the cleavage at the base of the pri-miRNA [103]. This results in the 
removal of its 5′- cap and 3′- poly A tail and the formation of the precursor miRNA 
(pre-miRNA) with a two-nucleotide-long 3ʹ overhang [104](Figure 1.2).  
1.7.3 MicroRNA processing and maturation in the cytoplasm 
The subsequent shorter miRNA strand, pre-miRNA, (∼60-70 nucleotides) is exported 
into the cytoplasm by exportin 5-Ran-GTP complex and undergoes further processing 
by the RNase III endonuclease Dicer [94, 105]. Dicer, along with its cofactors TRBP2 
(trans-activation response RNA-binding protein) and PACT (protein activator of 
dsRNA-dependent protein kinase), preferentially binds to the two-nucleotide-long 3ʹ 
overhang of the pre-miRNA and cuts out the duplex RNA (∼22 nucleotides) from the 
pre-miRNA. As a result, mature miRNA is formed. The miRNA-5p strand derives from 





Figure 1.2 Biogenesis pathway of microRNA 
In the nucleus the first steps of miRNA biogenesis involves the transcription of the pri-
miRNA by RNA polymerase II/III (Pol II/III) and the nuclear processing of pri-miRNA to 
pre-miRNA by the microprocessor complex (Drosha and DGCR8). Pre-miRNA is 
exported out of the nucleus by the exportin 5-Ran-GTP complex and undergoes 
cleavage by the RNase III endonuclease Dicer and its cofactors TRBP2 and PACT, to 
form the miRNA duplex. Finally, one strand of the miRNA duplex is loaded onto the 
Ago protein to form the RISC complex and mediate mRNA repression and degradation. 
Figure adapted from Winter et al. and created using Servier Medical Art, Les 
Laboratoires Servier. 
1.8 MicroRNA function 
During RNA silencing, either strand (5p or 3p) from the mature miRNA duplex can be 
loaded onto the Argonaute (Ago) proteins to form the ribonuclease complex, RNA-
induced silencing complex (RISC)[107]. For each miRNA, the proportion of 5p or 3p 
strands loaded onto Ago, varies greatly and depends on the cell state, type and 
developmental stage [108]. Furthermore, RISC, directed by complementary base 
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pairing of miRNA (6-8 nucleotides), mediates post-transcriptional messenger RNA 
(mRNA) repression, resulting in the inhibition of protein translation or induction of 
mRNA degradation [93, 107, 109] (Figure 1.2). Thus, miRNA plays an important role in the 
homeostasis of physiological processes such as differentiation, proliferation, stress 
response and immunity [96, 104, 110, 111]. In eukaryotic cells, miRNA have shown to 
primarily repress gene expression [112]. A single miRNA is believed to target and 
repress hundreds of distinct mRNA targets [113]. The dysregulation of miRNA has been 
associated with multiple pathological disorders including cancer, cardiovascular and 
metabolic diseases [114, 115].
1.9 Extracellular microRNA 
Extracellular miRNA have been identified in a range of biological fluids including: 
plasma, saliva, tears, urine, amniotic fluid and cerebrospinal fluid [116]. Cell-free 
miRNA are sensitive to RNase degradation within the circulation [117]. Hence, for 
stability and protection from degradation, circulating miRNA are bound to RNA-
binding proteins, encapsulated in extracellular vesicles or within high lipid density 
proteins [117-119]
1.9.1 MicroRNA associated with HDL 
The lipid based particles found in the plasma, low lipid density proteins (LDLs, 22nm) 
and high lipid density proteins (HDLs, 8-12nm) have been described to contain 
endogenous microRNA in human plasma [119]. HDLs isolated from familial 
hypercholesterolemia patients were demonstrated to have significantly distinct 
profiles of miRNA content compared to healthy patients [119]. Furthermore, the HDL-
miRNA isolated from the familial hypercholesterolemia patients were shown to 
induce differential gene expression of mRNA targets in hepatocyte cells in vitro [119]. 
Together, these results indicate that HDLs participate in the transport and cellular 
communication of extracellular miRNA. 
1.9.2 MicroRNA associated with protein complexes 
Through various size exclusion methods it was discovered that approximately 90% of 
miRNAs circulating in the plasma are associated with a ribonuclease complex [117, 120]. 
In vivo, it has been reported that circulating miRNA is primarily associated with 
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Argonaute 2 (Ago2), a key component of the RISC complex [117, 120]. Additionally, Wang 
et al. supported the theory that extracellular miRNA were predominantly associated 
with protein complexes. They discovered that Nucleophosmin-1 (NPM1), a nuclear 
protein involved in the shuttling of RNA and ribosomal proteins to the cytosol, is also 
involved in exporting and protecting of miRNA in the extracellular space [121]. 
However, the exact role NPM1 plays in vivo has yet to be described.  
It has been proposed that circulating protein-bound miRNA are a product of passive 
release from its cell of origin upon necrosis and apoptosis [120, 122]. This is supported 
by observations of circulating miRNA following cell toxicity and death [87, 123]. 
1.9.3 MicroRNA encapsulated in extracellular vesicles 
Extracellular vesicles (EVs) are small membrane bound vesicles that are secreted by 
various cells [124]. They can be detected in various biological fluids, including blood 
and urine [125-127]. Based on their size, origin and identifying markers, EVs are divided 
into three groups: apoptotic bodies, microvesicles and exosomes [128, 129] (Table 1.2).
Table 1.2 Extracellular vesicles characteristics 
Extracellular vesicles Size Biogenesis 
Apoptotic bodies 500-
2000nm 
Outward blebbing of the apoptotic cell 
membrane 
Microvesicles 50-1000nm Outward budding of the cell membrane 
Exosomes 30-100nm Endosomal pathway 
Table adapted from Andaloussi et al. [130]and Braicu et al. [131] 
Originally, EVs were regarded as cell debris with no significant biological role [130]. 
However, multiple studies have shown that exosomes and microvesicles encapsulate 
protein, lipids, mRNA and miRNA specific to the host cell [132, 133]. Furthermore, EVs 
have been observed to play an important role during intercellular communication, 
via the transfer of their contents [134]. In particular, miRNA have been observed to be 
selectively packaged and transported within EVs to neighbouring and distant cells 
[134]. Subsequently, this EV mediated transfer of miRNA results in extensive gene 
regulation in the recipient cell [134-137].  
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Interestingly, Arroyo et al, discovered that the profile of miRNA encapsulated in EVs 
differs from the Ago2 bound miRNA population. Indicating, that the circulating form 
of miRNA depends on the cell type of origin and its mechanism of release [117, 121] 
1.10 MicroRNA as a signalling molecule 
The presence of miRNA in the extracellular environment raised the hypothesis that 
the selective release of miRNA contributes to endocrine and paracrine cellular 
communication [134]. Following this hypothesis, it has since been well established that 
extracellular miRNA can be transported to recipient cells, altering gene expression 
and cell function [138-140]. MiRNA mediated cellular communication has been observed 
in vivo and in vitro via EVs, HDLs and Argo2 (Table 1.3). 
Numerous studies have shown that EVs mediate the transfer of miRNA from one cell 
to another under various physiological and pathological states. A considerable 
interest has been taken in exosomes as a cell signalling mediator. Exploration into the 
mechanism of release and uptake of exosomes has been extensive. Evidence suggests 
that exosomal secretion via the endosomal pathway is initiated by the neutral 
sphingomyelinase 2 (nSMase2) enzyme [141, 142]. This was further confirmed when the 
treatment of an nSMase2 inhibitor, GW4869, decreased both exosome and miRNA 
secretion [141, 142]. 
Cell targeting and miRNA uptake has been demonstrated to be through the 
interaction of exosomal surface proteins and receptors on recipient cells [120]. It has 
previously been described the hormonal regulation of EV uptake and transfer in cells, 
mice and humans. They observed that desmopressin, a vasopressin analogue, 
stimulated a significant uptake of EVs into kidney collecting duct cells (mCCDC11) and 
primary cortical collecting duct cells [143]. In mice, when vasopressin activity was 
inhibited by tolvaptan (a selective vasopressin V2 receptor antagonist), EV numbers 
significantly increased in the urine and significantly reduced in the kidney [143]. This 
highlighted that uptake and excretion of EVs is regulated by vasopressin in vivo. 
Lastly, these findings were consistent in patients with central diabetes insipidus, 
where desmopressin resulted in the reduced excretion of EVs from the glomerular 
and proximal tubular cells [143]. Furthermore, the functional transfer of exosomes and 
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small EVs miRNA has been demonstrated in a large number of in vitro and in vivo 
studies, influencing tumour development, cardiovascular disease and diabetes (Table 
1.3). 
In addition, it has been reported that isolated HDL-miRNA complexes found within 
the plasma can transmit their contents to other cells (Table 1.3). Unlike EVs, the 
export of HDL containing miRNA was observed to be negatively regulated by 
nSMase2 [144]. The delivery of HDL-miRNA was also dependent on the membrane 
bound receptor SR-BI [144]. Moreover, it was revealed that the HDL-miRNA content 
was influenced by disease states including atherosclerosis and cardiovascular 
diseases [144, 145]. The transport and delivery of miRNA, specifically miR-223, was 
shown to regulate gene expression and in turn have anti-inflammatory properties in 
endothelial cells and hepatocytes [145]. However, subsequent evaluation of HDL-
miRNA content has demonstrated that HDLs contain a small percentage of total 
circulating miRNA, with HDL-miR-223 contributing to only 8% of total circulating miR-
223 [146]. In addition, the study was unable to replicate the significant uptake of HDL-
miRNA observed in Vickers et al. study. Here, they found there was a non-significant 
uptake of HDL bound miRNA in endothelial, smooth muscle and peripheral 
mononuclear cells in vitro [146]. Hence, the importance of HDL-miRNA mediated 
cellular communication remains uncertain. 
As mentioned above, miRNA bound to protein complexes are believed to be passively 
released during cell death. Until recently, there was no indication of active release of 
Ago2-miRNA or selective uptake from recipient cells. However, Wang et al. 
uncovered that the passive release of Ago2-miR-122 from injured hepatocytes 
resulted in its significant uptake in alveolar macrophages [122]. Not only did this 
indicate selective uptake of protein bound miRNA for the first time, it also highlighted 
miRNA in this form induce a biological function in vivo (Table 1.3).  
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Table 1.3 Functional miRNA in intercellular communication 
microRNA Carrier Donor cell Recipient cell Target 
gene 







ICAM-1 Unknown- inhibits vascular 
inflammation** 
[145] 
miR-223 HDL Macrophages Hepatocytes (Huh7) RhoB, 
EFNA1 
Unknown  [144] 
miR-122 Ago2 Hepatocytes In vivo: Alveolar 
macrophages 
TLR7 Activates inflammatory responses [122] 
miR-155 Exosomes Adipose Tissue 
Macrophages  
L6 skeletal myoblast, 
primary hepatocytes 
PPARγ Promotes insulin resistance during 
obesity 
[147] 
miR-125b EVs Breast cancer cells-
4T1 and 4TO7 
Primary fibroblasts Tp53inp1 Fibroblast activation  [148] 
miR-27 
miR-28 
Exosomes Primary fibroblasts Primary  
cardiomyocytes 
Nrf2 Promotes oxidative stress during 
chronic heart failure 
[149] 





eEF-2K Maintains vascular integrity [150] 
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microRNA Carrier Donor cell Recipient cell Target 
gene 
Biological function Ref 




Gastric cancer cells 
(MFC,MGC-803) 
PTEN Suppresses cell apoptosis and 
enhances activation of PI3K/AKT 
signalling pathway 
[151] 
miR-133a Exosomes Primary muscle 
fibres 
Fibroblasts (NIH3T3) Smarcd1, 
Runx2 
Promote skeletal muscle 
myogenesis 
[152] 
miR-486 Exosomes Endothelial colony-
forming cells 
Endothelial cells 
(HUVEC) and in vivo 
caspase-3, 
PTEN 
Inhibits hypoxia-induced apoptotic 







Glioma stem cells CHD7 Promotes proneural-to-
mesenchymal transition and 
radiotherapy resistance 
[154] 
miR-210 EVs Bronchial epithelial 
cells (HBECs) 
Lung fibroblasts  ATG7 Regulates autophagy processes [155] 





ANXA2 Tumour suppressor [156] 
*Isolated from whole blood, **hypothesised source/function 
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1.11 MicroRNA as a biomarker of DILI 
In addition to their stability in the circulation, miRNA have shown to be highly 
conserved across mammalian genomes, making them translational from pre-clinical 
to clinical studies [157]. Furthermore, some miRNA species are tissue enriched 
meaning the dysregulation of certain miRNA can reflect a specific cell activity and 
disease state [158]. Hence, the application of miRNAs as a non-invasive biomarker has 
become a focus in research. Circulating miRNAs were first assessed as a diagnostic 
biomarker in the serum of diffuse B cell lymphoma patients [159]. Since then, the 
dysregulation of miRNA has been described in various diseases including: cancer, 
diabetes, viral infections, autoimmune diseases and DILI [157].  
 
In the search for new and improved biomarkers of DILI, miRNA expression profiles 
were assessed in the circulation of mice with paracetamol toxicity [123]. It was first 
noted that there were significant changes in the profile of miRNA in the circulation of 
mice following an overdose of paracetamol, compared to healthy controls [123]. From 
this study, several miRNA species were identified as biomarkers of paracetamol-
induced liver injury: miR-122, miR-192, miR-148a and miR-193 [123]. Out of the 
numerous miRNA species identified, miR-122 and miR-192 were the most abundant 
circulating miRNAs following liver injury. Furthermore, it was determined that their 
release into the circulation was dose and exposure dependent, paralleling liver 
degeneration. In addition, unlike ALT, both miRNA biomarkers could be detected 
prior to significant liver injury [86, 123].  
MiR-192 is highly expressed in other organs including the kidney and gastrointestinal 
tract [160]. Consequently, an increase in miR-192 is also associated with kidney 
dysfunction [87]. MiR-122, on the other hand, is highly enriched in the liver and has 
little-to-no expression elsewhere [160-162]. MiR-122 has been observed to remain 
stable in the presence of exercise-induced muscular injury and kidney dysfunction [87, 
163]. Moreover, the increase of miR-122 during DILI has been replicated in humans. A 
study has observed a 100-fold increase of miR-122 in the bloodstream of patients 
with paracetamol-induced liver injury, compared to a control population [82]. Again, 
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as observed in the mice, this increase in miR-122 return to baseline more rapidly, has 
greater sensitivity and comparable specificity compared to ALT activity (Table 1.4). 
Therefore, enabling greater confidence of prognosis and patient stratification, 
reduction in hospital bed occupancy and reduction in adverse drug reactions from 
unnecessary NAC treatment [82]. 















62 91 <0.0001 
ROC analysis determining plasma miR-122 and ALT activity to predict to development 
of ALI at first presentation to hospital following acetaminophen overdose (n=67). 
Table includes: ROC-AUC (area under the curve with 95% confidence interval), 
sensitivity (SENS at 90% specificity, with 95% confidence interval) at 90% specificity, 
positive (PPV) and negative (NPV) predictive value and statistical significance. MiR-
122 normalised by miR-1287. Data taken from Vliegenthart et al. [87].
1.12 Hepatic function of miR-122 
Within the liver, miR-122 is the most abundant miRNA, accounting for around 70% of 
hepatocyte’s total miRNA (66,000 copies/hepatocytes) [164]. MiR-122 is translational, 
found in humans, rodents, zebrafish, dogs, pigs and cynomolgus monkeys [82, 160, 165-
170]. In these species, miR-122, primarily bound to Ago2, is released into the 
bloodstream, accurately acting as a circulating predictive biomarker for DILI [117, 171]. 
However, miR-122 alone cannot distinguish between different etiologies of 
hepatocyte damage [172]. Thus, it has been frequently recommended to be used in 
combination with the biomarkers previously discussed in Section 1.6. Furthermore, 
miR-122 has shown to be a multifunctional RNA species involved in various 
physiological and pathological processes in the liver (Figure 1.3). 
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Through antisense targeting of miR-122, it was observed that the loss of miR-122 
resulted in the reduction of plasma cholesterol, increased hepatic fatty acid 
metabolism and a decrease in hepatic fatty acid and cholesterol synthesis [173]. 
Moreover, miR-122 has been shown to downregulate genes such as 3-hydroxy-3-
methylglutaryl-CoA-reductase (Hmgcr), a rate-limiting enzyme of endogenous 
cholesterol biosynthesis [173, 174]. Therefore, it has been indicated that miR-122 acts 
as a key regulator of cholesterol and fatty acid metabolism in the adult liver. 
MiR-122 has been suggested to play a central role in the development and 
differentiation in the liver. During mouse liver development, miR-122 has shown to 
gradually silence the transcription factor cut-like homeobox 1 (CUTL1), initiating 
terminal differentiation in multiple cell lines, including hepatocytes [150]. In addition, 
the loss of miR-122 in developing zebrafish resulted in delayed maturation of 
hepatocytes in vivo [175].  
The characterisation of miR-122 knockout mice has revealed that a reduction in miR-
122 expression is associated with various diseases in the liver. MiR-122 knockout 
mice have been shown to develop steatohepatitis, fibrosis and hepatocellular 
carcinoma (HCC) [176]. Additional studies have investigated this further, indicating 
miR-122 functions as a tumour suppressor in the liver. During HCC, miR-122 has been 
shown to mediate the repression of genes involved in the tumour progression such 
as cyclin G1 (CCNG1), a distintegrin and metalloprotease family 10 (ADAM10), insulin-
like growth factor 1 receptor (IGF-1R) and serum response factor (SRF) [177-179]. 
Furthermore, a decrease in miR-122 expression has been linked with poor prognosis 
and metastasis in hepatocellular carcinoma (HCC) [180]. Replenishing miR-122 in HCC 
has shown to reverse the tumourigenic properties of the cells and inhibit HCC 
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progression in vivo [165]. 
 
Figure 1.3 Physiological and pathological roles of miR-122 in the liver 
In physiological conditions, miR-122 regulates cholesterol and lipid metabolism, 
hepatocyte differentiation and maintenance. Under pathological conditions, it has 
shown to mediate hepatitis virus replication, inhibit the formation of hepatocellular 
carcinomas and progression of fibrosis. Figure adapted from Hornby et al. and 
Bandiera et al. [181, 182] and created using Servier Medical Art, Les Laboratoires Servier.
Additionally, miR-122 has been revealed to negatively regulate the production of 
collagen and progression of fibrosis in hepatic stellate cells (HSCs). During carbon 
tetrachloride (CCl4)-induced fibrosis, miR-122 was observed to significantly decrease 
with an inverse correlation of its mRNA target prolyl 4-hydroxylase (P4HA1- a key 
enzyme in collagen maturation) in HSCs [183]. The overexpression of miR-122 led to 
the reduction of P4HA1, collagen and excessive cellular matrix protein production 
[183]. Moreover, miR-122 has been described to repress fibrosis related genes: alpha 
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smooth muscle actin (α-SMA), fibronectin 1 (FN1) and α1 type I collagen (COL1A1), in 
HSCs and fibroblasts [184].  
Whilst examining hepatitis C virus (HCV) infection and replication, it was observed 
that there was a marked loss of viral replication following the loss of miR-122 in the 
liver cells [185]. Thus, further investigation determined that miR-122 directly binds to 
HCV, enhancing the stability and replication of viral RNA [185, 186]. As a result, miR-122 
is being investigated as a drug target for the treatment of HCV. 
1.13 Regulation of miR-122 
MiR-122 is significantly upregulated during embryogenesis and reaches maximal 
expression prior to birth [164, 187]. Upon investigation, it was identified that the 
expression of miR-122 is activated by the CCAAT/enhancer-binding protein, C/EBPα 
and the liver enriched transcriptional factors: HNF1α, HNF3α and HNF3β [187]. 
Furthermore, it was discovered that under circadian control, the orphan nuclear 
receptor, REV-ERBα, governs the transcription of the miR-122 gene [188]. 
Subsequently, the expression of pri-miR-122 and pre-miR-122 fluctuates, with its 
highest expression during the day [188]. Nonetheless, as mature miR-122 has an 
estimated half-life of 10.2 days in the liver, its expression remains stable over the 
circadian cycle [188, 189]. Within the circulation, the half-life of circulating miR-122 is 
uncertain, however, it has been described as significantly shorter than ALT which has 
an average half-life of 48 hours[86]. 
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1.14 Cellular communication of miR-122 
In addition to acting as a biomarker for DILI, there have been a number of studies 
investigating extracellular miR-122 as a cell signalling molecule. Recent studies have 
highlighted the transfer of miR-122 during physiological and pathological diseases 
including: cancer, alcohol-related liver disease and DILI.  
In breast cancer, the promotion of metastasis has been shown to be mediated by the 
transfer of miR-122 enriched exosomes from breast cancer cells to neighbouring and 
distant cells. This transfer of miR-122 was described to promote metastasis and 
facilitate disease progression via the downregulation of pyruvate kinase and glucose 
consumption in the pre-metastatic niche, in vivo and in vitro [137]. Furthermore, the 
use of miR-122 antagonists were shown to significantly reduce the development of 
metastasis in the brain and lung in vivo [137]. Suggesting, targeted therapy to dampen 
miR-122 signalling in breast cancer patients may be of benefit. 
Additionally, miR-122 transfected adipose tissue-derived MSCs (AMSCs) have shown 
to effectively package and deliver exosomal miR-122 to hepatocellular carcinoma 
(HCC) cells [190]. However, unlike breast cancer, an increase of miR-122 in the HCC 
cells has been shown to result in cell cycle arrest and increased apoptosis via the 
downregulation of ADAM10, CCNG1 and IGF-1R [190]. Furthermore, the HCCs with 
greater miR-122 content had increased sensitivity to the anti-tumour drug sorafenib 
[190]. Therefore, this study suggests that miR-122 export via AMSCs highlights a novel 
therapy to enhance HCC sensitivity to chemotherapy. 
In alcohol-related liver disease, hepatocyte derived exosomal miR-122 were 
exhibited to undergo horizontal transfer to monocytes. Consequently, the increase 
of miR-122 in the monocytes was described to inhibit the HO-1 pathway, increase 
sensitivity to LPS stimulation and enhance the production of pro-inflammatory 
cytokines.[191] Following ConA-induced acute hepatitis, Wang et al recently noted 
that miR-122 released from the liver enters the lung, activates alveolar macrophage 
TLR7/8 and in turn pulmonary inflammation [122]. Furthermore, the depletion of miR-




MiR-122 signalling has also been implicated during physiological conditions involving 
the synthesis of triglycerides. Free fatty acids have been described to activate the 
retinoic acid-related orphan receptor alpha (RORα) and in turn enhance primary, 
precursor and mature miR-122 expression in the liver [192]. Subsequently, this 
activation has been observed to induce liver secretion of miR-122 into the 
bloodstream and its uptake into skeletal muscle and white adipose tissue [192]. This 
increase in miR-122 expression was shown to significantly reduce miR-122 mRNA 
targets involved in triglyceride synthesis: AldoA, Agpat1 and Cpt1a in all three tissues 
[192]. Moreover, this study also demonstrated that fasting causes an increase in free 
fatty acids and miR-122 expression, which in turn reduces triglyceride synthesis and 
α-oxidation, utilising lipid accumulation as an energy source [192].
 
1.15 miR-122 in the kidney 
The main function of the kidney is to maintain physiological homeostasis by 
eliminating waste products and maintaining volume, electrolyte content and pH of 
the extracellular fluid [54]. In addition, the kidney is also involved in the synthesis of 
erythropoietin (Epo), renin and vitamin D [54]. Recently Rivkin et al. highlighted that 
miR-122 released from the liver enters the kidney and targets Epo expression. During 
LPS-induced liver inflammation, a significant increase in mature miR-122 was 
observed in the circulation and the kidney [193]. Alongside known miR-122 targets, 
Aldoa and AGPAT1, Epo expression was demonstrated to be inversely correlated with 
an increase in miR-122 [193]. Moreover, a prolonged increase of miR-122 and loss of 
Epo expression in the kidney, linked to liver inflammation, resulted in a reduction of 
bone marrow erythropoiesis and the development of inflammation-induced anaemia 
[193]. Thus, this study suggests that hepatocyte derived miR-122 can regulate gene 
expression in the kidney. 
A high oxygen demand paired with a low oxygen tension leaves the kidney vulnerable 
to hypoxia and acute kidney injury [194]. In addition, toxicity can be heightened in the 
proximal tubule cells due to their exposure to circulating chemicals and its role in 
extensive cellular uptake and clearance [195]. Examples of drugs that induce proximal 
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tubule injury include aminoglycosides, cisplatin and paracetamol [196, 197]. Cisplatin is 
a chemotherapeutic agent used for the treatment of solid-organ tumours [198]. 
Despite its high success rate, nephrotoxicity is a prevalent event associated with the 
intake of cisplatin [199]. Downregulation of miR-122 has been observed to contribute 
to tubular cell injury following cisplatin treatment [200]. Replenishing miR-122 
expression was shown to reduce cisplatin-induced tubular injury through inhibition 
of FOXO3, a core protein involved in the activation of the p53 cascade and initiation 
of apoptosis [200].  Recent studies have revealed that EVs isolated from the plasma of 
liver injured mice, containing a high concentration of miR-122, induced resistance to 
cisplatin-induced injury in mouse primary proximal tubule cells [201]. Together, these 




1.16 Hypothesis and aims 
ALF is often accompanied by acute kidney injury (AKI). Due to this, renal function is 
an important measure of patient prognosis during ALI and ALF. However, the 
mechanism behind the renal response to liver injury is poorly understood. It is well 
recognised that following a paracetamol overdose, the injured liver releases large 
amounts of miRNA. MiR-122, a miRNA highly expressed in the hepatocytes of the 
liver, displays the greatest release into the circulation in humans and murine models 
following a paracetamol overdose. In addition, miRNA, including hepatic miR-122, 
has shown to enter recipient cells, modulate RNA targets in vivo and promote cell 
viability in the kidney in vitro. Therefore, the studies in this thesis were carried out to 
explore whether hepatic miRNA, particularly miR-122, is transferred from the liver to 
the kidney. In addition, an investigation into whether liver-derived miRNA can 
modulate kidney mRNA expression and in turn nephrotoxic tubular injury was carried 
out. Thus, it was hypothesised that the large release of miR-122 from the liver to the 
circulation, during DILI, enters the kidney and induces resistance to subsequent 
injury. 
To address this hypothesis, the aims of the studies were to: 
1. Optimise and define an inducible model of liver-specific Dicer deletion in vivo. 
2. Investigate which organs are responsible for the uptake of miR-122 after its 
abundant release during paracetamol-induced liver injury. 












All experiments were performed in the Centre for Cardiovascular Science, Queen’s 
Medical Research Institute, apart from the in situ hybridisation (ISH) of miR-122 
(Section 2.9.3), immunohistochemistry (IHC) of CYP2E1 (Section 2.9.2) and mass 
spectrometry of the CYP450 enzymes (Section 2.12) which were carried out at 
AstraZeneca, Cambridge.  
2.2 Experimental Animals 
All studies carried out meet the following requirements as appropriate of the Animals 
(Scientific Procedures) Act 1986 / ASPA Amendment Regulations 2012 for work 
performed in the UK, or under the EU Directive 2010/EU/63. 
The animals were housed in groups of 4-8 with free access to standard chow and 
water at 22°C ± 1°C, 55% humidity. They were kept to a 12 hour light-dark cycle (lights 
on 07:00 and off at 19:00). The mice were allowed to acclimatise to this environment 
for at least a week before each study. Wild-type C57BL/6J mice were purchased from 
Charles River Laboratories, UK.
 
2.3 in vivo model: Liver specific DICER knockdown 
Homozygous Dicer1 flox/flox mice (B6.Cg-Dicer1tm1Bdh/J strain, The Jackson Laboratory, 
ME, USA) express loxP sites on either side of exon 23 of the Dicer1 gene. Cre-
mediated recombination leads to the loss of the Dicer1 gene and in turn ceases the 
production of mature miRNA.  
The homozygous Dicer1 flox/flox mice (both sexes, aged 8-12 weeks) were injected with 
a single tail vein injection of a hepatocyte-specific adeno-associated virus serotype 8 
(AAV8). To induce liver specific Dicer1 knockdown, a Cre-containing AAV8 with the 
promoter for the thyroxine binding globulin (TBG) was used (Table 2.1). An empty 
AAV8, Null-AAV8, was used as a negative control (Table 2.1).  
Similar to previous experiments carried out by Kylie Matchett (Centre for 
Inflammation Research, CIR) and Victoria Gadd (Centre for Regenerative Medicine, 
CRM), both AAV8 vectors were diluted to either 2.5x1011 or 6.25x1010 viral genomes 
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dose. Each dose was limited to 100µl in sterile PBS to limit hydrodynamic effects [202]. 
Mice were randomly selected to be injected with either the Cre-AAV8 or Null-AAV8. 
Untreated Dicer1 flox/flox (baseline) mice were used as controls where indicated. The 
mice were left under normal housing conditions for a maximum of four weeks where 
they were either humanely culled or underwent further treatment with paracetamol.
Table 2.1 Adeno-associated virus serotype-8 (AAV8) name and gene expression 
AAV8 Gene expression 
Null-AAV8 AAV8.TBG.PI.Null.bGH 
Cre-AAV8 AAV8.TBG.PI.Cre.rBG 
AAV8 vectors were purchased from Penn Vector Core, PA, USA. 
2.4 Paracetamol toxicity model 
Using methods previously described, paracetamol was used to induce acute DILI in 
male Dicer1 flox/flox mice [203]. First, mice were fasted for 12 hours (overnight) prior to 
paracetamol dosing with free access to water. This was done to deplete ATP and 
glutathione levels to ensure the mice had comparable conditions of paracetamol 
metabolism in humans [204]. Additionally, the act of fasting prior to drug treatment 
has shown to reduce variability and induce a greater extent of centrilobular injury, 
compared to non-fasted mice [205, 206]. 
On the day of treatment, paracetamol (4-Acetamindophenol; ACROS organics, Geel, 
Belgium) was prepared in sterile PBS (Sigma Aldrich, MO, USA) in an ultrasonic bath 
(37°C). Mice were randomly selected and administered with either sterile PBS 
(control), 150mg/kg paracetamol or 300mg/kg paracetamol via a single 
intraperitoneal injection and placed in a hot box (34°C) with free access to food (mash 
and standard chow) and water. Mice were euthanized 6 hours following dosing, as 
miR-122 has been shown to peak in the circulation at this time point [207].  
2.5 Carbon Tetrachloride (CCl4) toxicity model 
Male C57BL/6 mice (8 weeks old) were injected with a single dose of CCl4 as described 
previously [208-210]. After a 12 hour overnight fast, mice underwent an intraperitoneal 
34 
 
injection of 1ml/kg CCl4 (sterile CCl4 in a 1:3 ratio with olive oil) or with olive oil 
(control) at the equivalent volume.  
2.6 Blood and tissue sampling 
The mice were humanely culled via rising concentration of CO2 before 
exsanguinations according to the Humane Killing of Animals Under Schedule 1 to the 
Animals (Scientific Procedures) 1 Act 1986. 
Following blood collection via cardiac puncture, buffered sodium citrate solution 
(1.09mM) was immediately added as a 1:6 dilution. Whole blood was stored on ice 
until it was centrifuged for 10 minutes at 8000 x g at 4°C. Plasma was isolated and 
stored at -80°C. Tissue (brain, lung, heart, liver, kidney and spleen) were 
macroscopically dissected and placed in 4% paraformaldehyde (Sigma Aldrich), 
RNAlater (Sigma Aldrich) and dry ice. This prepared and maintained the integrity of 
the samples for histology, RT-qPCR and protein analysis respectively. 
2.7 RT-qPCR 
2.7.1 RNA extraction 
2.7.1.1 Blood 
Total RNA was extracted and purified from plasma using the miRNeasy Serum/Plasma 
Kit (Qiagen, Hilden, Germany). As recommended by the manufacturer, C. elegans 
miR-39 miRNA mimic (Qiagen) was added to each sample at 4x107 copies/μl as an 
external control. Following the manufacturing instructions RNA was eluted in 14µl of 




Following manufacturing instructions no more than 25mg of tissue was used to 
isolate RNA. The tissue was thoroughly homogenised in Qiazol (Qiagen) using sterile 
stainless steel beads on the TissueLyser II (Qiagen). Total RNA was extracted and 
purified from the homogenised tissue using the miRNeasy Mini Kit (Qiagen). Using 
the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, MA, 




2.7.2 Reverse Transcription 
cDNA was synthesised using the miScript II RT kit (Qiagen) according to the 
manufacturer instructions. Alongside each cDNA generation, a no RT control was 
included. The following volumes were used for tissue and plasma: 
Table 2.2 Reverse Transcription components and volumes used for plasma and 
tissue 
 Volumes 
Component Plasma Tissue 
5x miScript HiSpec Buffer 
 or 
5x miScript HiFlex Buffer* 
 
4µl HiSpec Buffer 4µl HiFlex Buffer 
10x miScript Nucleics Mix 2μl 2μl 
RNase-free water 7μl Variable** 
miScript Reverse Transcriptase Mix 2μl 2μl 
Template RNA 5μl Variable** 
Total Volume 20µl 
*5x HiFlex Buffer generated cDNA for the investigation of miRNAs and mRNA in the 
tissue. 5x HiSpec Buffer was used for the quantification of mature miRNA only in the 
plasma. 
** Variable template RNA and RNase-free water per tissue cDNA synthesis to 
generate a final concentration of 250ng. 
Samples were incubated for 1 hour at 37°C and then for 5 minutes at 95°C. Every 
sample was diluted 1:10 with RNase-free water and stored at -20°C. 
2.7.3 RT-qPCR analysis 
Real time PCR (RT-qPCR) detection was carried out on the Lightcycler 480 (Roche 
Diagnosis, Basel, Switzerland). For the quantification of mRNA and miRNA miScript 
SYBR green PCR kit (Qiagen) was used. As per the manufacturing instructions, 1µl of 
sample was added to 9 µl of the SYBR green components. To measure miRNA, the 
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sample was added to 1µl of 10x miScript Universal Primer, 1µl 10x miScript Primer 
Assay, 5µl 2x QuantiTect SYBR Green PCR Master Mix and 2µl RNase-free water. For 
the quantification of mRNA, the sample was added to 1µl 10x QuantiTect Primer 
Assay, 5µl 2x QuantiTect SYBR Green PCR Master Mix and 3µl RNase-free water. 
The Taqman Gene Expression Mix was used for the detection of primary miRNA (pri-
miRNA) transcripts (Life Technologies, CA, USA). For quantification, 5µl Taqman Gene 
Expression Master Mix, 0.5µl TaqMan Pri-miRNA Primer and 3.5µl RNase-free water 
was added to the 1µl sample. 
The real-time PCR cycles were set up according to the miScript (Qiagen), QuantiTect 
(Qiagen) and Taqman (Life Technologies) gene expression manuals. Melt curve 
analysis was completed to determine that there was no primer dimer formation and 
non-specific amplification. All samples were analysed in duplicate.
2.7.4 Relative quantification 
All tissue samples miRNA and mRNA Ct values were translated by the 2-ΔCT method 
[211]. The Ct values were normalised by an internal control using the following 
equation: 
2−ΔCT = [ (𝐶𝑡 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 − 𝐶𝑡 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)]   [211] 
2.7.5 Absolute quantification 
Plasma sample miRNA concentrations were determined using standard curves 
containing known 1:10 dilutions of miScript miRNA Mimics: Syn-hsa-miR-122-5p, Syn-
mmu-miR-192-5p and Syn-mmu-miR-151-3p (#219600, Qiagen). Standard curves 
were run three times, in duplicate and averaged. The raw Ct values were translated 
to copy number by absolute quantification analysis using linear interpolation. 
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2.7.6 Primer details 
2.7.6.1 miScript Primer Assay 
Table 2.3 miScript primers used for the quantification of miRNA 
Primer name Target Catalogue number  Target Sequence 
Hs_SNORD68_11 SNORD68 MS00033712  
Hs_SNORD95_11 SNORD95 MS00033726  
Hs_RNU6-2_11 RNU6-6P MS000033740  
Ce_miR-39_1 cel-miR-39-3p MS00019789 5’UCACCGGGUGUAAAUCAGCUUG 
Hs-miR-122a-1 hsa-miR-122-5p MS00003416 5’UGGAGUGUGACAAUGGUGUUUG 
Mm_miR-151-3p_1 mmu-miR-151-3p MS00032340 5’CUAGACUGAGGCUCCUUGAGG 
Mm_miR-192_2 mmu-miR-192-5p MS00011354 5’CUGACCUAUGAAUUGACAGCC 
Mm_miR-124_1 mmu-miR-124-3p MS0002921 5’UAAGGCACGCGGUGAAUGCC 
Mm_miR-196a_2 mmu-miR-196a-5p MS00032515 5’UAGGUAGUUUCAUGUUGUUGGG 
Mm_miR-1-2*_1 mmu-miR-1a-2-5p MS00011004 5’ACAUACUUCUUUAUGUACCCAUA 
Mm_miR-195_1 mmu-miR-195a-5p MS00001792 5’UAGCAGCACAGAAAUAUUGGC 
Mm_miR-146_1 mmu-miR-146a-5p MS00001638 5’UGAGAACUGAAUUCCAUGGGUU 
The pre-designed miScript primers were purchased from Qiagen, Hilden, Germany.
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2.7.6.2 QuantiTect Primer Assay 
Table 2.4 QuantiTect primers used in the measurements of mRNA in the tissue samples 
Primer name Target Catalogue 
number  
Mm_Gapdh_3_SG Glyceraldehyde-3-phosphate dehydrogenase (mouse) QT01658692 
Mm_Rn18s_3_SG 18S ribosomal RNA (mouse) QT02448075 
Mm_Actb_1_SG Beta actin (mouse) QT00095242 
Mm_Hprt_1_SG hypoxanthine guanine phosphoribosyl transferase (mouse) QT00166768 
Mm_Dicer1_1_SG Dicer 1, ribonuclease type III (mouse) QT00114702 
Mm_Cyp1a2_1_SG cytochrome P450, family 1, subfamily a, polypeptide 2 (mouse) QT00100674 
Mm_Cyp2e1_1_SG cytochrome P450, family 2, subfamily e, polypeptide 1 (mouse) QT00112539 
Mm_Aldoa_1_SG aldolase A, fructose-bisphosphate (mouse) QT00291753 
Mm_Tmed3_1_SG transmembrane emp24 domain containing 3 (mouse) QT00256907 
Mm_Ndrg3_1_SG N-myc downstream regulated gene 3 (mouse) QT00165767 
Mm_Foxo3_1_SG forkhead box O3 (mouse) QT00168623 
Mm_Havcr1_1_SG  hepatitis A virus cellular receptor 1 QT00112427 
The pre-designed QuantiTect primers were purchased from Qiagen, Hilden, Germany 
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2.7.7 Taqman Gene Expression Assay 
Table 2.5 Taqman Gene Expression Assay primers used for the quantification of pri-miRNA 122  
Primer name Target Catalogue number  
Mm99999915_g1 Gapdh 4331182 
Mm03024075_m1 Hprt 4331182 
Mm02619580_g1 Actb 4331182 
Mm03306556_pri mmu-mir-122 4427012 
The pre-designed Taqman primers were purchased from Thermo Fisher Scientific, MA, USA 
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2.7.8 Data evaluation and statistical analysis 
Data were analysed and presented as mean ±SD in Graphpad Prism (Version 8, CA, 
USA). For the experiments described in Chapter 3, linear regression was used to 
calculate the Cre-AAV8 treatment slope (expression/time) and determine whether it 
was significantly different from the control slope (Null-AAV8) and zero. For the 
variables of AAV8 treatment and paracetamol treatment (described in Chapter 4), 
statistical comparisons between the main effect and interaction of the treatments 
were assessed using a two-way analysis of variance (ANOVA, Tukey’s multiple 
comparison test). For data sets comparing two unmatched treatment groups a Mann 
Whitney U test or t-test were used to determine statistical significance. The p value 
for each statistical test was set at 0.05. A Pearson’s correlation was carried out to 
assess the correlation between two variables. The correlation coefficient, r, was used 
to interpret the strength and nature of the correlation. The confidence interval (set 
at 0.05) value was used to determine whether the correlation observed is not due to 
random sampling. 
2.8 Quantification of plasma ALT levels 
Mouse plasma ALT measurements were determined using methods previously 
described by The University of Edinburgh specialist assay service facilities [212]. To 
achieve this, a commercial ALT plasma kit (Alpha Laboratories Ltd., Eastleigh, UK) was 
adapted for use on either a Cobas Fara or Cobas Mira analyser (Roche Diagnostics 
Ltd, Welwyn Garden City, UK). Settings were set with a run precision of CV < 4% and 
an intra-batch precision of CV < 8%. 
2.9 Histology and immunohistochemistry of toxicity 
2.9.1 Formalin-Fixed Paraffin-Embedded (FFPE) tissue 
During sample collection, a portion of each tissue was fixed for overnight in 4% 
paraformaldehyde (Sigma Aldrich) at 4°C. Following fixation, the tissue was placed in 
70% ethanol ready for paraffin embedding. The tissue was then dehydrated, placed 
in paraffin-filled blocks and allowed to cool (carried out by the SURF histology team, 
The University of Edinburgh). 
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2.9.1.1 Haematoxylin and Eosin staining  
FFPE spleen, liver and kidney blocks were cut in 3µm sections. Once the sections were 
cut, they were baked on the Superfrost Plus Slides for 40 minutes at 70°C (Thermo 
Fisher Scientific). The tissue was rehydrated with 25% xylene (4x 5mins), 100% 
ethanol (2x 2mins) and 95% ethanol (1x 2mins). After this, the slides were washed 
with running water (1min) ready for staining. 
After rehydration, the slides were placed sequentially in haematoxylin (6mins), diH2O 
(1min), 1% acid alcohol (hydrochloric acid in 70% ethanol, 5mins), diH2O (1min), 
Scott’s tap water (1min), diH2O (1min) and aqueous eosin (4mins). Finally, the slides 
had their last wash with diH2O (1min) and were then dehydrated with the following 
protocol: 95% ethanol (30s), 100% ethanol (30s and 45s) and 25% xylene (4x 1min). 
DPX mounting media and coverslips were placed over the tissue ready for imaging.
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2.9.2 Immunohistochemistry (IHC) of cytochrome P450 2E1 in the liver and 
kidney 
FFPE liver and kidney blocks were cut at 3µm, placed on Superfrost Plus slides 
(Thermo Fisher Scientific) and baked at 70°C for 40 minutes. Staining was executed 
on the Discovery ULTRA Staining Module (Roche Diagnostics) with the following 
program using Roche Diagnostic’s reagents: 
First, the slides were deparaffized again (2x4 minutes, 70°C). For further staining 
preparation, the temperature was increased to 100°C (4 minutes) and incubated with 
Ventana Cell Conditioner 1 (5x 8 minutes). To enhance the specificity of the signal, 
the sections were exposed to 150µl of Ventana DISCOVERY inhibitor (8 minutes). This 
was followed by another incubation with casesin (1:10 dilution, 8 minutes). With the 
slides warmed up to 37°C, 150µl of the CYP2E1 antibody was added (Table 2.6, 60 
minutes). For the second time, the slide was exposed to a casesin (1:10 dilution, 1x 8 
minutes). Next, the slides were exposed to 150µl of anti-Rb HRP (Table 2.6, 10 
minutes). To initiate the signal, 150µl of the HRP-activated chromagen, DISCOVERY 
purple was added (40 minutes). Finally, 150µl of haemotoxylin (12 minutes) followed 
by 150µl of bluing reagent (4mins) was used as the counterstain. 
Before adding DPX mountant, the slides were dehydrated by placing and agitating in 
70% ethanol (1 minutes), 100% ethanol (2x 1 minutes) and 100% xylene (3x 1 
minutes). 
Table 2.6 Primary and secondary antibodies used for CYP2E1 IHC 
Target Host and 
Conjugate 




Rabbit Abcam, Cambridge UK (Ab 
28146) 
1:100 
Rabbit anti-rabbit IgG 
HRP 
Roche, Basel, Switzerland 





2.9.3 In situ hybridisation (ISH) of miRNA-122 
MiRNA-122 localisation was determined using the miRCURY LNA miRNA Detection 
Probes (Qiagen). FFPE blocks of liver and kidney were cut at 5µm, placed on 
Superfrost Plus slides (Thermo Fisher Scientific). The deparaffization and staining 
procedure was completed on Discovery ULTRA Staining Module (Roche Diagnostics). 
The programme was set according to methods established in AstraZeneca (Rebecca 
Sargeant, due for publication). 
During the staining programme, the miRCURY LNA miRNA Detection probes and 
controls were prepared using the miRCURY LNA miRNA ISH Buffer Set (FFPE) (Qiagen) 
mixed 1:1 with UltraPure DEPC water (Thermo Fisher Scientific) (Table 2.7). Alongside 
the miR-122-5p slides, the U6 probe was used to assess the sample quality, the 
scramble-miR and buffer mix alone acted as negative controls (Table 2.7).
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2.9.4 Imaging and scoring of histological slides 
Brightfield imaging of the H&E, IHC and ISH slides was achieved on the ZEISS Axio 
Scan.Z1 (ZEISS, Oberkochen, Germany). The Zen Blue edition software (ZEISS) was 
used for tissue visualisation. The Fiji (Fiji is just ImageJ, [213])software was used to 
assess the level of injury in the kidney and liver.  
The percentage of necrosis/staining in the centrilobular zone of the liver was 
calculated by: 
100x
distance (µm)between the central vein and edge of the necrotic/staining zone 
total distance (µm)between the central vein and portal triad
 
For each sample, ten measurements were chosen at random, measured and 
averaged. The average measurements of the Cre-AAV8 and Null-AAV8 treatment 
groups were then compared.
2.10 in vivo model: visualisation of Cre-recombination 
mT/mG mice (B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J, The Jackson 
Laboratory) globally express loxP-tdTomato (mT)-loxP (red fluorescence) at the cell 
membrane of all cell and tissue types. Following the exposure of a Cre-recombinase, 
the floxed tdTomato is deleted, enabling the downstream expression of the EGFP 
(mG) at the cell membrane. This results in the red fluorescent membrane to emit 
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green fluorescence. Untreated mT/mG mice were used as controls. Three weeks 
following a single AAV8 treatment as above (Section 2.3, 6.25x1010 viral 
genomes/100µl dose), the mice were sacrificed (as described in Section 2.6) and the 
tissue was harvested. mT/mG tissue (brain, lung, heart, liver, spleen and kidney) was 
fixed and imaged to visualise and assess the recombination of the Cre and Null-AAV8
2.10.1 mT/mG tissue preparation and cryopreservation with sucrose 
Tissue was harvested, immersed in methanol free 4% PFA and placed on a roller 
(Thermo Fisher Scientific, 2 hours, 4°C in the dark). The tissue was drained of PFA, 
washed twice with PBS and placed in 18% sucrose solution on a roller in the dark 
(overnight, 4°C). For cryopreservation, the tissue was drained of sucrose solution, 
dabbed dry and placed in a mould containing optimal cutting temperature compound 
(OCT, VWR, PA, USA). Tissue was allowed to acclimatise to the OCT (30mins, room 
temperature). During acclimatisation bubbles were removed for even preservation. 
The OCT-immersed tissue was flash frozen using a slurry (absolute ethanol and dry 
ice) and stored at -80°C
2.10.2 Imaging of fluorescent tissue 
Two hours before sectioning, the OCT embedded tissues were transferred from -80°C 
to -20°C. Each tissue was cut in 10µM sections and stored in the dark at -80°C. To 
prepre for imaging the slides were left at room temperature to air dry for 30mins. 
Once dry, ProLong™ Diamond Antifade Mountant with DAPI (Invitrogen, CA, USA) 
was added alongside a coverslip. Slides were again stored in the dark (overnight, 4°C) 
for imaging the next day. 
Fluorescent imaging of the mT/mG mouse sections was achieved on the ZEISS Axio 
Scan.Z1 (ZEISS). The green and red fluorescence was measured on the eGFP and 
Alexofluor555 channel. The DAPI counterstain (blue fluorescence, DAPI channel) was 
used to focus the microscope on the tissue. The Zen Blue edition software (ZEISS) was 
used for tissue visualisation. 
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2.11 Western Blotting 
Western Blotting analysis of CYP2E1 protein expression was investigated in the liver 
and kidney. Dicer protein expression was measured in the liver, spleen and kidney. 
Due to the differing molecular weights, western blotting of Dicer ~218kDa and 
CYP2E1 ~50-55kDa required different gel and transfer conditions.
2.11.1 Protein extraction 
To keep dephosphorylation and protein denaturing to a minimum, snap frozen tissue 
(⅓ of the left lateral lobe of the liver, ⅓ of the spleen and ½ of the kidney) were 
homogenised (as per section 2.7.1.2) in ice cold lysis buffer containing protease 
inhibitors. The lysis buffer was composed of filtered 250mM sucrose and 10mM 
triethanolamine in diH2O (7.6pH). After filtration, Merck cocktail III protease inhibitor 
(Calibochem, Merck-Millipore, CA, USA) was added to the lysis buffer at 10µl/ml. 
Following homogenisation, the samples were centrifuged for 2 minutes at 2000rpm 
and left to rest on ice for 15 minutes. The supernatant was placed in aliquots and 
stored at -80.
2.11.2 Bicinchoninic acid assay (BCA) assay and tissue preparation 
Protein concentrations were determined for gel electrophoresis (Section 2.11.3) and 
microsomal preparation (Section2.12) by adding samples (1:10 dilution in milliQ 
water) to the prepared Pierce BCA Protein assay in duplicate (Thermo Fisher 
Scientific). The assay was completed following the manufacturing instructions. The 
plate’s absorbance was read after incubation (37°C, 30 minutes) at 562nm. The 
samples were then diluted to 1µg/µl of protein in DTT (final concentration of 50mM), 
LDS sample buffer (NuPAGE™ x4, ThermoFisher Scientific, final concentration of x1) 
and deionised water. The sample preparation was vortexed, denatured at 70°C for 15 
minutes and centrifuged briefly before loading
2.11.3 Gel Electrophoresis 
For CYP2E1 expression, ten well, 4-20% gradient tris-glycine precast gels (Novex™, 
Wedgewell™, Invitrogen) were rinsed and placed in a Mini Gel Tank (Life 
Technologies). The tank was filled with electrophoresis running buffer (SDS-PAGE 
running buffer: 250mM trizma base, 190mM glycine and 0.1% SDS, pH 8.6). A protein 
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load of 30µg was added to each well alongside a PageRuler™ Plus Prestained Protein 
Ladder (ThermoFisher Scientific). The samples underwent gel electrophoresis at a 
constant voltage of 150V for 110 minutes. 
For the investigation of Dicer protein expression, ten well, 4-12% gradient tris-glycine 
precast gels (Novex™, Wedgewell™, Invitrogen) were used following the instructions 
above and ran at 150V for 80 minutes.
2.11.4 Protein transfer 
The 0.45µM PVDF membrane (Immobilon-P, Merck, NJ, USA) was cut and prepared 
for protein transfer by immersion in absolute methanol for 15 seconds, several 
washes in diH2O and in the transfer buffer (480µM Trizma Base, 3.84mM Glycine and 
10% v/v methanol, pH8.8) for 5 minutes. Taking care to avoid bubbles, the PVDF 
membrane was then placed on top of the gel, along with a sheet of blotting paper 
(Cytiva, Sheffield, UK) pre-soaked in transfer buffer. The gel was then flipped over 
and another pre-soaked sheet of electrode paper was added on top. For the wet 
protein transfer, the gel sandwiched with the PVDF membrane in between 2 sheets 
of electrode paper was placed in the XCell II Blot Module (XCell SureLock™, Invitrogen 
with sponges (pre-soaked in transfer buffer) on either side. The transfer was left at 
30V for 2 hours at room temperature. 
Using the same methods as above, protein transfer for Dicer was completed using 
chilled methanol-free transfer buffer (480µM Trizma Base, 3.84mM Glycine). 
Following the membrane preparation, the wet protein transfer was left at 90mA for 




The membrane was removed from the transfer module and incubated (1 hour at 
room temperature) in 20mls of blocking buffer (5% milk in wash buffer (TBS-T, 20mM 
Trizma base, 150mM NaCl and 0.1% v/v Tween-20, pH 7.6)). The primary antibody for 
Dicer or CYP2E1 (Table 2.8) was added to 1% milk (dissolved in TBS-T) and incubated 
with the membrane (overnight, 4°C). The membrane was washed with wash buffer 
(3x 10 minutes). The membrane was then transferred into 5mls of the HRP-secondary 
antibody (Table 2.8) diluted in 1% milk and placed on a roller (1 hour at room 
temperature). The membrane was washed as previously described and incubated 
with ECL reagent (Pierce™, ThermoFisher Scientific) (5 minutes at room 
temperature). Excess ECL was removed, the membrane placed in a plastic wallet, 
exposed to X-Ray film (CL-Xposure film, ThermoFisher Scientific), developed 
(Compact 4x, Xograph) and scanned. 
Table 2.8 Primary and secondary antibodies used for western blotting 

















β-actin Mouse,- Sigma Aldrich, A2228 1:20,000 
Secondary antibodies 
Rabbit IgG Goat, HRP Vector Laboratories , 
PI-1000-1 
1:3000 





2.11.6 Stripping and re-probing 
After the film development and analysis of Dicer or CYP2E1 expression, the 
membrane was stripped and re-probed for β-actin. To remove the antibodies on the 
membrane, the membrane was incubated 2x30 minutes in acid stripping buffer (30g 
glycine, 2g SDS, 20ml Tween-20 in 1L diH2O, pH 2.2). The membrane pH was then 
neutralised by 3x3 minute washes with PBS and placed into the blocking buffer (5% 
milk). The steps from Section 2.11.5 (immunoblotting) were repeated with the β-actin 
primary and secondary antibodies.
2.11.7 Quantification of protein bands 
Western blot analysis was achieved using ImageJ (National Institutes of Health, MD, 
USA). Images were converted to 8-bit and each lane density (intensity) was measured 
[214]. The relative density of each peak was then calculated from the baseline control 
sample on each gel.
2.12 Determination of CYP450 enzymatic activity  
2.12.1 Microsomal preparation 
Snap frozen kidney and liver from the tissue sampling (described in Section 2.6) were 
used for the microsomal preparation. To ensure there was sufficient protein for the 
detection of cytochrome P450 (CYP450) activity, five ½‘s of kidney were pooled for 
each group and homogenised together. As the CYP450 expression is high in the liver 
[215], these samples were not pooled. Consequently, there was an n=3 for livers and 
an n=1 for the kidneys per group. 
Tissues were weighed and added to buffer 1 (154 mM KCl, 50 mM Tris (Base) pH 7.4 
buffer) until the buffer and tissue combined was 4 times greater than the tissue 
alone. The tissues were then homogenised using sterile stainless steel beads on a 
TissueLyser II (Qiagen). The homogenate was centrifuged at 9000 xg (4°C, 20mins) 
and the supernatant transferred to ultracentrifuge tubes topped up with buffer 1. 
The supernatant was centrifuged at 100,000 xg (4°C, 1 hour). The pellet was 
reconstituted in 0.5ml of buffer 2 (50 mM potassium phosphate/20% glycerol, pH 7.4) 
per g of starting sample weight. Samples were aliquoted and stored at -80°C.  
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To determine protein content, the samples were diluted 1:20 with milliQ water and 
added to the Pierce BCA Protein assay in duplicate (Thermo Fisher Scientific) (Section 
2.11.2)
2.12.2 Cytochrome P450 enzyme assay using liquid chromatography- mass 
spectrometry (LC-MS) 
First, the liver and kidney samples were diluted to 1mg/ml and 3mg/ml respectively 
in phosphate buffer (pH 7.4) to make a total volume of 188µl. To set up the 
metabolism, a cocktail of 7 CYP450 substrates (x100) (As previously described [216, 217], 
Table 2.9) and 20nM of the reducing agent NADPH was added to the samples (in 
duplicate). The plate was incubated on a plate shaker at 450rpm, 38°C for 10 minutes.  
To halt the activity of the CYP450 enzymes, 40µl of the sample was added to 160µl of 
a quench solution (200nM of benzoxazol and 4nM of verapamil). Again, the samples 
were left to shake at 650rpm, 38°C for 10 minutes. After that, the plate was 
centrifuged down for 5 minutes and 50µl of supernatant was added to 150µl of 
ultrapure water. The individual plate wells were then analysed on a mass 
spectrometer (Xevo TQ-S, Waters, Milford, MA, USA). Data were collected on the 
Water’s Masslynx software (Waters Corporation, MA, USA).  
Activity of each CYP450 was determined by: 
𝑎𝑟𝑒𝑎 𝑢𝑛𝑑𝑒𝑟 𝑡ℎ𝑒 𝑐𝑢𝑟𝑣𝑒 (𝐴𝑈𝐶)𝑜𝑓𝑎𝑛𝑎𝑙𝑦𝑡𝑒
𝐴𝑈𝐶 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
For each CYP450 assessed (Table 2.9), a fixed concentration of verapamil was used as 
the internal control. 
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Table 2.9 Mass Spectrometry components and read settings to measure CYP450 activity 
Substrate Metabolite  MRM (Parent→Daughter) 
m/z 




Phenacetin Acetaminophen 152.02→109.96 0.02 15 15 
Bupropion Hydroxybupropion 256.06→139.02 0.02 15 30 
Amodiaquine n-Desethylamodiaquine 328.10→283.13 0.02 75 15 
Diclofenac 4-Hydroxydiclofenac 312.13→230.09 0.02 15 40 
Bufuralol 1-Hydroxybufuralol 278.16→186.12 0.02 55 20 
Midazolam 1-Hydroxymidazolam 342.05→168.24 0.02 75 40 
Chlorzoxazone 6-Hydroxychlorzoxazone 183.93→119.87 0.05 10 20 
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Chapter 3 Characterisation of 




MiR-122 has shown to be the miRNA with the greatest organ specificity [164]. It 
accounts for around 72% of hepatocytes total miRNA, with little-to-no expression in 
other organs [160-162]. This specificity has enabled studies to confidently determine 
that miR-122 measured in circulation of healthy and DILI patients has derived from 
the liver [86, 122]. Additionally, miR-122 has been shown to be trafficked between cells 
and organs eliciting an effect [121, 122, 137]. Thus, it has been indicated that miR-122 acts 
as a short and long distant cell-cell signalling molecule in physiological and 
pathological events.  
It was previously observed that the increase of miR-122 in the circulation, following 
paracetamol-induced liver injury, was paired with an increase in miR-122 in the 
kidney cortex and medulla of C57BL/6 mice [218]. Furthermore, the role of hepatic-
derived EV-bound miR-122 in the kidney proximal tubule cell was investigated in 
vitro. Replicating Lee et al. findings, Morrison found that isolated miR-122 enriched 
EV’s were taken up by primary kidney proximal tubule cells and reduced a known 
miR-122 mRNA target, FOXO3[200, 218]. Furthermore, incubation with miR-122 
enriched EV’s significantly protected the kidney proximal tubule cells from 
subsequent cisplatin-induced nephrotoxicity, compared to cells incubated with EV’s 
from control mice and mice with cardiac injury [218]. To explore this further, the aim 
of the studies in this chapter was to optimise and define an inducible model of liver-
specific Dicer deletion. In addition, exploration into the organs responsible for the 
uptake and clearance of liver-derived miR-122 was carried out in a non-DILI mouse. 
In the cytoplasm of the cell, Dicer, within the RISC loading complex (RLC), is involved 
in the cleavage and processing of pre-miRNA into mature miRNA [94, 219]. Encoded by 
a single locus, studies have shown that disruption of Dicer results in the loss of almost 
all miRNA, indicating Dicer is essential for miRNA production [220-222]. The global loss 
of Dicer1 and in turn miRNA is detrimental during the early stages of embryo 
development [223, 224]. Additionally, the use of Albumin-Cre; Dicer1flox/flox  [225] or 
AlfpCre;Dicer1flox/flox mice [226] as a model of hepatocyte specific Dicer1 knockdown 
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resulted in postnatal inflammation, liver damage and necrosis. However, inducing 
hepatocyte specific Dicer1 knockdown in adult Dicer1flox/flox mice has been shown to 
successfully abolish Dicer enzymatic activity and miRNA production, without 
disrupting hepatocyte proliferation prior to weaning [227]. Moreover, inducing Dicer1 
knockdown in the liver is not associated with chronic steatohepatitis, liver fibrosis 
and spontaneous hepatocellular carcinoma seen in the germline knockout of miR-122 
(miR-122-/-) [165, 176].  
As the inducible model of Dicer1flox/flox  mice was previously shown to display no signs 
of injury [227], Dicer1 flox/flox mice were used as an in vivo model to investigate the 
transfer of hepatocyte-derived microRNA to other organs .Homozygous Dicer1 flox/flox 
mice have a global expression of loxP sites on either side of exon 23 of the Dicer1 
gene. Cre-mediated recombination leads to the loss of the Dicer1 gene and in turn 
ceases the production of mature miRNA. With AAV8s known to preferentially direct 
themselves to hepatocytes [228], an AAV8-Tbg-Cre was used to induce Cre-
recombination in the liver of the Dicer1flox/flox mice. To further ensure liver specific 
Dicer1 deletion, the Cre-AAV8 used contained a thyroid hormone-binding globulin 
(TBG) promoter. 
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3.3 Experimental plan 
3.3.1 mT/mG mice 
The double-fluorescent Cre reporter mouse strain, mT/mG [229], were used to 
visualise and assess the Cre-recombination efficiency of the hepatocyte specific Cre-
AAV8 and its negative control (Null-AAV8). As described in Section 2.10, tissues were 
harvested 3 weeks post Cre and Null-AAV8 injection (6.25x1010 viral genomes/100µL 
dose). 
3.3.2 Dicer1 flox/flox mice 
Homozygous Dicer1 flox/flox mice (male and female) underwent a single tail vein 
injection of a hepatocyte-specific AAV8 (2.5x1011 viral genomes/100µL dose, Table 
2.1). Mice were randomly selected for an injection with either the Cre-AAV8 or its 
negative control, Null-AAV8 (Section 2.3). After injection, tissue and blood were 
collected weekly, for up to four weeks (n=20, n=5 per time point) (Figure 3.1). To 
assess the basal level of expression without the influence of an AAV8, tissue and 
plasma from baseline (untreated) mice (n=5) were used as a control (Figure 3.1). 
Dicer mRNA and protein expression were measured by RT-qPCR and western blotting 
respectively (as per methods). MiRNA expression was determined using RT-qPCR as 
described in Section 2.7. 
 
Figure 3.1 Schematic of the experimental plan used to determine the time course 




3.4.1 Successful Cre-recombination observed in the hepatocytes following Cre-AAV8 
treatment  
In the liver, 3 weeks post AAV8 injection, the Cre-AAV8 treated mT/mG mice primarily 
displayed positive recombination in the hepatocytes (green fluorescent 
membranes)(Figure 3.2C). Whereas, the baseline (untreated) and Null-AAV8 treated 
mT/mG mice globally expressed red fluorescent membranes in the liver, reflecting 
negative Cre-recombination (Figure 3.2A and B). 
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Figure 3.2 Fluorescent imaging of mT/mG livers following Null-AAV8 and Cre-AAV8 
treatment 
Liver sections of (A) baseline (untreated), (B) Null-AAV8 injected and (C) Cre-AAV8 
injected mT/mG mice. Images taken 3 weeks after a single AAV8 treatment (Null or 
Cre-AAV8). Negative Cre-recombination shown with the global expression of red 
fluorescence (tdTomato) at the cell membranes (A and B). Whilst, in the Cre-AAV8 
treated mice (C) the hepatocytes primarily express green fluorescence (EGFP), 
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reflecting positive Cre-recombination. Blue fluorescence is DAPI. Scale bar represents 
300µm, 20x magnification. Images representative of n=2. 
 
After visually assessing Cre-recombination in the mT/mG mice, the activity of the 
Null-AAV8 and Cre-AAV8 were investigated in the Dicer1flox/flox mice (Figure 3.1). 
Western blotting was carried out to determine if the Cre-AAV8 treatment resulted in 
the successful knockdown of Dicer protein expression in the hepatocytes. One week 
following Cre-AAV8 treatment, a total loss of Dicer protein was observed and 
maintained until week 4 (Figure 3.3A and B). Baseline (untreated) mice and the AAV8 
negative control, Null-AAV8, exhibited bands representing Dicer expression at 
~218kDa (Figure 3.3A and B). It can be seen in Figure 3.3A and B that the loading 
control, β-actin (~42kDa), remains consistent across each well. Relative density 
analysis of each band (Figure 3.3C and D) supported these findings further.  
Moreover, Dicer mRNA was measured in the liver to further define the activity of the 
AAV8 treatments. Interestingly, Cre-recombination following Cre-AAV8 treatment 
did not influence the expression of Dicer mRNA, in contrast to the Null-AAV8 treated 
mice (Appendix I).  
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Figure 3.3 Dicer protein expression in the liver post Null-AAV8 and Cre-AAV8 
treatment 
(A and B) Protein expression of Dicer (~218kDa, indicated by the red arrows) in the 
liver of the baseline (untreated) and week 1-4 of the Null-AAV8 and Cre-AAV8 treated 
Dicer1flox/flox mice, was determined by western blotting. For each western blot, β-actin 
(~42kDa) was used as a loading control. (C and D). To quantify Dicer protein 
expression, relative density of the ~218 kDa band was calculated in the Null (light 
grey) and Cre-AAV8 (dark grey) treated mice (week 1 to 4, post injection), normalised 
to the baseline control Dicer band (dotted line). Each western blot represents an n=1 
from each treatment group. 
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After confirmation that Dicer protein was knocked down in the liver, mature miRNA 
was measured using RT-qPCR. In the liver, previously described hepatocyte enriched 
miRNA species: miR-122, miR-192 and miR-151 were measured [86, 87, 123](Figure 3.4A). 
Two weeks post Cre-AAV8 treatment, all 3 miRNAs decreased in comparison to the 
Null-AAV8 treated mice (Linear Regression: miR-122: Cre slope=-24 week-1,Cre slope 
vs zero, p<0.0001; miR-192: Cre slope=-24 week-1, Cre slope vs zero p<0.0001; miR-
151: Cre slope -9.4 week-1, Cre slope vs zero p=0.014) (Figure 3.4A, Table 6.1). In the 
Cre-AAV8 treated mice, the loss of miR-122 and miR-192 was significantly different 
than the Null-AAV8 treated mice (Linear regression: miR-122: Null vs Cre p<0.0001; 
miR-192: Null vs Cre p=0.0004 (Figure 3.4A)). miR-151 did not significantly change in 
the Cre-AAV8 mice, compared to the Null-AAV8 mice (Linear Regression: Null vs Cre 
p=0.08).  
Three housekeeping genes: SNORD68, SNORD95 and U6 were assessed for the 
normalisation of miRNA in the liver. It was observed that all three housekeeping 
genes had significantly different Ct values in the Cre-AAV8 liver, when compared to 
the Null-AAV8 mice. Due to this, Figure 3.4 shows miR-122 normalised by SNORD68 
(B), SNORD95 (C) and U6 (D). Here, the loss of miR-122 was observed following the 
normalisation with each housekeeping gene (Figure 3.4). When comparing the means 
of the Null-AAV8 and Cre-AAV8 mice, SNORD68 exhibited the smallest difference 
(ANOVA: Null vs Cre difference in means=0.4). Due to this, Figure 3.4A is normalised 
to SNORD68.  
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Figure 3.4 Hepatocyte enriched miRNA in the liver of the AAV8 treated mice 
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Mature miRNA were measured in the liver by RT-qPCR and presented as 2-ΔT. (A) miR-
122, miR-192 and miR-151 in the liver of the Null-AAV8 (white) and Cre-AAV8 (black) 
treated mice, first normalised to SNORD68, and then converted as a percentage to 
the baseline mice (untreated, week 0, dotted line). Data represented as mean ±SD 
n=5. P values were calculated by linear regression, comparing the slopes of the Null-
AAV8 and Cre-AAV8 treated Dicer1 flox/flox mice (B-D) miR-122 normalised to SNORD68, 
SNORD95 and U6 respectively in the baseline (white), Null-AAV8 (light grey) and Cre-
AAV8 (dark grey) treated Dicer1flox/flox mice. Data are represented as mean ±SD, n=5. 
Significant differences were calculated from an unpaired Mann Whitney U test, 
comparing the expression of miR-122 in the Null-AAV8 and Cre-AAV8 treated mice at 
each week **p≤0.01. 
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Next, H&E staining was carried out in the liver sections to assess whether the Null or 
Cre-AAV8 induced liver injury (Figure 3.5). Baseline (untreated, A) and week 1-4 post 
Null-AAV8 (B-E) and Cre-AAV8 (F-I) treatments were assessed blindly. A skilled 
subjective opinion of histological appearances was provided without a formal scale. 
Across each treatment group it was determined that there were no signs of liver 
injury with: normal portal-central vascular relationships, uninflamed portal tracts, no 
bile duct inflammation, damage or loss, no interface inflammation or ductular 




Figure 3.5 H&E stained livers following AAV8 treatment 
H&E stained liver sections of baseline (untreated, A), Null-AAV8 (B-E) and Cre-AAV8 (F-I) treated Dicer1 flox/flox mice from week 1 to 4. 
Scale bar represents 200µm, 20x magnification. Images representative of an n=2.
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After assessing the H&E stained livers for injury, ALT was measured in the plasma of 
each treatment group described in Figure 3.1. This was carried out to determine if a 
single treatment of the AAV8 (Null or Cre) induced liver injury. It was observed that 
the Null-AAV8 and Cre-AAV8 treatments were not significantly different from 
eachother, with both inducing an increase in circulating ALT (ANOVA of each 
treatment mean, p>0.05). 
 
 
Figure 3.6 Plasma ALT levels after a single Null and Cre-AAV8 injection 
Plasma ALT activity (IU/I) was measured in the baseline (untreated, white squares), 
Null-AAV8 (light grey triangles) and Cre-AAV8 (dark grey circles) treated mice 1-4 
weeks post injection. Error bars represent mean ±SD, n=5. (Cre-AAV8 week 1 and 3 
and Null week 2, n=4). Multiple comparison two-way ANOVA determined there were 
no significant difference between the means of each treatment group and time point 
(p>0.05). 
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3.4.2 Mature miR-122 is decreased in the spleen following hepatocyte specific 
Dicer1 knockdown 
The mT/mG mice spleens were assessed following Null-AAV8 and Cre-AAV8 injection. 
This was carried out to determine if the hepatocyte specific AAV8s displayed off-
target Dicer1 knockdown in the spleen. Figure 3.7 confirms negative Cre-
recombination (global expression of red fluorescence at the cell membranes) in both 
the Null-AAV8 (A) and the Cre-AAV8 (B) treated mT/mG mice.  
 
Figure 3.7 Fluorescent imaging of the spleen following AAV8 treatment 
mT/mG spleen sections 3 weeks after Null-AAV8 (A) and Cre-AAV8 (B) treatment. 
Negative Cre-recombination shown with the global expression of red fluorescence 
(tdTomato) at the cell membranes (A, B). Blue fluorescence is DAPI. Scale bar 
represents 100µm, 20x magnification. Images representative of n=2. 
For each time point and treatment group outlined in the experimental plan (shown 
in Figure 3.1), Dicer protein expression was measured in the Dicer1 flox/flox spleens by 
Western blotting. Figure 3.8A and B highlights a consistent expression of Dicer 
protein (~218kDa) across each treatment group: baseline (untreated) and Null-AAV8 
and Cre-AAV8 treated mice from week 1 to 4. For both western blots, the loading 
control, β-actin (~42kDa), remains stable across each well (Figure 3.8A and B). 
Relative density analysis of each band (Figure 3.8C and D) quantified and validated 
these findings further. In addition to this, a non-significant difference in Dicer mRNA 




Figure 3.8 Dicer protein expression in the spleen after Null and Cre-AAV8 injection 
(A and B) Protein expression of Dicer (~218kDa, indicated by the red arrows) in the 
spleen of the baseline (untreated) and week 1 to 4 of the Null-AAV8 and Cre-AAV8 
treated mice, was determined by western blotting. For each western blot, β-actin 
(~42kDa) was used as a loading control. (C and D)To quantify Dicer protein expression, 
relative density of the ~218 kDa band was calculated in the Null (light grey) and Cre-
AAV8 (dark grey) treated mice (week 1 to 4, post injection), normalised to the baseline 
control Dicer band (dotted line). Each western blot represents an n=1 from each 
treatment group.
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Subsequently, mature miRNA was measured in the spleen to determine its 
involvement in the uptake of circulating hepatocyte-derived miR-122. MiR-146a, a 
miRNA described to be enriched in the splenocytes [230, 231], was measured alongside 
the hepatocyte enriched miR-122 (Figure 3.9A). As reflected in the liver (Figure 3.4A), 
miR-122 decreased from week 2 to 4 in the Cre-AAV8 treated group when compared 
to the Null-AAV8 treated group (Linear Regression: Cre slope=-24.8 week-1, Cre slope 
vs zero p=0.0003, Null vs Cre p=0.1). Furthermore, miR-122 was significantly lower in 
the Cre-AAV8 treated mice, in contrast to the Null-AAV8 mice at 2, 3 and 4 weeks 
post injection (Whitney U test: Null vs Cre p<0.01) (Figure 3.9B-C). Additionally, the 
evaluation of the raw Ct values of miRNA in the spleen highlights the loss of miR-122 
expression in the Cre-AAV8, in comparison to the Null-AAV8 treated mice (Table 6.2.). 
On the other hand, the slope of miR-146a expression was significantly greater in the 
Cre-AAV8 treated mice compared to the Null-AAV8 mice (Linear Regression: Cre 
slope= 15 week-1, Cre slope vs zero p=0.014, Null vs Cre p=0.005) (Figure 3.9A). 
Despite this, each AAV8 treatment displayed similar levels of miR-146a expression in 
comparison to the baseline (untreated mice, dotted line) (Figure 3.9A and Table I.2.). 
Three housekeepers were used in the measurement of miRNA in the spleen. When 
used as a normaliser, SNORD68 (B), SNORD95 (C) and U6 (D) displayed the same trend 
in miR-122 expression (Figure 3.9B-D). Nonetheless, it was determined that U6 was 
the gene with the greatest stability across the Null-AAV8 and Cre-AAV8 treatments. 
Hence, U6 was used as the normaliser for Figure 3.9A. 
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Figure 3.9 miR-122 and miR-146a expression in the spleen following a single Null-AAV8 and Cre-AAV8 treatment
71 
Mature miRNA was measured in the spleen by RT-qPCR and presented as 2-ΔT. (A) 
miRNA-122 and miRNA-146a in the spleen of the Null-AAV8 (white) and Cre-AAV8 
(black) Dicer1flox/flox mice, first normalised to U6, then converted as a percentage to 
the baseline mice (untreated, week 0, dotted line). Data represented as mean ±SD 
n=5. P values were calculated by linear regression, comparing the slopes of the Null-
AAV8 and Cre-AAV8 mice. (B to D) miRNA-122 normalised to SNORD68, SNORD95 and 
U6 respectively in the baseline (white), Null-AAV8 (light grey) and Cre-AAV8 (dark 
grey) mice. Data were represented as mean ±SD, n=5. Significant differences were 
calculated from an unpaired Mann Whitney U test, comparing the expression of miR-
122 in the Null-AAV8 and Cre-AAV8 treated mice at each week. ** p≤0.01. 
 
 
To investigate whether the loss of miR-122 had a detrimental effect on the health 
and morphology of the spleen, H&E stained spleens were evaluated in the Cre-AAV8 
mice and the baseline and Null-AAV8 treated controls (Figure 3.10). Whilst blinded, a 
skilled subjective opinion indicated that all the spleens, regardless of treatment and 
time point, displayed no signs of injury with normal red and white pulp (Figure 3.10). 
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Figure 3.10 Spleen H&E sections in the baseline, Null and Cre-AAV8 treated mice 
H&E stained spleen sections of the baseline (untreated, A), Null-AAV8 (B-E) and Cre-AAV8 (F-I) treated Dicer1flox/flox mice from week 1 to 
4. Scale bar represents 100µm, 20x magnification. Images representative of an n=2. Each image displays normal red and white pulp 
suggesting a lack of injury in the spleens.
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3.4.3 Mature miR-122 is lost in the kidney cortex and medulla following 
hepatocyte specific Dicer1 knockdown 
The whole kidney of the reporter mT/mG mice were visually assessed 3 weeks 
following Null-AAV8 and Cre-AAV8 injection. This was carried out to determine if the 
Null and Cre-AAV8 displayed any off-target Dicer1 knockdown. Confirmation of 
negative Cre-recombination (global expression of red fluorescence at the cell 
membranes) in both the kidney cortex and medulla of the Null-AAV8 (A and C) and 
the Cre-AAV8 (B and D) treated mT/mG mice (Figure 3.11). 
 
Figure 3.11 Fluorescent images of the kidney cortex and medulla following Cre-
AAV8 and Null-AAV8 treatment. 
Null-AAV8 injected (A and C) and Cre-AAV8 injected (B and D) mT/mG mice kidney 
cortex and medulla sections. Images taken 3 weeks post AAV8 injection. Negative Cre-
recombination shown with the global expression of red fluorescence (tdTomato) at 
the cell membranes (kidney cortex: A, B; kidney medulla: C and D). Blue fluorescence 
is DAPI. Scale bar represents 100µm, 20x magnification. Images representative of n=2.
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Dicer mRNA expression in the kidney cortex and medulla indicates constant 
expression across each treatment group described in (Figure 6.3). To explore this 
further, Dicer protein expression was then measured in the whole kidney. In Figure 
3.8A and B, the Dicer protein band (~218kDa) was stable across each treatment 
group: baseline (untreated) and Null-AAV8 and Cre-AAV8 treated mice from week 1 
to 4. It can be seen in Figure 3.12A and B that the loading control, β-actin, remains 
consistent across each well. Relative density analysis of each band (Figure 3.12C and 
D) confirmed these findings further.
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Figure 3.12 Dicer protein expression in the kidney following Cre-AAV8 and Null-
AAV8 treatment 
(A and B) Protein expression of Dicer (~218kDa, indicated by the red arrows) in the 
kidney of the baseline (untreated) and week 1 to 4 of the Null-AAV8 and Cre-AAV8 
treated mice, was determined by Western blotting. For each Western blot, β-actin 
(~42kDa) was used as a loading control. (C and D) To quantify the protein Dicer 
expression, relative density of the ~218 kDa band was calculated in the Null (light 
grey) and Cre-AAV8 (dark grey) treated mice (week 1 to 4, post injection), normalised 
to the baseline control Dicer band (dotted line). Each western blot represents an n=1 
from each treatment group 
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Similar to the spleen, mature miRNA were measured in the kidney cortex (Figure 
3.13) and medulla (Figure 3.14) to determine their involvement in the uptake of 
circulating hepatocyte-derived miR-122. MiR-196a, a miRNA described to be highly 
enriched in the kidney [231, 232] was measured alongside the hepatocyte enriched miR-
122 (Figure 3.13 and Figure 3.14). In addition to this, miR-192, a miRNA expressed in 
both the hepatocytes [86, 123] and the kidney was measured (Figure 3.13 and Figure 
3.14) 
In the kidney cortex, miR-192 and miR-196a were unaffected by the Cre-AAV8 
treatment, when compared to the Null-AAV8 treatment (Linear Regression: miR-192: 
Cre slope=-5 week-1, Cre slope vs zero p=0.018, Null vs Cre p=0.16; miR196a: Cre slope 
=-4 week-1, Cre slope vs zero p=0.57, Null vs Cre p=0.9) (Figure 3.13A). Nevertheless, 
miR-122 expression declines in the Cre-AAV8 treated mice from week 2 to 4 (Linear 
Regression: Cre slope=-25.7 week-1, Cre slope vs zero p=0.0004, Null vs Cre p=0.007) 
(Figure 3.13A-D). In Figure 3.13B-D, these findings were supported further, with a 
significant loss miR-122 expression in the Cre-AAV8 mice at week 3 and 4, compared 
to the Null-AAV8 controls (Mann Whitney U: Null vs Cre p≤0.01) (Table 6.3). 
The same expression of miRNA can be seen in the kidney medulla (Figure 3.14). 
Medullary miR-192 and miR-196a are unchanged in the Cre-AAV8 treated mice 
(Linear Regression: miR-192: Cre slope= 19, Cre slope vs zero p=0.0001, Null vs Cre 
p=0.009; miR196a: Cre slope 1.75 week-1, Cre slope vs zero p=0.7, Null vs Cre p=0.51) 
(Figure 3.14A). Furthermore, the Cre-AAV8 treated mice displayed a loss of miR-122 
expression in the medulla, in contrast to the baseline and Null-AAV8 treated mice 
(Linear Regression: Cre slope=-22.6 week-1, Cre vs zero p=0.0002, Null vs Cre p=0.15). 
This loss was deemed significant at week 2, 3 and 4 post Cre-AAV8 injection, when 
compared to the Null-AAV8 treated mice (Mann Whitney U: Null vs Cre p<0.01)( 
Figure 3.14B-D) (Table 6.4). 
To ensure miRNA were normalised correctly in the kidney cortex and medulla, three 
housekeeping genes were used for the measurements of miRNA-122: SNORD68 
(Figure 3.13B and Figure 3.14B), SNORD95 (Figure 3.13C and Figure 3.14C) and U6 
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(Figure 3.13 and Figure 3.14D). All three normalisers highlighted the same trend in 
miRNA expression. However, as U6 exhibited the greatest stability across each 
treatment group, U6 was carried forward as the internal control for all 3 miRNA 
(Figure 3.13A and Figure 3.14A).  
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Figure 3.13 miR-122 and renal enriched miRNA measurements in the kidney cortex following AAV8 treatment 
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RT-qPCR determined the expression of mature miRNA in the kidney cortex. (A) miR-
122, miR-192 and miR-196a expression in the Null-AAV8 (white) and Cre-AAV8 (black) 
Dicer1flox/flox mice, first normalised to U6, then converted as a percentage to the 
baseline (untreated, week 0, dotted line) mice. Data presented as 2-ΔT (mean ±SD 
n=5). P values were calculated from linear regression comparing the slopes of the Null-
AAV8 and Cre-AAV8 treated mice. (B-D) miRNA-122 normalised to SNORD68, 
SNORD95 and U6 respectively in the baseline (white), Null-AAV8 (light grey) and Cre-
AAV8 (dark grey) mice. Data was represented as mean ±SD, n=5. Significant 
differences were calculated from an unpaired Mann Whitney U test, comparing the 
expression of miR-122 in the Null-AAV8 and Cre-AAV8 treated mice at each week. * 
p≤0.05, ** p≤0.01. 
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Figure 3.14 Measurements of miR-122 and renal enriched miRNA in the kidney medulla after a single AAV8 injection 
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RT-qPCR determined the expression of mature miRNA in the kidney medulla. (A) miR-
122, miR-192 and miR-196a expression in the Null-AAV8 (white) and Cre-AAV8 (black) 
Dicer1 flox/flox mice, first normalised to U6, then converted as a percentage to the 
baseline (untreated, week 0, dotted line) mice. Data presented as 2-ΔT (mean ±SD 
n=5). P values were calculated from linear regression comparing the slopes of the Null-
AAV8 and Cre-AAV8 treated mice. (B-D) miR-122 normalised to SNORD68, SNORD95 
and U6 respectively in the baseline (white), Null-AAV8 (light grey) and Cre-AAV8 (dark 
grey) mice. Data was represented as mean ±SD, n=5. Significant differences were 
calculated from an unpaired Mann Whitney U test, comparing the expression of miR-
122 in the Null-AAV8 and Cre-AAV8 treated mice, ** p≤0.01. 
 
 
To evaluate whether the loss of miR-122 in the kidney was damaging, whole kidney 
sections were stained with H&E and assessed for any signs of injury. It was concluded 
from a skilled objective that the each kidney section regardless of treatment 
(baseline, Null-AAV8 and Cre-AAV8) and time point (week 0-4 post injection), that 
there were no signs of injury (Figure 3.15). 
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Figure 3.15 H&E stained kidneys after Null-AAV8 and Cre-AAV8 injections 
H&E stained kidney sections of baseline (untreated, A), Null-AAV8 (B-E) and Cre-AAV8 (F-I) treated Dicer1flox/flox mice from week 1 to 4. 
Scale bar represents 200µm. Images representative of an n=2.
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3.4.4 Expression of miRNA in the heart, lung and brain is unaltered following Cre-
AAV8 injection. 
The heart, lung and brain of the reporter mT/mG mice were visually assessed 
following Null-AAV8 and Cre-AAV8 injection. This was done to determine if the 
hepatocyte specific AAV8’s induced an off-target Dicer1 knockdown. Confirmation of 
negative Cre-recombination (global expression of red fluorescence at the cell 
membranes) in the heart (A, B), lung (C and D) and brain (E, F) of the Null-AAV8 and 
the Cre-AAV8 treated mT/mG mice (Figure 3.16). 
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Figure 3.16 Fluorescent imaging in the heart, lung and brain after a single AAV8 
injection 
Null-AAV8 injected (A, C, E) and Cre-AAV8 injected (B, D, F) mT/mG heart (A, B), lung 
(C and D) and brain (E, F) sections. Negative Cre-recombination was visualised in all 3 
tissues, with the global expression of red fluorescence (tdTomato) at the cell 
membranes. Blue fluorescence is DAPI. Scale bar represents 100µm, 20x 
magnification. Images representative of n=2. 
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After Dicer mRNA was assessed (Figure 6.4), mature miRNA was measured in the 
heart, lung and brain (Figure 3.17). MiR-122 expression was evaluated in all three 
tissues to determine if they play a role in its uptake and clearance from the 
circulation. Alongside this, miRNA known to be specific or highly enriched in the 
heart, lung and brain were assessed too. MiR-1 was measured in the heart, miR-195a 
in the lung and miR-124 in the brain (Figure 3.17). To ensure the tissue miRNA were 
normalised correctly, three housekeeping genes used: SNORD68, SNORD95 and U6. 
All three housekeepers highlighted the same trend in miRNA expression. However, 
SNORD95 in the heart and brain and U6 in the lung exhibited the greatest stability 
across each treatment group. Due to this, these housekeepers were used to 
normalise the data in Figure 3.17.  
In the heart, miRNA-1 was unaffected following Cre-AAV8 injection (Cre slope= -12.7 
week-1, Cre slope vs zero p=0.73, Null vs Cre p=0.5). Cre-AAV8 treated mice displayed 
similar miR-122 expression to the baseline mice, with a non-significant difference in 
expression compared to the Null-AAV8 treated mice (Cre slope=-15.3 week-1, Cre 
slope vs zero p=0.007, Null vs Cre p=0.42)(Figure 3.17A).  
In the lung, miR-122 and miR-195a expression did not change following the Cre-AAV8 
injection, in contrast to the Null-AAV8 treatment (Linear Regression: miR-122: Cre 
slope=-12.6 week-1, Cre slope vs zero p=0.004, Null vs Cre p=0.6; miR-195a: Cre 
slope=-2.9 week-1, Cre slope vs zero p=0.76, Null vs Cre p=0.6)(Figure 3.17B).  
Figure 3.17C highlights miR-122 and miR-124 did not differ in the brain between the 
Null and Cre-AAV8 treated mice (Linear Regression: miR-122: Cre slope= -13.9 week-
1, Cre slope vs zero p=0.006, Null vs Cre p=0.8; miR-124: Cre slope=-12.7 week-1, Cre 
slope vs zero p=0.004, Null vs Cre p=0.26)(Figure 3.17B).  
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Figure 3.17 miRNA in the heart, lung and brain after Cre-AAV8 and Null-AAV8 
treatments 
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RT-qPCR determined the expression of mature miRNA in the heart, lung and brain. (A) 
miR-122 and miR-1 expression in the heart, (B) miR-122 and miR-195a in the lung and 
(C) miR-122 and miR-124 in the brain of the baseline Null-AAV8 (white) and Cre-AAV8 
(black) Dicer1flox/flox mice. MiRNA expression was first normalised to SNORD95 (heart 
and brain) or U6 (lung), then converted as a percentage to the baseline (untreated, 
week 0, dotted line) mice. Data represented as mean ±SD n=5. P values were 
calculated by linear regression between the Null-AAV8 and Cre-AAV8 slopes (p>0.05). 
 
3.4.5 The primary transcript of miR-122 in the liver, spleen and kidney cortex and 
medulla is stable following Cre-AAV8 treatment 
To ensure the loss of miRNA-122 observed in the liver, spleen, kidney cortex and 
medulla was not due to alterations in its de novo synthesis, the primary transcript of 
miR-122 (pri-miR-122) was measured. 
The liver had the greatest expression of pri-miR-122 with an average Ct value of 24.8 
(Table 6.8). Following the injections of the Null and Cre-AAV8 there was a slight 
incline in expression from week 1 to 4 (Figure 3.18A). When comparing between the 
Null and Cre-AAV8 treated mice, there was no significant difference in pri-miR-122 
expression (Linear Regression: Cre slope=92 week-1, Cre slope vs zero p=0.005, Null 
vs Cre p=0.13). 
The spleen, had a minimal Ct levels of pri-miR-122 (Table 6.8). This expression was 
unchanged between the Cre-AAV8 and Null-AAV8 treated mice (Linear Regression 
Cre slope= -5.2 week-1, Cre slope vs zero p=0.3, Null vs Cre p=0.2) (Figure 3.18B). 
Low levels of pri-miR-122 were also observed in both the kidney cortex and medulla 
(average Ct=35) (Table 6.9). In both the kidney cortex and medulla, there was no 
significant difference between the Null-AAV8 and Cre-AAV8 treated groups (Linear 
Regression: kidney cortex: Cre slope=1.8 week-1, Cre slope vs zero p=0.8, Null vs Cre 
p=0.8; kidney medulla: Cre slope=-8 week-1, Cre slope vs zero p=0.24, Null vs Cre 
p=0.26)(Figure 3.18C). Lastly, pri-miR-122 was undetectable in the brain, heart and 
lung of the Dicer1flox/flox mice, regardless of treatment. 
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Figure 3.18 Primary transcript of miR-122 after Null-AAV8 and Cre-AAV8 treatment
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Pri-miR-122 expression measured by RT-qPCR in the (A) liver, (B) spleen (C) kidney 
cortex and (D) kidney medulla. Pri-miR-122 expression of the Null-AAV8 (white) and 
Cre-AAV8 (black) treated Dicer1flox/flox mice were first normalised to GAPDH, then 
converted as a percentage to the baseline (untreated, week 0, dotted line) mice. Data 
represented as mean ±SD n=5. P values were calculated from a two-way ANOVA 
between the Null-AAV8 and Cre-AAV8 treated mice. 
 
 
3.4.6 Circulating miRNA profile is altered in response to AAV8 treatment 
Moreover, the circulating miRNA profile was investigated in the Null-AAV8 and Cre-
AAV8 treated mice. MiRNA known to be released after a paracetamol overdose was 
measured [86, 87, 123]. Hence, Figure 3.19 shows the expression of miR-122 (A), miR-192 
(B) and miR-151 (C) in the plasma. Measurements of the 3 miRNAs were taken at each 
time point for the baseline (untreated), Null-AAV8 and Cre-AAV8 treated mice (Figure 
3.19, Table 6.10). With a high level of variability seen in the mice treated with either 




Figure 3.19 Circulating miR-122, miR-192 and miR-151 increases after AAV8 
treatment 
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Circulating miRNA in the plasma were measured using RT-qPCR (Section 2.7). (A) miR-
122, (B) miR-192 and (C) miR-151 were measured for each treatment group and time 
point. Copy number was determined by absolute quantification, error bars represent 
mean ±SD (n=5; Cre-AAV8 week 1 and 3 and Null week 2, n=4). For each miRNA 
measured, a multiple comparison two-way ANOVA was carried out to see if there 
were a significant differences between each treatment group and time point (p>0.05). 
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A Pearson’s correlation coefficient analysis was carried out to determine if plasma 
miR-122 was correlated to known liver injury marker ALT and miR-122 expression in 
the liver. Both correlation analyses were calculated in the baseline, Null and Cre-
AAV8 treated mice, week 0-4 post AAV8 injection. Plasma miR-122 expression and 
ALT activity displayed a significant positive correlation (Pearson’s correlation: r=0.6, 
p<0.0001). Whereas, the correlation was not significant when plasma miR-122 




Figure 3.20 Plasma miR-122 correlation with ALT and liver miR-122 expression  
Pearson’s correlation was calculated to determine if there was a correlation between 
circulating miR-122 levels and (A) ALT, (B) liver miR-122 expression. This was assessed 
in the untreated AAV8 (week 0, baseline, white) mice and week 1-4 weeks post Null-
AAV8 (light grey) and Cre-AAV8 (dark grey) treatment in the Dicer1flox/flox. For each 
data set, correlation coefficient, r, and its confidence interval, p, was determined. 
Correlation was deemed significant if p≤ 0.05.
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3.4.7 Main Findings 
 Successful and sustained knockdown of Dicer was observed in the Dicer1 
flox/flox livers, 1 week after a single Cre-AAV8 injection. 
 A loss of hepatocyte enriched miRNA was seen in the liver, 2 weeks after Cre-
AAV8 injection. 
 There was no histological evidence of liver injury, despite variability in 
circulating ALT and miR-122 
 MiR-122 expression decreased in the spleen and kidney (cortex and medulla) 
from week 2 post Cre-AAV8 injection. 
 MiR-122 was unchanged in the heart, lung and brain following Cre-AAV8 
injection. 
 Dicer expression in the spleen, kidney cortex and medulla, heart, lung and 
brain were unaffected by the Cre-AAV8 treatment. 
 Other miRNA in the spleen, kidney cortex and medulla, heart, lung and brain 
were stable in all three treatment groups. 
 
3.5 Discussion 
Dicer, within the RISC loading complex (RLC), is essential for the cleavage and 
processing of pre-miRNA into mature miRNA [94, 219-222]. In this chapter, Dicer and 
mature miRNA were knocked down in the hepatocytes to determine which organs 
were responsible for the uptake of circulating miR-122 in a healthy mouse.  
As previously described, Dicer expression was significantly reduced in the 
hepatocytes one week following a single Cre-AAV8 injection in the Dicer1 flox/flox mice 
[227]. With the pri-miR-122 unchanged following Cre-AAV8 treatment, it was 
confirmed that the loss of miRNA was due to a knockdown of Dicer1 only and not due 
to a disruption further upstream in its de novo synthesis [219, 233]. Subsequently, 
mirroring previous findings [227], the loss of Dicer1 in the hepatocytes resulted in the 
significant loss of miR-122, miR-192 and miR-151 in the liver, two weeks post Cre-
95 
AAV8 treatment. The delay in the loss of miRNA following Dicer knockdown indicates 
that miRNA is highly stable in quiescent hepatocytes of the adult liver [227]. Moreover, 
this result is consistent with miR-122 having a half-life of 10 days in adult 
hepatocytes[189]. Dicer expression was stable in the spleen, kidney cortex and 
medulla, heart, lung and brain. Additionally, across all 6 tissues, the organ enriched 
miRNAs remained consistent in expression. Therefore, the stable Dicer and miRNA 
production per time point and treatment, highlights the Cre-AAV8 activity is 
restricted to the hepatocytes. 
Liver histology and measurements of known biomarkers of hepatocyte injury: ALT 
and miR-122, were assessed in each treatment group [86, 87, 123]. The blinded 
histological assessments determined that there was no evidence of liver injury. 
However, from week 1-4 post AAV8 injection, plasma miR-122 and ALT activity were 
variable in the Null-AAV8 and Cre-AAV8 treated mice. Despite the group means being 
non-significantly different from the untreated AAV8 mice (baseline), some individual 
mice, particularly in the Null-AAV8 treatment groups, displayed high levels of 
circulating ALT and miR-122. Moreover, the plasma miR-122 and ALT activity had a 
significant positive correlation in the baseline, Null-AAV8 and Cre-AAV8 treated mice, 
(Figure 3.20). Yet, there was a lack of correlation observed between miR-122 
expression in the liver and plasma miR-122. Therefore, this data implies that the liver 
had a mild response to the AAV8 infection rather than a global knockdown of miRNA 
in the hepatocytes. (Figure 3.5). 
Previous studies detailed that an injection of a Cre-AAV8, and consequently deletion 
of Dicer, does not cause liver injury, DNA damage, death, or abnormal proliferation 
in hepatocytes of Dicer1 flox/flox mice [227]. Personal communications with Victoria Gadd 
(CRM) and Kylie Matchett (CIR), the AAV8 dose used in this study was higher than 
required to produce optimal Cre-recombination. Perhaps, with a lower dose of AAV8, 
the variability of ALT and miR-122 observed would be reduced or eliminated. Thus, 
for further experiments (Chapter 4), a lower dose was used in the hope that the mild 
response to the AAV8 injections would be reduced or eliminated.  
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MiR-122 is regularly described as an abundant, liver specific miRNA [164, 165, 193]. This 
chapter was consistent with these findings as even though miR-122 was detected in 
all seven tissues investigated, the expression was found to be at least 400 fold greater 
in the liver (Section I.4). Furthermore, as reflected in the lack of primary transcript in 
the other tissues, miR-122 production occurs almost exclusively in the liver. 
Nevertheless, it has been previously noted that genes enriched in cells and tissues 
such as macrophages, spleen, kidney, thymus and lung, are significantly altered 
during global miR-122 knockdown [189]. This suggests that miR-122 has a role in 
silencing and activating genes out with the liver. Due to this, miR-122 expression was 
measured in the plasma, heart, lung, brain, spleen and kidney cortex and medulla. 
In the heart, lung and brain, miR-122 expression was unchanged following Cre-AAV8 
treatment. However, the loss of hepatic miRNA was observed to cause a significant 
reduction in the expression of miR-122 in the spleen and kidney. For both organs, the 
primary transcript of miR-122 was lowly expressed. These findings demonstrate that 
in a healthy, uninjured mouse, miR-122 expression in the spleen and kidney is reliant 
on the transfer of miR-122 from the liver.  
These findings are agreement with Rivkin et al, who found that the depletion of 
macrophages resulted in the loss of miR-122 expression in the kidney. Consequently, 
they proposed the primary source of kidney miR-122 is from circulating miR-122 
originating from the liver [193]. Additionally, a previous study revealed the spleen 
displays a significant uptake of miR-122 during ConA-induced liver injury, implying 
that circulating miR-122 released from the liver is greater in the portal circulation 
compared to the systemic circulation [122]. Interestingly, the same study found that 
following ConA-induced liver injury, miR-122 preferential enters the lung causing 
acute pulmonary inflammation. Nevertheless, in this chapter, miR-122 levels were 
non-significantly reduced in the lung following Dicer knockdown in the liver, 
suggesting this mechanism of transfer does not occur during health. However, to 
investigate this further, Chapter 4 describes two models of acute liver injury to 




Figure 3.21 Diagram of main findings from Chapter 3 
Hepatocyte specific Dicer1 knockdown resulted in the total loss of mature miRNA in the hepatocytes. This in turn led to the loss of mature 
miR-122 expression in the spleen and kidney (both the cortex and medulla). This highlights that in a healthy mouse, the spleen and kidney 
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Organ damage can result in the release of miRNA into the circulation and urine [234]. 
A range of miRNAs are released from the liver into the bloodstream during drug-
induced liver injury (DILI) [87, 123]. In both humans and mice, miR-122 and miR-192 
have been described to significantly increase in the circulation following paracetamol 
induced liver injury, compared to healthy controls [82, 86, 87]. Additionally, miR-122 and 
miR-192 have been shown to predict DILI earlier and at lower paracetamol doses than 
ALT [117, 123, 171]. Due to this, both miRNAs have been extensively researched as non-
invasive biomarkers for the diagnosis and prognosis during a suspected paracetamol 
overdose [46, 82, 123].  
In the previous chapter, I presented data demonstrating the involvement of the 
kidney and spleen in the uptake and clearance of circulating miR-122 in healthy mice. 
The studies presented in the current chapter aimed to determine if the mechanism 
of hepatic miR-122 uptake seen in chapter 3 is altered in the setting of paracetamol 
DILI. To achieve this, two well described models of acute liver toxicity were used in 
this investigation: paracetamol in the Dicer1 flox/flox mice and carbon tetrachloride 
(CCl4.) in wild type C57BL/6 mice.
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4.2 Experimental plan 
4.2.1 Dicer flox/flox mice 
Compared to Chapter Chapter 3, a lower dose of the Cre-AAV8 and its control, Null-
AAV8 (6.25x1010 viral genomes/100µl dose), was used to induce Dicer1 knockdown 
in the liver. This was based on unpublished studies (personal communications with 
Victoria Gadd, CRM) identifying the same level of Cre-recombination at 2.5x1011and 
6.25x1010 viral genomes/dose. As described in Chapter Chapter 3, Dicer1 and miRNA 
significantly decreased in the Cre-AAV8 treated mice two weeks post injection. Due 
to this, three weeks post AAV8 treatment was used for the paracetamol dosing and 
tissue collection time point. 
Male homozygous Dicer1 flox/flox mice (9 weeks old) had a single tail vein injection of 
the hepatotropic Cre-AAV8 or its negative control, Null-AAV8 (6.25x1010 viral 
genomes/100µL dose, Table 2.1). Mice were randomly selected for either AAV8 
treatment and left under normal conditions for 3 weeks (n=15 per group, Section 
2.3). Running parallel, baseline (untreated) mice were used as a control to determine 
the response of DILI in this strain of mouse (n=15). Three weeks after the AAV8 
injection, mice were then injected with either saline (PBS), 150mg/kg or 300mg/kg 
paracetamol (n=5 per group) keeping to the methods described in Section 2.4(Figure 
4.1). Tissue and blood were collected 6 hours following the paracetamol dosing and 
measured for mRNA and miRNA expression (as per methods). Tissues were perfused 








4.2.2 C57BL/6 mice 
Carbon tetrachloride (CCl4.), is an environmental toxin which is widely used in 
experimental models to induce liver injury. Similar to paracetamol toxicity, CCl4 is 
metabolised into a toxic metabolite by the CYP450 enzyme, CYP2E1 [235, 236]. The toxic 
metabolite, CCl3•−, has been shown to be responsible for hepatotoxicity characterised 
by lipid peroxidation, depletion of GSH, a rise in ALT and liver fibrosis [235, 237, 238]. 
Subsequently, in this chapter, CCl4 was used as a second model of acute liver injury 
to investigate the transfer of hepatic miR-122 in C57BL/6 mice. 
Male C57BL/6J mice (8 weeks old) were fasted for 12 hours overnight prior 
treatment. After fasting, mice underwent an intraperitoneal injection of 1ml/kg CCl4 
(sterile CCl4 in a 1:3 ratio with olive oil) or with olive oil (control) at the equivalent 
volume (n=6 per group). To assess the time course of hepatic miRNA release, blood 
was collected via tail bleeds at 6 and 12 hour time points. Tissue and blood were 
harvested 24 hours after treatment. MiRNA known to be expressed in the 
hepatocytes were measured in the plasma and tissue at each time point using RT-
qPCR described in Section 2.7(Figure 4.2). 
 
 
Figure 4.2 Experimental plan of acute liver injury induced by carbon tetrachloride 




4.3.1 Loss of mature miRNA leads to a significant increase in centrilobular 
necrosis following paracetamol-induced liver injury 
Due to a reduction in the AAV8 dose (compared to Chapter 3, Section 3.3.2), Dicer 
mRNA expression was first assessed in the liver (Figure 6.5). There was a significant 
reduction of Dicer mRNA observed in the Cre-AAV8 saline group compared to the 
Null mice. 
The miRNA expression was then assessed following PBS, 150mg/kg and 300mg/kg of 
paracetamol (Figure 4.3). Regardless of paracetamol dosing, it was observed that the 
Null-AAV8 did not alter the expression of miRNA in the liver, compared to the 
baseline mice (ANOVA: baseline vs Null: p>0.05) (Figure 4.3A-C). In the baseline and 
Null-AAV8 treated mice, miR-122 expression remained stable in the liver across all 
three paracetamol doses (Figure 4.3A). However, miR-192 and miR-151 expression 
decreased with increasing paracetamol treatment (Figure 4.3B-C). 
Following Cre-AAV8 and a PBS injection, all three of the hepatocyte enriched miRNA 
were significantly reduced in the liver (Figure 4.3A-C). The expression of miR-122 in 
the Cre-AAV8 treated mice was significantly reduced across all three paracetamol 
treatments (Figure 4.3A). The significant loss of miR-192 and miR-151 displayed in 
the Cre-AAV8 group was maintained until 300mg/kg paracetamol dosing. Due to a 
loss of miR-192 and miR-151 in the baseline and Null-AAV8 mice at the 300mg/kg 





Figure 4.3 The expression of hepatocyte enriched miRNA following Dicer deletion 
and paracetamol treatment 
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Hepatocyte enriched (A) miR-122, (B) miR-192 and (C) miR-151 expression were 
measured in the liver following saline, 150mg/kg paracetamol and 300mg/kg 
paracetamol in the baseline (untreated, white squares), Null-AAV8 (light grey 
triangles) and Cre-AAV8 treated Dicer1 flox/flox mice (dark grey circles). MiRNA 
measurements were taken 3 weeks post AAV8 treatment and 6 hours following 
paracetamol dosing. Each point was normalised to U6, error bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine if expression 
was significantly different across all 9 treatment groups.
 
Next, in situ hybridisation of miR-122 was carried out to determine its localisation in 
the livers of the Null-AAV8 and Cre-AAV8 treated mice after a single dose of saline, 
150mg/kg and 300mg/kg paracetamol (Figure 4.4). Alongside the miR-122 in situ 
hybridisation, there were 3 controls, no probe (S), scrambled miRNA control (T) and 
U6 (U) (Figure 4.4).  
The Null-AAV8 and saline treated livers had an even dispersal of miR-122 in the 
cytoplasm of the hepatocytes (Figure 4.4A-C). The Null-AAV8 livers after 150mg/kg 
paracetamol (Figure 4.4G-I) and 300mg/kg paracetamol (Figure 4.4M-O) displayed a 
gradient of miR-122 staining (expression), with the greatest staining in the viable 
hepatocytes closest to the centrilobular necrotic areas. In contrast, the Cre-AAV8 
treated mice had minimal to no miR-122 staining which was not altered in the 
presence of paracetamol (Figure 4.4 saline: D-F, 150mg/kg paracetamol: J-L and 




Figure 4.4 In situ hybridisation of miR-122 in the Null-AAV8 and Cre-AAV8 liver 
sections following paracetamol dosing 
In situ hybridisation of miR-122 was carried out on the Dicer1 flox/flox liver sections. 
Images represent miR-122 expression (silver dots) 3 weeks after Null-AAV8 or Cre-
AAV8 treatment, followed by 6 hours a single paracetamol dosing of either saline (A-
D), 150mg/kg paracetamol (E and F) or 300mg/kg paracetamol (G and H). Controls 
for staining (I) No probe, (J) Scrambled miRNA and (K) U6 ran alongside the staining 
and used as comparison for the analysis. Scale bar represents 100µm or 20µm (C and 
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To assess the influence miRNA knockdown has on liver injury, H&E stained livers were 
assessed in the saline, 150mg/kg and 300mg/kg paracetamol treated mice (Figure 
4.6). As seen in Chapter 3, the saline (PBS, control) treated baseline, Null-AAV8 and 
Cre-AAV8 mice displayed no signs of liver injury (Figure 4.6A, D, G). For all three 
groups, increasing levels of centrilobular necrosis were present with increasing doses 
of paracetamol. It was noted following 300mg/kg paracetamol, that the Cre-AAV8 
mice had larger areas of necrosis than the baseline and Null AAV8 mice (Figure 4.6C, 
F, I). The greater extent of necrosis in the Cre-AAV8 treated mice was significant when 
the percentage of necrosis was calculated and compared (Figure 4.6J: ANOVA 




Figure 4.6 H&E staining and percentage of necrosis measurements in the liver 
(A-I) H&E stained livers 3 weeks after baseline, Null-AAV8 and Cre-AAV8 treatment and 6 hours following saline, 150mg/kg and 300mg/kg 
paracetamol. Scale bar represents 200µm, 20x magnification. Images representative of n=5. (J) In reference to the H&E stained livers, 
the level of necrosis was calculated as a percentage for each liver section: baseline (untreated, white squares), Null-AAV8 (light grey 
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triangles) and Cre-AAV8 treated (dark grey circles) Dicer1 flox/flox mice. Error bars represent mean ±SD, n=5. A multiple comparison two-
way ANOVA was used to determine if the percentage of necrosis was significant between treatment groups. 
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ALT activity was measured in the plasma as another measure of liver injury (Figure 
4.7). In the baseline and Cre-AAV8 treated mice, ALT significantly increased following 
300mg/kg paracetamol in comparison to their equivalent saline controls (ANOVA: 
baseline saline vs baseline 300mg/kg p=0.01; Cre saline vs Cre 300mg/kg p<0.0001). 
Nevertheless, the mean activity of circulating ALT is greater in the Cre-AAV8 treated 
mice at the 300mg/kg paracetamol dose in comparison to the baseline and Null-AAV8 
treated mice (ANOVA: Null 300mg/kg vs Cre 300mg/kg p=0.02). In the Null-AAV8 





Figure 4.7 Circulating ALT activity following AAV8 and paracetamol treatment 
Plasma ALT activity (IU/I) were measured in the baseline (untreated, white squares), 
Null-AAV8 (light grey triangles) and Cre-AAV8 (dark grey circles) treated mice 6 hours 
post-saline, 150mg/kg and 300mg/kg paracetamol injection. Bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine significance 
across the 9 treatment groups.
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4.3.2 Increase of miR-122 in the spleen during paracetamol toxicity is significantly 
reduced when miRNA is knocked down in the hepatocytes 
First, it was confirmed that Dicer mRNA was not reduced in the spleen following Cre-
AAV8 treatment (Figure 6.6). Subsequently, miRNA was measured in the spleen to 
determine if DILI altered the uptake of miR-122 displayed in Chapter 3. The 
hepatocyte enriched miR-122 displayed a 25-fold increase in the baseline mice and a 
9-fold increase in the Null-AAV8 mice following 300mg/kg paracetamol verses the 
saline treatment (ANOVA: baseline saline vs 300mg/kg, p<0.0001; Null saline vs 
300mg/kg, p=0.002). In the Cre-AAV8 mice, an increase in miR-122 was not seen 
following 300mg/kg paracetamol (ANOVA: 300mg/kg paracetamol: baseline vs Cre, 
p<0.0001; Null vs Cre, p<0.0001).  
The splenocyte enriched miR-146a increased 3.6-fold and 2.6-fold in the 150mg/kg 
and 300mg/kg paracetamol treated baseline mice respectively, in contrast to the 
saline control (ANOVA: baseline; saline vs 150mg/kg, p<0.0001, saline vs 300mg/kg, 
p<0.0001) (Figure 4.8B). On the other hand, the Null-AAV8 treated mice had a 4-fold 
greater expression of miR-146 than baseline following saline treatment (ANOVA: 
baseline saline vs null saline p<0.0001), which decreased with increasing paracetamol 
dosing. Lastly, at the saline dose, Cre-AAV8 mice had comparable expression of miR-
146 to the baseline mice (ANOVA: baseline saline vs Cre saline, p>0.05). However, 
this expression was not influenced by paracetamol treatment and remained 
significantly lower than the baseline mice (ANOVA: baseline 150mg/kg vs Cre 




Figure 4.8 miR-122 and tissue enriched miRNA expression in the spleen 
MiR-122 (A) and miR-146a (B) were measured in the spleen of the male Dicer1 flox/flox 
mice. MiRNA measurements were carried out via RT-qPCR 3 weeks following baseline 
(white squares), Null-AAV8 (light grey triangles) and Cre-AAV8 (dark grey circles) 
treatment and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. Each 
point was normalised by SNORD95, error bars represent mean ±SD, n=5. A multiple 
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comparison two-way ANOVA was used to determine if the expression is significantly 
different between treatment groups. 
 
Next, H&E stained spleens were assessed to see if the loss of miR-122 results in a 
susceptibility to injury during DILI. Figure 4.9 shows the spleens of the Null-AAV8 and 
Cre-AAV8 Dicer1flox/flox mice following saline, 150mg/kg and 300mg/kg paracetamol. 
Here, it can be seen that the morphology of the spleens remain unchanged and 




Figure 4.9 H&E stained spleens following AAV8 and paracetamol treatment 
H&E staining of whole spleen sections 3 weeks after Null-AAV8 (A-C) and Cre-AAV8 (D-F) treatment and 6 hours following saline (A, D), 




4.3.3 When miRNA is diminished in the hepatocytes the transfer of miR-122 to 
the kidney is lost during paracetamol toxicity 
Dicer, miR-122, miR-192 and miR-196 were measured in the kidney cortex (and 
kidney medulla of the baseline, Null-AAV8 and Cre AAV8 treated mice, after saline, 
150mg/kg and 300mg/kg paracetamol (Figure 4.10). In both sections of the kidney, 
Dicer mRNA expression did not significantly decrease following Cre-AAV8 or 
paracetamol treatment (Figure 6.6). Moreover, tissue enriched miR-192 and miR-196 
did not decrease in the Cre-AAV8 treated mice (Figure 4.10B-C and Figure 4.10B-C).  
In the cortex, miR-122 increased 8-fold in the baseline and 7-fold in Null-AAV8 treated 
mice following 300mg/kg paracetamol, in comparison to the saline group (ANOVA: 
baseline saline vs 300mg/kg, p=0.003; Null saline vs Null 300mg/kg, p=0.0009). With 
miR-122 expression decreased in the kidney cortex of the Cre-AAV8 treated mice, this 
increase in expression following paracetamol-induced liver injury was not observed 
(ANOVA: baseline 300mg/kg vs Cre 300mg/kg, 18-fold difference p=0.0009; Null 
300mg/kg vs Cre 300mg/kg, 19-fold difference, p=0.0002). 
A similar trend was exhibited in the medulla, with miR-122 increasing 11-fold in the 
baseline and 13-fold in the Null-AAV8 mice treated with 300mg/kg paracetamol 
(ANOVA: baseline saline vs baseline 300mg/kg, p>0.05; Null saline vs Null 300mg/kg, 
p=0.001). Again, the Cre-AAV8 miR-122 expression remained unchanged and 
significantly lower following increasing paracetamol doing (ANOVA: Null 300mg/kg vs 




Figure 4.10 MiR-122, miR-192 and miR-196 expression in the kidney cortex after 
paracetamol-induced liver injury  
MiR-122 (A) and miR-192 (B) and miR-196 (C) were measured in the kidney cortex of 
the male Dicer1 flox/flox mice. MiRNA measurements were carried out via RT-qPCR 3 
weeks following baseline (white squares), Null-AAV8 (light grey triangles) and Cre-
AAV8 (dark grey circles) treatment and 6 hours after saline, 150mg/kg and 300mg/kg 
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of paracetamol. Each point was normalised by SNORD68, error bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine if the 




Figure 4.11 miR-122, miR-192 and miR-196 expression in the kidney medulla 
following paracetamol-induced liver injury 
MiR-122 (A), miR-192 (B) and miR-196 (C) were measured in the kidney medulla of 
the male Dicer1 flox/flox mice. MiRNA measurements were carried out via RT-qPCR 3 
weeks following baseline (white squares), Null-AAV8 (light grey triangles) and Cre-
AAV8 (dark grey circles) treatment and 6 hours after saline, 150mg/kg and 300mg/kg 
122 
 
of paracetamol. Data were normalised by U6, error bars represent mean ±SD, n=5. A 
multiple comparison two-way ANOVA was used to determine if the expression is 
significantly different between treatment groups. 
H&E stains of whole kidney sections were assessed to determine if a loss of miR-122 
alters the extent of injury following DILI (Figure 4.12). Assessments were carried out 
on the Null-AAV8 and Cre-AAV8 treated kidney sections with either saline (A, B), 
150mg/kg paracetamol (C, D) or 300mg/kg paracetamol (E, F). For all paracetamol 
doses, in the Null and Cre-AAV8 treated mice, there were no signs of acute tubular 




Figure 4.12 H&E staining of the kidney after AAV8 and paracetamol treatment 
Assessments were carried out 3 weeks following Null-AAV8 and Cre-AAV8 treated kidney sections and 6 hours after saline (A, B), 




4.3.4 Increase of miR-122 during paracetamol DILI is reduced in the heart, lung 
and brain following Cre-AAV8 injection 
As before, Dicer mRNA expression did not decrease in the heart, lung and brain with 
the exposure of Cre-AAV8 (Figure 6.7). 
3.4.4.1. MiR-122 and miR-1 expression in the heart 
MiR-122 and miR-1 were measured in the baseline, Null and Cre-AAV8 treated mice 
6 hours post paracetamol dosing (Figure 4.13). At the highest dose of paracetamol 
(300mg/kg), there was a 10-fold and 50-fold increase of miR-122 in comparison to 
the saline dose in the baseline and Null-AAV8 treated mice respectively (ANOVA: 
Baseline saline vs 300mg/kg, p<0.0001; Null saline vs Null 300mg/kg, 
p<0.0001)(Figure 4.13A). In the Cre-AAV8 treated group, there was no increase in 
cardiac miR-122 (ANOVA: Baseline 300mg/kg vs Cre 300mg/kg, p<0.0001; Null 
300mg/kg vs Cre 300mg/kg, p<0.0001) (Figure 4.13A). 
With increasing doses of paracetamol, it was observed that miR-1 increases in the 
baseline and Null-AAV8 treated mice (ANOVA: Baseline saline vs 300mg/kg, p<0.01; 
Null saline vs Null 300mg/kg, p<0.03). This increase was exhibited in the Cre-AAV8 




Figure 4.13 miR-122 and miR-1 expression in the heart of the AAV8 and 
paracetamol treated Dicer1 flox/flox mice 
MiR-122 (A) and miR-1 (B) was measured in the heart of the male Dicer1 flox/flox mice. 
MiRNA measurements were carried out via RT-qPCR 3 weeks following baseline 
(white squares), Null (light grey triangles) and Cre-AAV8 (dark grey circles) treatment 
and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. Each point was 
normalised by U6. Error bars represent mean ±SD, n=5 (300mg/kg Null-AAV8 mice, 
n=4). A multiple comparison two-way ANOVA was used to determine if the expression 
is significantly different between treatment groups. 
126 
 
3.4.4.2. MiR-122 and miR-195a expression in the lung 
MiR-122 and miR-195a expression were measured in the lung of the baseline, Cre-
AAV8 and Null-AAV8 treated mice following saline, 150mg/kg and 300mg/kg 
paracetamol (Figure 4.14). MiRNA expression was investigated to see if paracetamol 
toxicity influences the uptake of hepatic miRNA into the lung.  
In Figure 4.14 A, miR-122 expression of the saline and 300mg/kg of paracetamol 
treated baseline and Null-AAV8 treated mice was observed to be non-significant. 
Additionally, miR-122 expression at the 300mg/kg paracetamol dose, compared to 
the saline treated mice was not significant in the Cre-AAV8 treatment (Figure 
4.14A).In Figure 4.14B, a non-significant difference was displayed in the miR-195a 




Figure 4.14 miR-122 and miR-195 expression in the lung post-AAV8 and 
paracetamol related DILI 
MiR-122 (A) and miR-195a (B) were measured in the lung of the male Dicer1 flox/flox 
mice. MiRNA measurements were carried out via RT-qPCR 3 weeks following baseline 
(white squares), Null (light grey triangles) and Cre-AAV8 (dark grey circles) treatment 
and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. Each point was 
normalised by U6, error bars represent mean ±SD, n=5 (Null: saline, 150mg/kg and 
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300mg/kg and Cre: saline, n=4). A multiple comparison two-way ANOVA was used to 
determine if the expression is significantly different between treatment groups.
3.4.4.3. MiR-122 and miR-124 expression in the brain after paracetamol dosing 
A significant increase in miR-122 expression was displayed in the 300mg/kg baseline 
treated mice, in comparison to its saline control (ANOVA: baseline saline vs baseline 
300mg/kg, p<0.0001, 5-fold change difference). The increase of miR-122 in the 
baseline 300mg/kg treated mice was significantly greater than both the Null-AAV8 
and Cre-AAV8 treated mice at the equivalent dose (ANOVA: baseline 300mg/kg vs 
Null 300mg/kg, p<0.0001; 6-fold change difference; Baseline 300mg/kg vs Cre 
300mg/kg, p<0.0001, 12-fold change difference). In contrast, miR-124 expression 
increases with increasing doses of paracetamol regardless of AAV8 treatment. A 
significant increase was seen in the Cre-AAV8 300mg/kg treated mice when 




Figure 4.15 miR-122 and miR-124 expression in the brain following AAV8 and 
paracetamol treatment 
MiR-122 (A) and miR-124 (B) were measured in the brain of the male Dicer1 flox/flox 
mice. MiRNA measurements were carried out via RT-qPCR 3 weeks following baseline 
(white squares), Null (light grey triangles) and Cre-AAV8 (dark grey circles) treatment 
and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. Data were 
normalised to U6, error bars represent mean ±SD, n=5. A multiple comparison two-
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way ANOVA was used to determine if the expression is significantly different between 
treatment groups.
4.3.5 Primary transcript of miR-122  
Primary transcript of miR-122 (pri-miR-122) was measured in the liver, spleen, kidney 
cortex and medulla following AAV8 treatment and saline, 150mg/kg and 300mg/kg 
paracetamol dosing (Figure 4.16). As seen in Chapter 3 (Section 3.4.5), pri-miR-122 
was expressed at minimal levels in the spleen, kidney cortex and medulla regardless 
of AAV8 and paracetamol treatment (Ct ~33-35 in the baseline mice treated with 
saline). Whereas the liver displayed the greatest level of pri-miR-122 expression in 
comparison to the spleen, kidney cortex and medulla (Ct~22 in baseline mice treated 
with saline). 
In the liver, at the saline dose, the Cre-AAV8 treated mice had significantly higher 
levels of pri-miR-122 than the baseline and Null-AAV8 treated mice (ANOVA: baseline 
saline vs Cre saline p<0.0001; Null saline vs Cre saline p<0.0001) (Figure 4.16A). 
However, with increasing doses of paracetamol, pri-miR-122 expression decreases in 
all three treatment groups and are non-significantly different from each other 
(ANOVA: p>0.05). In the spleen, the Cre-AAV8 mice had higher pri-miR-122 
expression than the baseline treated mice (ANOVA: Baseline saline vs Cre saline 
p=0.036) (Figure 4.16B). Again, this significantly greater expression of pri-miR-122 in 
the Cre-AAV8 mice, compared to the baseline and Null-AAV8 mice, is not observed in 
the spleen at the 150mg/kg or 300mg/kg paracetamol dose. 
In the kidney cortex and medulla, there were no significant differences between the 
three AAV8 treated mice (Baseline, Null-AAV8 and Cre-AAV8) after saline, 150mg/kg 








Pri-miR-122 was measured in the liver (A), spleen (B), kidney cortex (C) and medulla 
(D) of male Dicer1 flox/flox mice. MiRNA measurements were carried out via RT-qPCR 3 
weeks following baseline (white squares), Null-AAV8 (light grey triangles) and Cre-
AAV8 (dark grey circles) treatment and 6 hours after saline, 150mg/kg and 300mg/kg 
of paracetamol. In the liver and spleen the data were normalised by GAPDH, in the 
kidney cortex and medulla data were normalised to Hprt and β-actin respectively.  
Error bars represent mean ±SD, n=5. Multiple comparison two-way ANOVA was used 
to determine if the expression was significantly different between treatment groups. 
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4.3.6 The characteristic increase of circulating hepatic miRNA following 
paracetamol toxicity is lost with Cre-AAV8 treatment  
Assessment of miRNA were carried out in the plasma to determine whether Dicer1 
knockdown in the hepatocytes (via Cre-AAV8 injection) influences the circulating 
profile of liver toxicity (Figure 4.17).  
In the baseline mice, miR-122, miR-192 and miR-151 significantly increased following 
a single dose of 300mg/kg paracetamol (average copy numbers and ANOVA: baseline 
saline vs baseline 300mg/kg: miR-122, 6700 vs 310000, p<0.0001; miR-192: 0.6 vs 
7000 p=0.003 and miR-151: 3 vs 54, p<0.0001) (Figure 4.17). Circulating miR-122, 
miR-192 and miR-151 in the 300mg/kg treated Null-AAV8 mice was not significantly 
different compared to its saline control (average copy number and ANOVA: Null 
saline vs Null 300mg/kg: miR-122: 4000 vs 120000, p>0.05; miR-192: 0.1 vs 2000, 
p>0.05 and miR-151: 2 vs 12, p>0.05). In the Cre-AAV8 treated mice, miRNA 
expression remained unchanged and significantly lower than the baseline mice at 
300mg/kg paracetamol (average copy number and ANOVA: baseline 300mg/kg vs Cre 
300mg/kg: miR-122: 310000 vs 1600, p<0.0001; miR-192: 7000 vs 0.3, p=0.003; miR-




Figure 4.17 Circulating hepatocyte enriched miRNA expression following AAV8 
and paracetamol-related DILI 
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MiR-122 (A), miR-192 (B) and miR-151 (C) were measured in the plasma of the male 
Dicer1 flox/flox mice. MiRNA measurements were carried out via RT-qPCR 3 weeks 
following baseline (white squares), Null (light grey triangles) and Cre-AAV8 (dark grey 
circles) treatment and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. 
Copy number was determined by absolute quantification, error bars represent mean 
±SD (n=5; Null saline n=4). A multiple comparison two-way ANOVA was used to 
determine if the expression is significantly different between treatment groups 
4.3.7 Transfer of miR-122 is not observed following CCl4-induced liver injury 
To investigate the profile of miRNA release from the liver into the circulation, plasma 
was collected and analysed from C57BL/6 mice, 6 hours, 12 hours and 24 hours 
following a single injection of CCl4 (Figure 4.2). Hepatocyte enriched miRNA, miR-122, 
miR-192 and miR-151 were measured in the plasma (Figure 4.18A-C). 
It was observed that miR-122 significantly increased in the plasma 24 hours after CCl4 
treatment, when compared to the 6 hour and 12 hour time points (Average copy 
number: 6 hours= 110, 12 hours= 820, 24 hours= 16600)(ANOVA: CCl4 6 vs 24 hours, 
p=0.01; CCl4 12 hours vs 24 hours, p=0.015) (Figure 4.18A). This increase was also 
significant when compared to the control group at 24 hours (olive oil) (ANOVA: 24 
hours, olive oil vs CCl4, p=0.014). At the 6-hour and 12-hour time point, miR-122 
expression in the circulation did not significantly differ between the olive oil and CCl4 
treatments (ANOVA: p>0.05) (Figure 4.18A). 
MiR-192 and miR-151 expression was at its highest in the circulation 24 hours after a 
single treatment of CCl4 (miR-192: average copy number: 6 hours= 0.003, 12 hours= 
0.2, 24 hours= 35) (miR-151: average copy number: 6 hours= 3, 12 hours= 4, 24 
hours= 21). However, this was not significant in comparison to both the controls and 









Using RT-qPCR, miRNA were measured in the plasma of the male C57BL/6 mice. 
Hepatocyte enriched miRNA: (A) miR-122, (B) miR-192 and (C) miR-151 were 
measured in the plasma 6 (circles), 12 (triangles) and 24 hours (squares) after a single 
injection of olive oil or CCl4. Copy number was determined by absolute quantification, 
error bars represent mean ±SD, n=6. A multiple comparison two-way ANOVA was 
used to determine if the expression is significantly different between treatment 
groups. 
 
Figure 4.18 Continued 
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To see whether an increase in circulating hepatocyte enriched miRNA reflected the 
extent of liver injury, H&E stained livers were investigated at the 24 hours following 
acute exposure to CCl4 (Figure 4.19). In the control group (injection of olive oil), there 
were no signs of injury observed (Figure 4.19A-B). Whereas in the CCl4 treated mice 




Figure 4.19 H&E staining and measurements of centrilobular in the liver 24 hours after a single CCl4 injection 
H&E staining of whole liver sections 24 hours after a single injection of olive oil (A and B) and CCl4 (C and D). Scale bar represents 200µm, 
20x magnification. Images representative of n=4. (E) In reference to the H&E stained livers, the level of necrosis was calculated as a 
percentage for each section (as per Section 2.9.4): control (olive oil, white circles) and CCl4 (Black circles). Error bars represent mean ±SD, 




Next, miRNA were measured in the tissues to investigate whether hepatocyte miRNA 
is transferred from the liver to other organs during CCl4-induced liver injury. Hence, 
miR-122, miR-192 and miR-151 were measured in the liver, kidney cortex, kidney 
medulla, spleen, heart, lung and brain (Figure 4.20A-C).  
In the liver, miR-122 and miR-192 expression were significantly reduced in the CCl4 
treated mice, in contrast to the olive oil control (Unpaired t-test: miR-122, p=0.05; 
miR-192, p=0.02) (Figure 4.20A, B). However, a loss of miR-151 was not observed in 
the liver following CCl4 (Figure 4.20C). Across the six non-hepatic tissues (spleen, 
kidney cortex and medulla, heart, brain and lung), miRNA-122, miR-192 and miR-151 
expression remained unchanged after CCl4 treatment, compared to the control mice 




Figure 4.20 miRNA expression in the liver and 6 non-hepatic tissues following CCl4 related liver injury
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Using RT-qPCR, miRNA were measured in 7 tissues from male C57BL/6 mice treated with either olive oil (control white) or CCl4 (black). 
Hepatocyte enriched miRNA: miR-122(A-G), miR-192 (H-N) and miR-151 (O-U) were measured in the liver (A, H, O), spleen (B, I, P), kidney 
cortex (C, J, Q) and medulla (D, K, R), heart (E, L, S), lung (F, L, T) and brain (G, N, U). Data were normalised to U6, error bars represent 
mean ±SD, n=6. In each tissue, an unpaired t-test was used to determine whether the expression significantly differed between the control 











4.3.8 Main findings 
 Successful Dicer1 and miRNA knockdown was observed in the livers of the 
Dicer1 flox/flox mice following a lower dose of Cre-AAV8. 
 A loss of hepatic miRNA resulted in an increased susceptibility of paracetamol 
toxicity in the liver. 
 The characteristic increase of circulating miR-122 and miR-192 during 
paracetamol toxicity was lost following Cre-AAV8 injection. 
 The significant uptake of miR-122 in the spleen, kidney (cortex and medulla) 
and heart during paracetamol injured liver injury was diminished in the Cre-AAV8 
mice. 





MiR-122 has been extensively researched for its application as a biomarker of liver 
injury in a clinical setting. However, there have been few studies focussing on the 
destination of miR-122 following its release during DILI. Hence, this chapter focussed 
on identifying the organs involved in the uptake and clearance of miR-122 when it is 
abundant in the circulation. To achieve this, two models of toxicity were investigated: 
paracetamol toxicity in the Dicer1 flox/flox mice and acute CCl4 toxicity in C57BL/6 mice.
 
Figure 4.3 confirmed that the lower Cre-AAV8 dose (Victoria Gadd, CRM; 6.25x1010 
viral genomes/dose) caused a significant loss of Dicer mRNA expression in the saline 
Cre-AAV8 treated Dicer1 flox/flox mice, compared to the baseline and Null-AAV8 treated 
mice. Moreover, as seen in Chapter Chapter 3 and previous reports [227], the induction 
of Dicer1 knockdown resulted in the significant loss of mature hepatic enriched 
miRNA in the liver. The loss of miR-122 and miR-192 was maintained in the liver of 
the Cre-AAV8 mice regardless of paracetamol dosing. Nevertheless, mirroring earlier 
findings [123], the baseline and Null-AAV8 (negative control) livers displayed a loss of 
miR-192 and miR-151 with increasing doses of paracetamol. Compared to the 
baseline and Null-AAV8 treated mice, the Cre-AAV8 mice had equal or greater 
expression of pri-miR-122. This implies that the loss of mature miR-122 observed was 
due to Dicer1 knockdown, rather than an alteration in the components upstream the 
de novo synthesis.  
A loss of hepatic miRNA in the Cre-AAV8 mice was mirrored in the plasma. However, 
as previously described, the baseline and Null-AAV8 control mice displayed a 
significant increase of miR-122, miR-192 and miR-151 in the circulation following 
paracetamol toxicity [82, 86, 87, 123, 239]. As before, Dicer mRNA expression did not 
decrease after Cre-AAV8 treatment in the spleen, kidney cortex and medulla, heart, 
lung and brain (Appendix). Additionally, the stable expression of the tissue enriched 
miRNA at the saline dose: miR-146a (spleen), miR-192 and miR-196 (kidney cortex 
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and medulla), miR-1 (heart), miR-195a (lung) and miR-124 (brain), reinforced the 
hepatocyte specificity of the Cre-AAV8.  
MiRNA are regularly described as regulators of gene function and consequently 
biological responses [172, 240]. Unsurprisingly, multiple studies have indicated a 
dysregulation of various miRNAs can influence the progression of cell injury and 
death during acute liver injury [172, 241, 242]. Additionally, they have been extensively 
described to modulate drug metabolism by negatively regulating the translation of 
the cytochrome P450 enzymes (CYP450) [203, 243-247]. As the reactive metabolite of 
paracetamol metabolism (N-acetyl-p-benzoquinone imine, NAPQI) is a product of 
CYP450 mediated oxidation [37, 46, 248], the Dicer1floxed/flox livers were assessed to 
determine if a loss of hepatic miRNA alters its response and survival during 
paracetamol toxicity.  
The mechanism of paracetamol-induced liver injury is a defined by the accumulation 
of NAPQI through CYP450 mediated oxidation, depletion of glutathione (GSH) and in 
turn hepatotoxicity and centrilobular hepatic necrosis [247, 249]. As proposed by other 
studies, an increase in circulating ALT [82, 250] and hepatic miRNA [82, 86, 123] after 
paracetamol dosing accurately reflected the level of hepatocyte death and injury 
displayed in the liver sections. In the baseline, Null-AAV8 and Cre-AAV8, increasing 
doses of paracetamol increased the percentage of necrosis, circulating ALT and 
miRNA. Furthermore, as observed in Chapter 3 and previous studies, miR-122 in the 
circulation had a significant positive correlation with ALT in the absence and presence 
of liver injury (Section 3.4.2)[86]. However, assessment of all three measures indicated 
that the loss of total hepatic miRNA increased the extent of centrilobular necrosis 
and injury induced by paracetamol toxicity. In the next chapter, I will explore the 
activity of CYP450 enzymes following miRNA depletion.  
Gender has shown to impact the pharmacokinetics and pharmacodynamics of a drug 
[251]. Furthermore, extensive research has discovered that male mice have a greater 
susceptibility to paracetamol-induced acute liver injury, in comparison to female 
mice [252-254]. In this chapter, like many studies of paracetamol-induced liver injury, 
only male mice were used. Consequently, a limitation of this study was that female 
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mice were not examined. Although, due to time constraints it was not feasible to 
analyse both sexes, it would be interesting to see if the total loss of miRNA in female 
livers caused a comparable increase in injury seen in the male mice. I suspect there 
would be a greater extent of injury in the female mice with the loss of miRNA but 
perhaps not to the same degree as their male counterparts.  
Previously miR-122 has been described, via in situ hybridisation, to have a strong even 
expression across healthy hepatocytes [177]. In the presence of paracetamol-induced 
liver injury, miR-122 expression is lost from the necrotic cells around the central vein 
and in turn released into the circulation [87]. Matching previous findings, there was a 
uniform dispersal of miR-122 in the hepatocytes of the saline treated Null-AAV8 mice. 
Increased dosing of paracetamol in the Null-AAV8 mice caused a loss of miR-122 
expression in the necrotic areas and an upregulation of miR-122 expression in the 
healthy hepatocytes surrounding the centrilobular necrotic areas. This loss was not 
reflected in the RT-qPCR results, with the upregulation in the healthy cells 
counteracting the loss of miR-122 from the necrotic. 
Interestingly, this non-significant change in miR-122 expression in the baseline and 
Null-AAV8 treated mice did not mirror previous findings [123]. Instead, following 
300mg/kg paracetamol, a significant loss of miR-122 in the liver was previously 
observed [123]. In their study, miR-122 was measured in the liver 24 hours after dosing. 
Whereas, in this chapter, following previous reports [203, 207], miR-122 investigations 
were carried out 6 hours after dosing. Furthermore, centrilobular necrosis and 
circulating ALT has been observed to be greater at 24 hours compared to 6 hours [204, 
207, 255]. However, miR-122 peaks in the circulation at 6 hours post-treatment [207]. 
Indicating, the differences seen in this chapter could be due to differing levels of 
paracetamol metabolism, necrosis, inflammation and immune related responses at 
each time point [204]. In future studies, it would be interesting to investigate miR-122 
expression and localisation past the 6 hour time point. Perhaps 24 hours after dosing, 
the loss of miR-122 in the liver Wang et al. observed would be replicated.  
As seen in the RT-qPCR data, a loss of miR-122 was visualised in both the healthy and 
necrotic hepatocytes of the Cre-AAV8 mice across all three paracetamol doses. This, 
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along with the increased levels of injury and necrosis in the Cre-AAV8 treated mice 
suggests the increase of miR-122 in the healthy cells (surrounding the necrotic areas) 
in the Null-AAV8 may be protective against further injury. The potential mechanism 
of protection could be linked to its known repression of the CYP enzymes. An 
increased concentration of miR-122 in these areas would reduce the activity of the 
CYP enzymes and hence production of NAPQI. 
In Chapter 3, it was discovered that the spleen and kidney (cortex and medulla) were 
involved in the clearance of miR-122 from the circulation in a healthy mouse. In this 
chapter, it was found that during paracetamol-induced liver injury (300mg/kg), the 
release of miR-122 into the plasma of baseline and Null-AAV8 mice resulted in a 
significant increase of miR-122 in the spleen and kidney cortex and medulla. This 
increase in miR-122 expression was not observed following hepatocyte Dicer and 
miRNA knockdown in the liver. Moreover, the expression of miR-122 in the kidney 
cortex, kidney medulla and the spleen had a significant positive correlation when 
plotted against plasma miR-122 in the presence of paracetamol-induced liver injury. 
Therefore, as discussed in Chapter 3, these results support previous findings 
indicating miR-122 is transferred from the liver to the spleen and kidney via the portal 
and systemic circulation [122, 193]. 
Surprisingly, despite no transfer observed in a healthy mouse, miR-122 was also 
observed to be significantly greater in the heart of the baseline and Null-AAV8, 
300mg/kg paracetamol, treated mice. The Cre-AAV8 treated mice had a significantly 
reduced level of miR-122 expression at the 300mg/kg paracetamol dose, suggesting 
the dependency of miR-122 transfer from an injured liver to produce this 
upregulation.  
Multiple studies have shown that through a negative feedback loop, miR-146a 
mediates the innate inflammatory response by controlling cytokine and toll-like 
receptor (TLR) signalling  As seen in Chapter Chapter 3, miR-146a expression was 
unchanged in the spleen following Cre-AAV8 and saline treatment, compared to the 
baseline mice. During paracetamol toxicity, it has been demonstrated that there is a 
modest but significant increase in circulating miR-146a [172]. In this study, Bala et al. 
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indicated that the increase of miR-146a in the circulation was a result of hepatocyte 
and immune cell death in the liver, rather than an increase in the inflammatory 
response [172]. 
In this chapter, there was a significant increase in miR-146a expression in the spleen 
of the paracetamol treated baseline mice. In turn, the loss of hepatic Dicer1 and 
miRNA inhibited the increase of miR-146a in the spleen of the Cre-AAV8 treated mice. 
Hence, it is possible that like miR-122, miR-146a is transferred from the liver to spleen 
during paracetamol DILI. Indeed, the innate immune response has been described to 
be mainly beneficial during paracetamol toxicity, contributing to tissue repair [256]. 
Therefore, the loss of miR-146a may be a contributor to the increased susceptibility 
to injury seen in the Cre-AAV8 mice. Nevertheless, further investigations into the 
circulating profile of miR-146a, its interaction and de novo synthesis in other tissues 
and potential targets once entering the spleen is required for confirmation of hepatic 
transfer and function. Interestingly, in the brain, it was found that miR-122 increased 
significantly in the baseline mice following 300mg/kg paracetamol, in comparison to 
the saline and 150mg/kg paracetamol treated mice. This suggests that miR-122 is 
transferred from the liver to the brain during paracetamol toxicity. However, a 
notable finding was that the empty AAV8 control, Null-AAV8, did not display the same 
pattern of expression. It was observed that the Null-AAV8 had a reduced increase of 
miR-122 after 300mg/kg paracetamol, comparable to the Cre-AAV8 mice. Studies 
have shown that although inefficient, AAV8’s can enter and transduce cells in the 
brain [228, 257]. Yet, Dicer mRNA and its tissue enriched miR-124 expression was 
unchanged, indicating that the lack miR-122 increase in the brain could be due to a 
response to an AAV8 infection rather than the occurrence off-target Dicer1 deletion.  
Recently it was demonstrated that the lung had significantly increased levels of miR-
122, 6 hours following Concanavalin (ConA)-induced liver injury [122]. Here, Wang et 
al. highlighted that during DILI, the lung contained the highest level of miR-122 in 
comparison to the heart, spleen, lung, kidney and colon [122]. Nevertheless, in this 
chapter, miR-122expression in the lungs of the 300mg/kg paracetamol treated 
baseline and Null-AAV8 mice were not significantly different from the saline controls. 
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Although the outcome of paracetamol and Con-A-induced liver injury is similar, both 
leading to inflammation, cell death and an increase in circulating biomarkers such as 
ALT, there are fundamental differences in the cause and progression of injury [258]. In 
paracetamol toxicity, the formation of NAPQI drives hepatocyte necrosis [37]. 
Whereas, in Con-A-induced liver injury, the recruitment and activation of T-cells and 
natural killer cells initiates apoptotic cell death in the hepatocytes and liver sinusoidal 
endothelial cells [258-261]. Perhaps, the different mechanism of cell death and in turn 
release of miR-122 explains the inconsistency of miR-122 uptake between the two 
models of liver toxicity.  
In the early stages of CCl4-induced liver injury, miRNA, including known 
hepatotoxicity markers, miR-122 and miR-192, have been described to significantly 
increase in the circulation [262-264]. 24 hours after CCl4 dosing, a significant loss of miR-
122 in the liver was paired with a significant increase in the circulation. Furthermore, 
the increase of miR-192 and miR-151 observed 24 hours after CCl4 dosing were non-
significant. Nonetheless, as seen in paracetamol toxicity, the increase in circulating 
hepatic miRNA reflected the presence of centrilobular necrosis in the liver [262-264].  
 
In comparison to the 150mg/kg and 300mg/kg paracetamol treated mice, the CCl4 
mice had around a 5-fold greater and a 19-fold lower concentration of circulating 
miR-122 respectively. Moreover, unlike 300mg/kg paracetamol toxicity, the increase 
in circulating miR-122 did not result in its significant uptake in the spleen, kidney, 
heart, lung and brain. These findings suggest that like 150mg/kg paracetamol, the 
increase in circulating miR-122 produced after 0.25ml/kg CCl4 treatment was not 
sufficient enough to produce a significant uptake elsewhere. Perhaps a greater dose 
of CCl4, and in turn greater extent of hepatocyte injury, is required to observe a 
significant transfer and uptake of miR-122 to other organs. Thus, for future study, it 
would be interesting to investigate whether an increase in CCl4 dosage induces a 
selective and significant uptake of hepatic miRNA in other organs. Alternatively, the 
different nature of acute hepatocyte injury, and subsequent mechanism of miRNA 
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release from the CCl4 injured liver could influence the expression profile of circulating 
miRNA.  
 
Previous studies have shown that the profile of circulating miRNA following CCl4 
toxicity differs from paracetamol, with miRNA such as miR-802-5p and miR-34a-5p 
described to increase significantly in the bloodstream during CCl4 toxicity but not 
during paracetamol-induced liver injury [87, 263, 264]. Consequently, it would be 
interesting to expand the range of miRNA investigated in the bloodstream and organs 
following both CCl4 and paracetamol toxicity. This would enable us to observe if other 
miRNA are taken up by other organs during paracetamol-related DILI. I suspect there 
would be a large overlap of miRNA transfer between the two models of 
hepatotoxicity, however, like miR-122, some of the miRNA transferred will be specific 




Figure 4.21 Diagram of Chapter 4’s key findings 
Hepatocyte specific Dicer1 knockdown resulted in the total loss of mature miRNA in the hepatocytes. This in turn lead to the loss of 
circulating miRNA, such as miR-122 and miR-192 following paracetamol toxicity. Interestingly, a loss of circulating miR-122 lead to the 
loss of miR-122 transferred from the liver to the spleen, kidney (cortex and medulla) and heart. Indicating, during paracetamol toxicity, 





Chapter 5 The functional impact 
of miR-122 transfer from the 





Cytochrome P450 (CYP450) enzymes are a superfamily of haem-containing enzymes 
involved in the oxidation of endogenous and exogenous compounds [48]. 
Approximately 75% of all known drugs are metabolised via CYP450 mediated 
oxidation, including paracetamol [265].  In humans, the CYP450 enzymes involved in 
the oxidation of paracetamol into its highly reactive metabolite, NAPQI, are: CYP1A2, 
CYP2E1 and CYP3A4 [38, 70, 248]. Following a comparison study with humans, mice were 
found to lack the cyp3a4 enzyme, but express fully functional cyp1a2 and cyp2e1 
enzymes[266]. The CYP2E1 enzyme is deemed the most prominent contributor in 
paracetamol bioactivation [70, 203]. CYP2E1, like others in its superfamily, is 
predominately found in the liver [215, 267-270]. Nevertheless, studies have shown that 
CYP2E1 is found in other organs including the kidney and lung [49-51].  
It has been well described that miRNA plays an important role in the regulation of the 
CYP450 enzymes expression and activity [243, 244, 271, 272]. Recently, miR-122 has been 
described to negatively regulate multiple CYP450 enzymes, including CYP2E1 [203, 246]. 
In both reports, it was noted that a loss of miR-122 resulted in an increased 
expression of CYP2E1 and CYP1A2, increased production of NAPQI and hence toxicity 
in the liver following paracetamol overdose [203, 246]. Due to these findings and an 
observed significant loss of miR-122 in the kidney in Chapter 3 and 4, the aim of the 
studies in this chapter was to investigate whether the loss of miR-122 transfer during 
paracetamol-induced liver injury has an impact on CYP2E1 expression and activity in 
the kidney. To investigate this, liver and kidney samples collected from the healthy 
and paracetamol treated Dicer1 flox/flox mice from Chapter 3 and 4 were assessed.
5.2 Experimental animals 
5.2.1 Dicer1 flox/flox mice 
Tissue harvested from healthy and DILI Dicer1 flox/flox mice described in Chapter 3 
(Section 3.3.2) and Chapter 4 (Section 4.2.1) were investigated in this chapter.  
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Chapter 3 described male and female Dicer1 flox/flox mice treated with the hepatocyte-
specific Null-AAV8 and Cre-AAV8 (2.5x1011 viral genomes/100µL dose). Following the 
AAV8 injection, tissue was collected weekly for up to 4 weeks. Untreated Dicer1 flox/flox 
mice were used as a control (baseline mice, week 0). This was done to investigate 
hepatic miRNA transfer during health. In this chapter, mRNA and protein expression 
were investigated in the liver and kidney by RT-qPCR and western blotting described 
in Chapter 2. 
Male Dicer1 flox/flox mice described in Chapter 4, were injected with either a Null-AAV8 
or Cre-AAV8 (6.25x1010 viral genomes/100µL dose). Again, untreated Dicer1 flox/flox 
mice (baseline) were ran alongside the experiment as a control. Three weeks after 
the injection, DILI was induced via saline (control), 150mg/kg paracetamol or 
300mg/kg paracetamol. Six hours later, tissue was harvested. In this chapter, results 
of mRNA and protein expression measurements are described. Additionally, 
immunohistochemistry and CYP450 enzyme activity were measured in the Null-AAV8 




5.3.1 Expression of multiple miR-122 mRNA targets significantly increase in the liver 
of the healthy Dicer1 flox/flox mice, following a single Cre-AAV8 injection 
First, RT-qPCR was carried out to explore whether the time dependent loss of hepatic 
miRNA (observed in Chapter 3, Section 3.4.1), resulted in a change of mRNA 
expression in the liver. Due to the high abundance of miR-122 in healthy hepatocytes 
and its observed loss in the hepatocytes of the Cre-AAV8 treated mice (Figure 3.4), 





Figure 5.1, it was observed that the mRNA expression of Aldoa, Ndrg3 and Tmed3 
were significantly greater in the Cre-AAV8 treated mice, compared to the Null-AAV8 
mice (Linear Regression, Aldoa: Cre slope=235 week-1, Cre slope vs zero p<0.0001, 
Null vs Cre p=0<0.0001; Tmed3: Cre slope=200 week-1, Cre slope vs zero p<0.0001, 
Null vs Cre p=0.008; Ndrg3: Cre slope=94 week-1, Cre slope vs zero p=0.0001, Null vs 
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Cre p=0.02). Comparisons at week 4 only, highlighted there was a significant 
difference in Aldoa and Tmed3 expression between the Null-AAV8 and the Cre-AAV8 
treated mice (Mann Whitney U test, Null vs Cre: Aldoa, p=0.008; Tmed3, p=0.008). 
Whereas, at week 4, there was no significant difference in Ndrg3 expression between 





Figure 5.1 Expression of miR-122 mRNA targets in the liver of the Dicer1 flox/flox 
mice following the loss of total hepatic miRNA 
Known mRNA targets of miR-122 were measured in the liver by RT-qPCR. (A and B) 
Aldoa, (C and D) Tmed3 and (E and F) Ndrg3 in the liver of the Null-AAV8 (white) and 
Cre-AAV8 (black) treated mice (male and female). (A, C and E) data were first 
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normalised to Hprt, and then converted as a percentage to the baseline mice 
(untreated, week 0, dotted line). (B, D and F) data from week 4 post-Null-AAV8 (white) 
and Cre-AAV8 (dark grey) injection were normalised by Hrpt. Data represented as 
mean ±SD n=5. (A, C and E) P values were calculated by linear regression, comparing 
the slopes of the Null-AAV8 and Cre-AAV8 treated Dicer1 flox/flox mice. (B, D and F) P 
values were calculated by Mann Whitney U test. *p≤0.05, **p≤0.01.
Furthermore, additional targets of miR-122, cyp1a2 and cyp2e1 were measured in 
the liver of the healthy AAV8 treated Dicer1 flox/flox mice (Figure 5.2). The mRNA 
expression of cyp1a2 was significantly higher in the Cre-AAV8 treated mice, in 
comparison to the Null-AAV8 mice (Linear Regression: Cre slope=230 week-1, Cre 
slope vs zero p<0.0001, Null vs Cre p=0.0001). However, cyp2e1 mRNA expression 
did not differ between the Cre-AAV8 and Null-AAV8 mice (Linear Regression: Cre 
slope=73 week-1, Cre slope vs zero p=0.008, Null vs Cre p=0.3).Comparisons at week 
4 only, highlighted there was a significant difference in cyp1a2 expression between 
the Null-AAV8 and the Cre-AAV8 treated mice (Mann Whitney U test, Null vs Cre: 
p=0.02). Whereas, at week 4, cyp2e1 expression was not significantly different 





Figure 5.2 mRNA of cyp1a2 and cyp2e1 in the liver of the Dicer1 flox/flox mice 
following a single treatment of AAV8 
Known mRNA targets of miR-122 were measured in the liver by RT-qPCR. (A and B) 
cyp1a2 and (C and D) cyp2e1 in the liver of the Null-AAV8 (white) and Cre-AAV8 
(black) treated mice (male and female). (A and C) data were first normalised to Hprt, 
and then converted as a percentage to the baseline mice (untreated, week 0, dotted 
line). (B and D) data from week 4 post-Null-AAV8 (white) and Cre-AAV8 (dark grey) 
injection were normalised by Hrpt. Data represented as mean ±SD n=5. (A and C) P 
values were calculated by linear regression, comparing the slopes of the Null-AAV8 
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and Cre-AAV8 treated Dicer1 flox/flox mice. (B and D) P values were calculated by Mann 
Whitney U test. *p≤0.05.
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In addition to measuring mRNA expression, protein expression of cyp2e1 was 
measured in the liver of the baseline, Null-AAV8 and Cre-AAV8 treated mice, from 
week 1-4 post injection (Figure 5.3). Mirroring the mRNA measurements, cyp2e1 
protein (~55kDa) did not differ across the 3 treatment groups regardless of time 
(Figure 5.3A and B). For both western blots, the loading control, β-actin (~42kDa), 
remains stable across each well (Figure 3.8A and B). The relative density analysis of 
each band (Figure 5.3C and D), supported these findings further.
 
 
Figure 5.3 Protein expression of cyp2e1 in the liver of the Dicer1 flox/flox mice 
following Cre-AAV8 treatment 
(A and B) Protein expression of cyp2e1 (~55kDa, indicated by the red arrows) in the 
liver of the baseline (untreated) and week 1 to 4 of the Null-AAV8 and Cre-AAV8 
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treated mice (male and female), was determined by western blotting. For each 
western blot, β-actin (~42kDa) was used as a loading control. (C, D)To quantify cyp2e1 
protein expression, relative density of the ~55kDa band was calculated in the Null-
AAV8 (light grey) and Cre-AAV8 (dark grey) treated mice (week 1 to 4, post injection), 
normalised to the baseline control cyp2e1 band (dotted line). Each western blot 
represents an n=1 from each treatment group
5.3.2 Expression of cyp2e1 decreases in the liver following paracetamol treatment 
After measuring mRNA targets of miR-122 in the liver in the absence of paracetamol 
DILI, investigations were then carried out in the paracetamol treated Dicer1 flox/flox 
mice. In Chapter 4, it was discovered that the significant reduction in hepatic miRNA 
following Cre-AAV8 treatment was maintained following paracetamol dosing (Figure 
4.3). First, mRNA expression of the two CYP450 enzymes, cyp1a2 and cyp2e1, were 
assessed in the liver via RT-qPCR, 3 weeks following baseline, Null-AAV8 and Cre-
AAV8 treatment and then 6 hours after saline, 150mg/kg and 300mg/kg paracetamol.  
At the saline dose, cyp1a2 mRNA expression was 2-fold and 1.7-fold greater in the 
Null-AAV8 and Cre-AAV8 mice respectively, in contrast to the baseline mice mean 
expression (ANOVA saline baseline vs Null, p=0.02). With increasing doses of 
paracetamol, expression of cyp1a2 mRNA in the liver was significantly reduced in the 
baseline, Null-AAV8 and Cre-AAV8 groups (ANOVA: Null: saline vs 150mg/kg, 
p=0.0001, saline vs 300mg/kg, p<0.0001; Cre: saline vs 150mg/kg, p=0.007, saline vs 
300mg/kg, p=0.04). At 300mg/kg paracetamol, the Cre-AAV8 the expression of 
cyp1a2 was not significantly different, compared to the baseline and Null-AAV8 mice 
at the equivalent dose (ANOVA: p>0.05, baseline vs Cre 1.75-fold difference; Null vs 
Cre 3.8-fold difference). 
Similarly, at the saline dose, cyp2e1 mRNA expression in the liver was non-
significantly greater following Null-AAV8 and Cre-AAV8 treatment, compared to the 
baseline mice (ANOVA p>0.05; baseline vs Null fold difference of 2; baseline vs Cre 
fold difference 1.3). Nevertheless, the expression of cyp2e1 in the Null-AAV8 mice 
decreases significantly with increasing doses of paracetamol (ANOVA: Null: saline vs 
167 
 
150mg/kg, p=0.009, saline vs 300mg/kg, p=0.0005). This is not observed in the 






Figure 5.4 cyp1a2 and cyp2e1 expression in the liver of Dicer1 flox/flox mice 
following paracetamol dosing 
mRNA expression of the CYP450 enzymes (A) cyp1a2 and (B) cyp2e1 were measured 
in the liver following saline, 150mg/kg paracetamol and 300mg/kg paracetamol in 
the baseline (untreated, white squares), Null-AAV8 (light grey triangles) and Cre-AAV8 
treated male Dicer1 flox/flox mice (dark grey circles). mRNA measurements were taken 
3 weeks post AAV8 treatment and 6 hours following paracetamol dosing. Each point 
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was normalised to β-actin, error bars represent mean ±SD, n=5. A multiple 
comparison two-way ANOVA was used to determine if expression was significantly 
different across all 9 treatment groups.
 
Subsequently, cyp2e1 expression was further evaluated in the paracetamol treated 
livers via western blotting. In Figure 5.5, cyp2e1 protein (~55kDa) was measured in 
the baseline, Null-AAV8 and Cre-AAV8 mice 6 hours following saline, 150mg/kg and 
300mg/kg paracetamol. As observed with the PCR data, cyp2e1 protein expression 
was greater in the saline treated mice, in comparison to the 150mg/kg and 300mg/kg 




Figure 5.5 cyp2e1 protein expression in the liver following a single dose of 
paracetamol 
(A and B) Protein expression of cyp2e1 (~55kDa, indicated by the red arrows) in the 
liver of the baseline (B, untreated), Null-AAV8 (N) and Cre-AAV8 (C) male Dicer1flox/flox 
mice treated with either saline, 150mg/kg paracetamol or 300mg/kg paracetamol, 
was determined by western blotting. For each western blot, β-actin (~42kDa) was 
used as a loading control. (C and D) To quantify cyp2e1 protein expression, relative 
density of the ~55kDa band was calculated in the baseline (white), Null-AAV8 (light 
grey) and Cre-AAV8 (dark grey) treated mice (following saline, 150mg/kg and 
300mg/kg paracetamol), normalised to the baseline saline cyp2e1 band (dotted line). 
Each western blot represents an n=1 from each treatment group.
 
Immunohistochemistry of cyp2e1 was carried out to determine if the loss of miRNA 
in the hepatocytes lead to changes in cyp2e1 expression and localisation. Figure 5.6 
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visualises the expression of cyp2e1 in the liver of the Null-AAV8 and Cre-AAV8 mice 
treated with either saline, 150mg/kg and 300mg/kg paracetamol. In addition, 
positive and negative control liver sections from healthy C57BL/6 mice were ran 
alongside the treatment groups (S and T). From the images and supporting 
percentage of cyp2e1 staining calculated (Figure 5.6U), there was no significant 




Figure 5.6 Immunohistochemistry of cyp2e1 in the liver of the paracetamol treated Null-AAV8 and Cre-AAV8 Dicer1 flox/flox mice 
Immunohistochemistry of cyp2e1 was carried out on the male Dicer1 flox/flox liver sections. Images represent cyp2e1 expression (purple 
staining) 3 weeks after Null-AAV8 or Cre-AAV8 treatment, followed by 6 hours a single paracetamol dosing of either saline (A and D), 
150mg/kg paracetamol (B and E) or 300mg/kg paracetamol (C and F). Liver sections from C57BL/6 mice were used as a positive (G) and 
negative control (no antibody, H) ran alongside the staining and used as comparison for the analysis. (I) Analysis was carried out following 
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To explore whether the loss of hepatic miRNA alters the CYP450 enzymatic activity in 
the liver, the relative levels of phenacetin (cyp1a2), bupropion, amodiaquine, 
diclofenac , bufuralol, midazolam and chlorzoxazone (cyp2e1) hydroxylase activities 
were determined in the saline treated Null-AAV8 and Cre-AAV8 Dicer1 flox/flox mice 
(Figure 5.7). It was found that the loss of hepatic miRNA had nosignificant impact on 
midazolam, diclofenac and bufuralol hydroxylase activity in the liver, in comparison 
to the Null-AAV8 controls (Mann Whitney U; Null vs Cre p>0.05, Figure 5.7). However, 
it was found that there was a significant increase in phenacetin (cyp1a2), bupropion. 
amodiaquine, and chlorzoxazone (cyp2e1) hydoxylase activity in the Cre-AAV8 mice 
compared to the Null-AAV8 mice (Mann Whitney U, Null vs Cre: phenacetin 
hydroxylase (cyp1a2) p=0.01; bupropion hydroxylase p=0.02; amodiaquine 
hydroxylase p=0.01; chlorzoxaxzone hydroxylase (cyp2e1) p=0.01).  
 
Figure 5.7 CYP450 activity was measured in the liver of the saline treated AAV8 mice 
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CYP450 activity was calculated in the liver following the methods described in Section 
2.12. Measurements were taken in the Null-AAV8 and Cre-AAV8 treated male Dicer1 
flox/flox mice 3 weeks following AAV8 injection and 6 hours following a single injection 
of saline. The CYP450 enzymatic activity was determined via measurements of 
phenacetin (cyp1a2), bupropion, amodiaquine, diclofenac , bufuralol, midazolam and 
chlorzoxazone (cyp2e1) hydroxylase activity. . Data are represented as mean ±SD, 
Null-AAV8 n=3, Cre-AAV8 n=2 (in duplicate). A Mann Whitney U test was used to 
determine whether the activity of each CYP450 activity was significantly different 
between the Null-AAV8 and Cre-AAV8 mice. 
5.3.3 cyp1a2 and cyp2e1 expression remains unchanged in the kidney cortex and 
medulla of Dicer1 flox/flox mice, following the loss of hepatic miRNA 
A significant loss of miR-122 is observed in the kidney cortex and medulla of the non-
DILI Dicer1 flox/flox mice treated with the Cre-AAV8 (Chapter 3, Section 3.4.3). Hence, 
mRNA expression of the known miR-122 targets, cyp2e1 and cyp1a2 were measured 
in the kidney cortex and medulla (Figure 5.8 and Figure 5.9). First, it was noted that 
compared to the liver (average Ct values of cyp1a2 and cyp2e1=20), the mRNA 
expression of cyp1a2 and cyp2e1 were lower in both sections of the kidney (average 
Ct values: cyp1a2: cortex=34, medulla=32; cyp2e1: cortex=21, medulla=23) (Table 
6.12 and Table 6.13). 
In the kidney cortex, the mRNA expression of cyp1a2 and cyp2e1 were unchanged 
following the loss of hepatic miRNA, including miR-122, in contrast to the Null-AAV8 
treated mice (Linear Regression cyp1a2: Cre slope=-8.4 week-1, Cre slope vs zero 
p=0.45, Null vs Cre p=0.7; cyp2e1: Cre slope=-8.2 week-1, Cre slope vs zero p=0.21, 
Null vs Cre p=0.15). 
Similarly, the kidney medulla displayed no significant change in cyp1a2 and cyp2e1 
expression in the Cre-AAV8 treated mice, compared to the Null-AAV8 mice (Linear 
Regression cyp1a2: Cre slope=4 week-1, Cre slope vs zero p=0.67, Null vs Cre p=0.8; 





Figure 5.8 mRNA expression of cyp1a2 and cyp2e1 in the kidney cortex of the Dicer1 
flox/flox mice  
Known mRNA targets of miR-122 were measured in the kidney cortex by RT-qPCR. (A) 
CYP1A2 and (B) CYP2E1 in the kidney cortex of male and female Null-AAV8 (white) 
and Cre-AAV8 (black) treated mice, first normalised to β-actin, and then converted as 
a percentage to the baseline mice (untreated, week 0, dotted line). Data represented 
as mean ±SD n=5. P values were calculated by linear regression, comparing the slopes 




Figure 5.9 mRNA expression of cyp1a2 and cyp2e1 in the kidney medulla of the 
Dicer1 flox/flox mice  
Known mRNA targets of miR-122 were measured in the kidney medulla by RT-qPCR. 
(A) cyp1a2 and (B) cyp2e1 in the kidney medulla of male and female Null-AAV8 (white) 
and Cre-AAV8 (black) treated mice, first normalised to β-actin, and then converted as 
a percentage to the baseline mice (untreated, week 0, dotted line). Data represented 
as mean ±SD n=5. P values were calculated by linear regression, comparing the slopes 
of the Null-AAV8 and Cre-AAV8 treated Dicer1 flox/flox mice.
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5.3.4 Expression and activity of cyp2e1 were significantly upregulated in the 
Dicer1 flox/flox kidney following Cre-AAV8 and 300mg/kg paracetamol 
treatments. 
As in the liver, the mRNA, location and response of the CYP450 enzymes were 
measured in the kidney cortex and medulla following paracetamol dosing. Replicating 
the methods in the liver, cyp1a2 and cyp2e1 were measured in the 2 sections of the 
kidney (cortex and medulla, Figure 5.10 and Figure 5.11). The kidney cortex and 
medulla, displayed minimal levels of cyp1a2 mRNA expression (average Ct values: 
cortex and medulla=34). However, for both kidney sections, the saline treated mice 
(baseline, Null-AAV8 and Cre-AAV8) cyp1a2 expression was not significantly different 
compared to the 150mg/kg and 300mg/kg treated mice (Figure 5.10 and Figure 5.11).  
MRNA of cyp2e1 was greater in the kidney cortex and medulla, in contrast to cyp1a2 
mRNA expression (average Ct values: cortex=20 and medulla=21). Furthermore, the 
kidney cortex exhibited a higher concentration of cyp2e1 mRNA compared to the 
medulla. In the kidney cortex, cyp2e1 was significantly higher in the saline treated 
baseline mice in contrast to the Null-AAV8 and Cre-AAV8 mice at the equivalent dose 
(Figure 5.10, ANOVA: saline: baseline vs Null p<0.0001; baseline vs Cre p=0.0002).  
However, with increasing doses of paracetamol, cyp2e1 mRNA decreases 
significantly in the baseline mice (ANOVA: saline vs 150mg/kg p<0.0001; saline vs 
300mg/kg p=0.01). MRNA expression of cyp2e1 is unaltered in the Null-AAV8 mice 
regardless of paracetamol. Whereas, cyp2e1 mRNA in the Cre-AAV8 mice increased 
significantly at the 300mg/kg paracetamol dose (ANOVA: saline vs 300mg/kg 
p=0.0006; 150mg/kg vs 300mg/kg p=0.0005). Moreover, the cyp2e1 expression in the 
300mg/kg paracetamol treated Cre-AAV8 mice was significantly higher than the 
baseline and Null-AAV8 mice (ANOVA: baseline vs Cre p=0.03; Null vs Cre p=0.004). 
In the medulla, cyp2e1 mRNA expression is not significantly different across the 
baseline, Null-AAV8 and Cre-AAV8 mice. At the saline and 150mg/kg paracetamol 
dose, cyp2e1 expression was not significantly different (Figure 5.11, ANOVA: p>0.05). 
However at the 300mg/kg dose, cyp2e1 expression increases in all three groups, with 
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Figure 5.10 cyp1a2 and cyp2e1 mRNA in the kidney cortex of the AAV8 and 
paracetamol treated mice 
mRNA expression of the CYP450 enzymes (A) cyp1a2 and (B) cyp2e1 were measured 
in the kidney cortex following saline, 150mg/kg paracetamol and 300mg/kg 
paracetamol in the baseline (untreated, white squares), Null-AAV8 (light grey 
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triangles) and Cre-AAV8 treated male Dicer1 flox/flox mice (dark grey circles). MRNA 
measurements were taken 3 weeks post AAV8 treatment and 6 hours following 
paracetamol dosing. Each point was normalised to β-actin, error bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine if expression 
was significantly different across all 9 treatment groups.
 
 
Figure 5.11 cyp1a2 and cyp2e1 expression in the kidney medulla of the baseline, 
Null-AAV8 and Cre-AAV8 mice 
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MRNA expression of the CYP450 enzymes (A) cyp1a2 and (B) cyp2e1 were measured 
in the kidney medulla following saline, 150mg/kg paracetamol and 300mg/kg 
paracetamol in the baseline (untreated, white squares), Null-AAV8 (light grey 
triangles) and Cre-AAV8 treated male Dicer1 flox/flox mice (dark grey circles). MRNA 
measurements were taken 3 weeks post AAV8 treatment and 6 hours following 
paracetamol dosing. Each point was normalised to β-actin, error bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine if expression 
was significantly different across all 9 treatment groups. 
 
As cyp2e1 displayed minimal expression in the kidney medulla (Figure 5.11), further 
assessments into CYP2E1 mRNA expression was assessed in the kidney cortex only. 
To determine if there was a correlation between CYP2E1 mRNA and miR-122 
expression in the kidney cortex, a Pearson’s correlation coefficient test was carried 
out. As there was an observed significant increase of CYP2E1 in the 300mg/kg treated 
Cre-AAV8 mice, compared to controls (baseline and Null-AAV8 mice), correlation 
analysis was carried out at this dose only alongside the paracetamol treatments 
combined (saline, 150mg/kg and 300mg/kg paracetamol). In Figure 5.12A, there was 
no-correlation between CYP2E1 and miR-122 expression in the kidney cortex of the 
saline, 150mg/kg and 300mg/kg treated mice (Pearson’s correlation: r=-0.05, p=0.8). 
However, a significant negative correlation was observed between miR-122 and 
CYP2E1 expression in the kidney cortex of the 300mg/kg paracetamol treated mice 




Figure 5.12 cyp2e1 mRNA expression correlated with miR-122 expression in the 
kidney cortex 
Pearson’s correlation was calculated to determine if there was a correlation between 
cyp2e1 mRNA and miR-122 expression in the kidney cortex of (A) all paracetamol 
groups (saline, 150mg/kg and 300mg/kg paracetamol) and (B) in the 300mg/kg 
paracetamol treated mice only. Both assessments were carried out in the untreated 
AAV8 (baseline, white), Null-AAV8 (light grey) and Cre-AAV8 (dark grey) Dicer1flox/flox 
mice. For each data set, correlation coefficient, r, was used to interpret the strength 
and nature of the correlation. Correlation was deemed significant if p≤ 0.05.
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As mRNA expression displayed minimal levels of cyp1a2 expression, cyp1a2 protein 
was not measured in these tissues. Nevertheless, western blotting of cyp2e1 was 
carried out in the whole kidney of the baseline, Null-AAV8 and Cre-AAV8 Dicer1 flox/flox 
mice, 1 to 4 weeks following the AAV8 injection. The protein bands were analysed to 
determine whether the stable mRNA expression of cyp2e1 was exhibited at the 
protein level.  
In Figure 5.13A, it was observed that the protein expression of CYP2E1 remained 
unchanged in the Dicer1 flox/flox mice presence of AAV8 treatment. Relative density 
analysis of each CYP2E1 band (Figure 5.13B) supported these findings further.In 






Figure 5.13 Kidney CYP2E1 protein expression in the AAV8 treated mice
(A)Protein expression of cyp2e1 (~55kDa, indicated by the red arrows) in the whole 
kidney of baseline (untreated) and week 1 to 4 of the Null-AAV8 and Cre-AAV8 treated 
mice, was determined by western blottingβ-actin (~42kDa) was used as a loading 
control. (B) To quantify cyp2e1 protein expression, relative density of the ~55kDa 
band was calculated in the Null (light grey) and Cre-AAV8 (dark grey) treated mice 
(week 1 to 4, post injection), normalised to the baseline control cyp2e1 band (dotted 
line). Each western blot represents an n=1 from each treatment group. 
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Subsequently, the localisation and distribution of cyp2e1 were assessed in the whole 
kidney by immunohistochemistry (Figure 5.14 and Figure 5.15). In the kidney cortex, 
shown in Figure 5.14, the expression of cyp2e1 (purple staining) was localised to the 
tubules. With increasing doses of paracetamol, there was no observed increase in 
cyp2e1 expression in the kidney cortex of the Null-AAV8 or Cre-AAV8 mice (Figure 




Figure 5.14 CYP2E1 staining in the kidney cortex 
Immunohistochemistry of cyp2e1 was carried out on the Dicer1 flox/flox kidney sections. Images represent cyp2e1 expression in the kidney 
cortex (purple staining) 3 weeks after Null-AAV8 or Cre-AAV8 treatment, followed by 6 hours a single paracetamol dosing of either saline 
(A and D), 150mg/kg paracetamol (B and E) or 300mg/kg paracetamol (C and F). Liver sections from C57BL/6 mice were used as a positive 
(G) and negative control (no antibody, H) ran alongside the staining (Figure 5.6). Scale bar represents 200µm, 20x magnification. Each 




Figure 5.15 CYP2E1 staining in the kidney medulla  
Immunohistochemistry of CYP2E1 was carried out on the Dicer1 flox/flox kidney sections. Images represent CYP2E1 expression in the kidney 
medulla (purple staining) 3 weeks after Null-AAV8 or Cre-AAV8 treatment, followed by 6 hours a single paracetamol dosing of either 
saline (A and D), 150mg/kg paracetamol (B and E) or 300mg/kg paracetamol (C and F). Liver sections from C57BL/6 mice were used as a 
positive (G) and negative control (no antibody, H) ran alongside the staining (Figure 5.6). Scale bar represents 200µm, 20x magnification. 
Each image represents an n=3 per AAV8 and paracetamol dosing.
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CYP450 enzymatic activity was then measured in the whole kidney. This was carried 
out to investigate whether the loss of hepatic miR-122 transfer resulted loss of 
CYP450 downregulation in the kidney. 
In the saline treated mice, it was observed that the activities of midazolam, 
bupropion, diclofenac and bufuralol hydroxylase were lower in the Cre-AAV8 mice, 
in comparison to the Null-AAV8 treated mice (Figure 5.16). At the saline and 
300mg/kg dose, chlorzoxazone hydroxylase (cyp2e1) activity was greater in the Cre-




Figure 5.16 CYP450 enzyme activities in the Null-AAV8 and Cre-AAV8 mice treated with paracetamol 
CYP450 enzymatic activity was calculated in the kidney following the methods described in Section 2.12.2. Measurements were taken in 
the Null-AAV8 and Cre-AAV8 treated Dicer1 flox/flox mice, 3 weeks following AAV8 injection and 6 hours following a single injection of 
saline. The CYP450 enzymatic activity was measured by was determined via measurements of (A) midazolam, (B) amodiaquine, (C) 
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diclofenac, (D) bufuralol, (E) bupropion, (F) phenacetin (cyp1a2) and (G) chlorzoxazone (cyp2e1) hydroxylase activity. (H) Verapamil was 
used as a control. Data are represented as mean ±SD, n=1 (5 individual samples pooled, in duplicate). 
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5.3.5 KIM-1 mRNA expression was unchanged following AVV8 and paracetamol 
treatment 
KIM-1 is primarily found in the proximal tubule cells of the kidney cortex [276] . Due to 
this, assessments into its expression were explored in the kidney cortex only. First, 
KIM-1 mRNA expression was measured in the baseline, 150mg/kg and 300mg/kg 
paracetamol treated baseline, Null-AAV8 and Cre-AAV8 mice via RT-qPCR. In Figure 
5.17, the expression of KIM-1 did not increase in the kidney cortex, with increasing 
doses of paracetamol. Interestingly, there was a significant increase in the 150mg/kg 
paracetamol Null-AAV8 treated mice, however, this was not maintained at the 




Figure 5.17 KIM-1 expression does not significantly increase with increasing 
paracetamol doses 
KIM-1 mRNA expression was measured in the kidney cortex of the male Dicer1 flox/flox 
mice. MRNA measurements were carried out via RT-qPCR 3 weeks following baseline 
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(white squares), Null (light grey triangles) and Cre-AAV8 (dark grey circles) treatment 
and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. Each point was 
normalised by β-actin. Error bars represent mean ±SD, n=5. A multiple comparison 
two-way ANOVA was used to determine if the expression is significantly different 




5.3.6 Main findings 
 Total loss of hepatic miRNA alters mRNA targets of miR-122 in the liver. 
 Response of multiple CYP450 enzymes significantly increase in the liver of 
the saline treated Cre-AAV8 mice. 
 In the absence of hepatic miRNA and 300mg/kg paracetamol, CYP2E1 




In the two previous chapters, the loss of hepatic miRNA resulted in the significant loss 
of miR-122 in the kidney in the absence of DILI (Chapter 3) and paracetamol-related 
DILI (Chapter 4, paracetamol toxicity). Hence, in this chapter, the functional role of 
hepatic miR-122 transferred from liver to kidney was investigated following in the 
AAV8 treated Dicer1 flox/flox mice. 
In Chapter 3, a time dependent loss of hepatic miRNA was observed following the 
conditional knockdown of Dicer in the Dicer1 flox/flox mice. Thus, the studies in this 
chapter aimed to determine if there was a change in gene expression as a 
consequence of hepatic miRNA loss. Induction of Aldoa, Tmed3 and Ndgr3 following 
the loss of miR-122 has frequently been observed in the liver [174, 274, 277]. Additionally, 
previous reports found a slow increase of these genes following the conditional 
knockdown of Dicer and total miRNA in the liver [227]. Mirroring previous reports, the 
mRNA expression of these three genes were significantly higher in the Cre-AAV8 
mice, compared to the Null-AAV8 treated mice. Highlighting that the knockdown of 
Dicer and loss of hepatic miRNA results in the derepression of miR-122 targets in the 
liver. 
Recently, miRNA, including miR-122 have been shown to negatively regulate cyp1a2 
and cyp2e1 expression in the liver [203, 246]. For both CYP450 enzymes, the suggested 
mechanism of miR-122 mediated downregulation is believed to be indirect. For 
cyp1a2, miR-122 targets and repress well described transcription factors of cyp1a2: 
Ahr (Aryl hydrocarbon receptor), Med1 (Mediator 1) and Ctcf [187, 203, 278, 279], which 
consequently contributes to the loss of cyp1a2 expression. Whereas, following liver 
specific miR-122 knockdown, the mechanism of miR-122 mediated cyp2e1 
suppression is unknown, with an upregulation of the enzyme observed at the protein 
level only [203]. However, previous results suggest it is due to enhanced translation, 
rather than alterations in protein turnover or stability [203, 246]. Hence, the localisation, 




cyp1a2 and cyp2e1 accounts for around 12% and 20% of the total hepatic CYP450 
enzyme expression respectively [280]. Through immunohistochemistry, expression of 
cyp1a2 and CYP2E1 have been described to be localised around the central vein 
(centrilobular zone) of the liver [44, 281, 282]. cyp2e1 localisation via 
immunohistochemistry further confirmed these findings with the treated Cre-AAV8 
mice having a non-significantly greater area of staining compared to the Null-AAV8 
mice.  
In the absence of paracetamol-induced liver injury, cyp1a2 mRNA was significantly 
greater in the Cre-AAV8 treated livers in comparison to the Null-AAV8 treated mice. 
As seen before, cyp2e1 mRNA expression was non-significantly different following 
the loss of miR-122 [203]. Unlike other reports, the protein expression of cyp2e1 did 
not significantly increase following the loss of miR-122 [203, 246]. Nevertheless, in the 
studies described in this chapter, total hepatic miRNA was significantly reduced in the 
liver, rather than miR-122 alone. Subsequently, previously described miRNA, such as 
miR-378 [244, 246, 271], involved in the regulation of cyp2e1 have been altered too. This 
could explain the lack of cyp2e1 protein upregulation in the liver following the loss of 
miR-122 in the Cre-AAV8 treated Dicer1 flox/flox mice.  
As seen in earlier studies, a loss of cyp1a2 and cyp2e1 mRNA and protein expression 
was observed with paracetamol treatment in all three AAV8 treatment groups [246]. 
Furthermore, enzymatic activity of cyp1a2 and cyp2e1 were significantly higher in the 
saline treated Cre-AAV8 mice, compared to the Null-AAV8 mice. However, in both 
AAV8 treatment groups, the activity of the two CYP450 enzymes decrease 
considerably following paracetamol dosing (data not shown). A reduction in cyp2e1 
mediated paracetamol oxidation would reduce the accumulation of the reactive 
metabolite, NAPQI, during a paracetamol overdose [38, 248]. Thus, repressing cyp2e1 
expression in the liver in response to paracetamol dosing reveals a potential 
protective mechanism to injury. However, it was noted that there were no significant 
differences in expression between the Null-AAV8 and Cre-AAV8 mice. Highlighting, 
the total loss of hepatic miRNA does not significantly influence the mechanism of 
cyp2e1 and cyp1a2 repression following paracetamol exposure.
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cyp2e1Although cyp2e1 is highly enriched in the liver, its expression and activity has 
also been noted in the kidney [49-51, 283]. For example, the knockdown of cyp2e1 in the 
kidney prevents reactive metabolite production and nephrotoxicity following 
cisplatin treatment [49]. Mirroring previous findings, mRNA expression was lower in 
kidney in comparison to the liver before and after paracetamol-related DILI in the 
Dicer1 flox/flox mice [283, 284]. Furthermore, it was noted that mRNA expression of cyp2e1 
was present primarily in the kidney cortex with minimal expression in the kidney 
medulla. Localisation of cyp2e1 via immunohistochemistry supported these findings 
further as staining was present in the kidney cortex tubules and absent in the medulla 
[49, 285]. 
Prior to paracetamol-related DILI, a non-significant difference of cyp1a2 and cyp2e1 
mRNA expression was observed in the kidney cortex and medulla following the loss 
of hepatic miRNA. Protein expression also determined that, overall, there were no-
significant differences in cyp2e1 across all three treatment groups.  
In the studies described in Chapter 4, there was an increase in paracetamol-induced 
liver injury in the Cre-AAV8 treated mice, compared to the baseline and Null-AAV8 
mice. However, there were no signs of kidney injury across the AAV8 and 
paracetamol treatment groups (Chapter Chapter 4). It was discovered that the 
distribution and intensity of cyp2e1 staining in the kidney did not differ between the 
Cre-AAV8 and Null-AAV8 treated mice, or in the presence of paracetamol treatment. 
Nonetheless, mRNA expression of cyp2e1 was observed to increase in the kidney 
cortex of all three AAV8 treatment groups at the 300mg/kg paracetamol dose. The 
Cre-AAV8 mice had significantly greater cyp2e1 expression compared to the baseline 
and Null-AAV8 mice treated at the 300mg/kg paracetamol dose. Therefore, this 
suggests that paracetamol toxicity alone increases cyp2e1 expression in the kidney 
cortex and the loss of hepatic miRNA heightens this increase further.  
Alternatively, the marked increase in cyp2e1 in the kidney cortex of the 300mg/kg 
paracetamol treated Cre-AAV8 mice could be related to the increase in liver toxicity, 
rather than a loss of hepatic miRNA transfer. Due to this, a future study matching the 
level of toxicity rather than the dose of paracetamol may be a better comparison 
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between the Cre AAV8 mice and Null-AAV8 mice. Additionally, an increase in cyp2e1 
mediated metabolism of chlorzoxazone was calculated to have a greater response in 
the kidney of the Cre-AAV8 mice, in contrast to the Null-AAV8 mice ([286], Section 
2.12).Therefore, it was identified that hepatic miRNA, including miR-122, transferred 
from the liver to the kidney, during DILI, alters the expression and activity of cyp2e1 
in the kidney cortex.  
It could be proposed that an upregulation of miR-122 and resultant decrease of 
cyp2e1 activity in the kidney, during DILI, reduces the extent of drug metabolism and 
toxicity in the kidney. Consistent with this theory of miR-122 mediated protection, 
non-recovering patients of ALF have shown to exhibit lower levels of circulating miR-
122, than patients that recover from ALF [287]. However, the loss of miR-122, and in 
turn, an increase of cyp2e1 in the kidney of the Cre-AAV8 mice did not induce an 
increase in KIM-1 expression in the kidney cortex or visible injury following 
histological analysis, compared to the baseline and Null-AAV8 treated mice. In 
paracetamol toxicity, kidney injury is a rare event and is not consistently observed in 
pre-clinical models or humans [288]. Hence, to explore the influence hepatic miRNA 
has during kidney injury, I would suggest using a known nephrotoxic agent such as 
cisplatin, rather than paracetamol, in the Cre-AAV8 Dicer1 flox/flox mice. Nevertheless, 
the results in this chapter has uncovered a potential new avenue in the 




Figure 5.18 The loss of hepatic miRNA transferred from the liver to the kidney during 300mg/kg paracetamol dosing results in the 
derepression of cyp2e1 in the kidney 
Hepatocyte specific Dicer1 knockdown resulted in the total loss of mature miRNA in the hepatocytes. Consequently, the loss of hepatic 
miRNA lead to the significant reduction of miR-122 transferred from the liver to the kidney during health and paracetamol toxicity. 
Following 300mg/kg paracetamol dosing, there was an increase of cyp2e1 expression and activity in the kidney cortex following the loss 
of miR-122 transfer. Indicating, an upregulation of miR-122 in the circulation and kidney, and resultant decrease of cyp2e1 activity during 






Chapter 6 Conclusions 
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ALF is a sudden and severe clinical disease which is often accompanied by acute 
kidney injury (AKI) [289]. Therefore, investigations aimed to better understand the 
mechanism of hepatocyte to renal signalling are of clinical importance. MiR-122’s 
enrichment in the hepatocytes of the liver and little-to-no expression elsewhere [164], 
enabled us to confidently identify the origin of transfer. Furthermore, miRNA, 
including miR-122, have been demonstrated to mediate cellular signalling and alter 
cellular activity in both neighbouring and distant cells [138-140, 190]. Thus, the work in 
this thesis aimed to better understand the role of hepatocyte enriched miR-122, 
following its release from the liver.  
6.1 Summary of key findings  
The hypothesis of the work carried out in this thesis proposed that the large release 
of miR-122 from the liver to the circulation during DILI results in miR-122 entering 
the kidney and inducing resistance to subsequent injury. Therefore, the key research 
aims chosen to address the hypothesis included: characterise an inducible model of 
liver-specific Dicer deletion, investigate which organs are responsible for the uptake 
of circulating microRNA-122 during DILI and, lastly, investigate if the loss of miRNA-
122 signalling from the liver to the kidney has a functional effect. Consequently, it 
was discovered that the spleen and kidney are involved in the uptake of circulating 
hepatocyte-derived miR-122, during health and liver injury. Following its uptake, it 
was revealed that hepatocyte derived miRNA may play a role in regulating the 
transcriptome in the kidney.  
6.1.1 MiR-122 is transferred from the liver to the spleen and kidney in vivo during 
health 
The studies described in Chapter 3 aimed to characterise an inducible model of 
hepatocyte-specific Dicer and mature miRNA knockdown in Dicer1flox/flox mice. After 
a single injection of a hepatocyte specific Cre-AAV8, we were able to demonstrate 
successful knockdown of Dicer and total hepatic miRNA in the liver of the Dicer1flox/flox 
mice. Alongside the Cre-AAV8 treatment, untreated AAV8 (baseline) mice and mice 
that were treated with an empty AAV8, Null-AAV8, were observed to have stable 
expression of hepatic Dicer and miRNA.  
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Matching previous studies, the loss of hepatic Dicer was observed one week following 
Cre-AAV8 injection and a significant reduction in miRNA was demonstrated a week 
later [227]. The hepatocyte specificity of the AAV8 was confirmed via the unchanged 
expression of Dicer and tissue enriched miRNA in the spleen, kidney (cortex and 
medulla), heart, lung and brain. Furthermore, there was no histological evidence of 
injury in the liver, spleen and kidney, following Null-AAV8 or Cre-AAV8 treatment. 
Nevertheless, it was identified that the total loss of hepatic miRNA led to the 
significant reduction of miR-122 expression in the spleen and kidney cortex and 
medulla. This highlights that in a healthy mouse, the spleen and kidney are involved 
in the uptake and clearance of circulating miR-122 released from the liver. 
Additionally, it indicates that miR-122 is involved in inter-organ signalling proposed 
in the hypothesis.  
It is often difficult to define the origin of miRNA that are ubiquitous in expression [239]. 
This was seen with miR-192, a miRNA described to be enriched in both the 
hepatocytes [86, 123] and the kidney [158, 290]. In the liver, miR-192 was significantly lost, 
however, unlike miR-122, its expression remained unchanged in the kidney. 
Potentially, the loss of hepatic miR-192 transfer was concealed due to its local 
synthesis in the kidney. Nevertheless, it is likely that multiple miRNA species are 
transferred from the liver to other organs. In order to investigate this further, the 
consequence the total loss of hepatic miRNA transfer should be conducted through 
the analysis of miRNA and mRNA in each tissue. 
6.1.2 MiR-122 transfer increases during liver injury 
As Chapter 3 investigated the transfer of hepatocellular miRNA during health, 
Chapter 4 aimed to underpin the impact DILI has on the transfer of hepatocyte 
enriched miRNA to other tissues. The well described increase of circulating miR-122 
and miR-192 during paracetamol toxicity (300mg/kg) was observed in the untreated 
AAV8 (baseline) and Null-AAV8 treated mice. Subsequently, as suggested in the 
hypothesis, the uptake of miR-122 in the spleen and kidney was significantly 
upregulated, compared to the saline treated mice. Furthermore, miR-122 was 
observed to increase significantly in the heart which was not observed in Chapter 3, 
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during health. The increase of miR-122 in the circulation and consequently in the 
spleen, kidney and heart following paracetamol toxicity was diminished in the Cre-
AAV8 mice. Moreover, the loss of mature miRNA in the hepatocytes resulted in a 
significant increase of cellular death in the livers of the Cre-AAV8 treated mice. In the 
kidney and spleen, injury was not observed across all AAV8 and paracetamol 
treatment groups. 
6.1.3 During paracetamol toxicity, hepatic miRNA transfer represses cyp2e1 activity 
and expression in the kidney 
Lastly, Chapter 5 investigated whether the loss of hepatic miRNA, including miR-122, 
transferred from the liver to the kidney had an impact on renal CYP450 expression 
during health and DILI. During physiological conditions, the loss of hepatic miRNA 
resulted in the increase of known miR-122 mRNA targets including: Aldoa, Ndrg3, 
Tmed3 and cyp1a2 targets in the liver. Nevertheless, cyp2e1, another CYP450 
enzyme believed to be targeted by miR-122, did not alter at the mRNA or protein 
level. In the kidney, there was also a non-significant change in cyp2e1 expression 
following the loss of hepatic miRNA transfer. 
Following a single dose of 300mg/kg paracetamol, it was observed that the cyp2e1 
increases in the kidney in all AAV8 treatment groups. However, the absence of 
hepatic miRNA transfer to the kidney and in turn a loss of miR-122 mediated 
repression, the increase in cyp2e1 mRNA expression and activity was significantly 
greater in the Cre-AAV8 mice. Correlation analysis supported these findings further 
with an observed negative correlation between miR-122 and cyp2e1 expression in 
the cortex following a single dose of 300mg/kg paracetamol in all three groups. The 
loss of miR-122 and in turn, an increase of cyp2e1 in the kidneys of the Cre-AAV8 
mice did not induce an increase in KIM-1 expression or visible injury following 
histological analysis, compared to the baseline and Null-AAV8 treated mice. 
Nonetheless, in line with Rivkin et al., these findings indicate that hepatocyte derived 
miR-122 influences mRNA expression and cellular activity in the kidney [193]. 
Furthermore, the alteration of the kidneys ability to perform cyp2e1 oxidation 
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suggests miR-122 has the ability to modify kidney mediated drug metabolism and the 
formation of toxic metabolites.  
6.1.4 Limitations 
Due to time and resources, the studies in this thesis were restricted to 5 mice per 
treatment group and time point. Due to this, a limitation of the studies described 
throughout this thesis are the low n numbers providing a greater chance of type I and 
type II error. Furthermore, using the data collected in Chapter 3: mean miR-122 
expression in the kidney of the Null-AAV8 (0.14, SD=0.13) and Cre-AAV8 mice (0.007, 
SD=0.004), a sample size of 8 mice per group would provide 80% power (α=0.05). 
Thus, it would be recommended to use an n=8, rather than an n=5, for future studies 
in this mouse model. 
The low numbers of mice per group also meant that kidney samples used for the 
investigation of CYP450 activity were measured as an n=1 for each group (5 kidneys 
from 5 mice, pooled, in duplicate). This was carried out as CYP450 expression is much 
lower in the kidney, in comparison to the liver [215]. Thus, a limitation of the results 
presented in Figure 5.16 was that statistical analysis could not be performed to 
produce a reliable p value. Therefore, with greater time and resources, it would be 
necessary to repeat these measures in a greater number of mice to determine if the 
results seen in Figure 5.16 are not influenced by chance.  
In addition, due to limited tissue collected, protein expression of CYP2E1 was not 
investigated in the kidney of the Dicer1 flox/flox mice treated with paracetamol. In 
future investigations, it would be interesting to measure the protein expression of 
CYP2E1 in the kidney to see whether the observed changes in mRNA expression and 




6.2 Future work 
The results in this thesis highlight that hepatic derived miR-122 released from the 
liver is taken up by the spleen and kidney during health and paracetamol induced 
liver injury. Furthermore, it was identified that the loss of hepatic miRNA transferred 
from the liver to the kidney significantly altered the expression and activity of 
previously identified miR-122 mRNA targets. However, as this phenotype was 
observed following the loss of total hepatic miRNA, it raises the question of whether 
hepatocyte-derived miR-122 alone acts as a regulator of kidney function and immune 
response during DILI. To clarify this, homozygous miR-122flox/flox mice [165, 291], could 
undergo Cre-AAV8 and Null-AAV8 (negative control) treatment described in this 
thesis. The treatment with Cre-AAV8 would lead to hepatocyte-specific miR-122 
knockdown only, rather than the total hepatocyte miRNA knockdown observed in 
this thesis. In this mouse model, the production and expression of miR-122 would 
cease in the liver only, with miR-122 biogenesis and expression unaffected elsewhere 
in the body.  
6.2.1 Characterise the effect hepatocyte-derived miR-122 has on renal 
physiology and its response to injury 
Alongside liver injury biomarkers, markers of kidney function such as serum 
creatinine and KIM-1 are important factors used to determine patient prognosis and 
stratification for liver transplantation during ALI and ALF [91, 92]. Rivkin et al. published 
evidence that kidney miR-122 expression is reliant on its transfer from the liver. 
Additionally, they discovered that an increase of miR-122 transfer following liver 
inflammation resulted in the repression of the miR-122 mRNA target Epo [193]. 
Furthermore, data collected in this thesis indicates hepatic miRNA, including miR-122 
plays a role in regulating cyp2e1 expression and activity in the kidney.  
To understand whether hepatic derived miR-122 is a protective mediator of kidney 
injury (AKI), we could use the miR-122flox/flox mouse model mentioned above 
alongside established model of renal injury. Following liver specific miR-122 
knockdown, we could investigate miR-122’s role during acute kidney injury by 
nephrotoxicity or ischemia-reperfusion. It would be particularly interesting to see its 
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role during cisplatin nephrotoxicity, as miR-122 has been described to decrease 
cisplatin-induced apoptosis and repress gene expression of the key enzyme involved 
in its oxidation, cyp2e1 [200, 203, 246]. If following the loss of miR-122 in the liver and in 
turn a loss of renal miR-122 expression leads to an increase in kidney injury, it would 
confirm that miR-122 transferred from the liver to the kidney is protective.  
AKI is characterised by the sudden loss of kidney excretory function [292]. The rapid 
decline of glomerular filtration rate (GFR) during AKI is usually associated with a 
reduction in renal blood flow [292]. The diagnosis of AKI is determined by the 
accumulation of the by-products of nitrogen metabolism, biomarkers of kidney injury 
and decreased urine output [292, 293]. Therefore, to evaluate the extent of kidney 
injury, multiple assessments would be measured in the miR-122flox/flox mice. To assess 
the haemodynamic and excretory response to AKI, biomarkers reflecting GFR, such 
as blood urea nitrogen and serum creatinine, and markers of kidney damage 
including KIM-1 could be measured. In addition, kidney histology could be 
investigated to assess the extent of injury and fibrosis. Immune cells have been 
described to mediate kidney injury and repair. Furthermore, hepatic derived miR-122 
has been previously described to be taken up by macrophages initiating an immune 
response [122]. Thus, staining for neutrophils, T-cell and macrophages could also be 
carried out to determine if the loss of miR-122 influences the immune response to 
kidney injury. 
6.2.2 Investigate the effect hepatocyte-derived miR-122 has on leukocyte 
response during acute liver injury 
Hyper-stimulation and over-activation of inflammatory signalling can provoke further 
injury during ALI [294]. Nonetheless, inflammatory signalling is also required for the 
regeneration and repair of the liver via the shift of pro-inflammatory monocytes to 
pro-reparative monocytes [294, 295]. Patients displaying low levels of blood monocytes, 
lymphocytes and NK cells during ALI, have been described to have poor clinical 
outcomes [296]. Therefore, sterile inflammation is a key feature of ALI and monocytes 
are measured in the blood to help determine clinical outcome in ALI patients. Hence, 
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understanding the role of the immune response and its mediators is important for 
developing therapeutics and improving patient care during ALI.  
During ALI, miR-122 has been described to activate alveolar macrophages and 
inflammation in the lung [122]. Thus, it would be interesting to explore the influence 
miR-122 has on the dynamic leucocyte response to acute liver injury and 
regeneration. To investigate this, I would propose using the miR-122 model described 
above (Section6.2). As the Dicer and hepatic miRNA knockout mice had greater levels 
of liver necrosis, compared to the Null-AAV8 mice (Chapter 4), I would first carry out 
a dose comparison study between the Cre-AAV8 and Null-AAV8 treated miR-
122flox/flox mice. From this experiment, a dose providing comparable levels of injury 
will be determined and used for both AAV8 treatment groups. 
Subsequently, the effect of miR-122 depletion on leucocyte expression and response 
could be explored. A paracetamol overdose (300mg/kg) has been described to induce 
a distinct phase of injury (0-24 hours) and a period of injury resolution (24-72 hours) 
in C57/BL6 mice [297]. Thus, to investigate miR-122’s role in paracetamol injury and 
liver regeneration, tissue and blood could be collected after a single injection of 
300mg/kg paracetamol, at various time points across the injury and resolution 
phases. The extent of injury could be assessed at each time point by histology and 
measurements of circulating biomarkers such as ALT, AST and GLDH. In the liver, 
dynamic changes of macrophages, kupffer cells and the proportion of Ly6CHi and 
Ly6CLo monocytes could be assessed and quantified by flow cytometry. 
6.2.3 Identify which leukocytes and renal cell populations are regulated by 
hepatocyte-derived miR-122 
MiR-122 has been described to mediate various pathways following its release from 
the liver. In the lung, hepatic miR-122 has also been suggested to play a role in the 
activation of alveolar macrophages in the lung and initiate pulmonary inflammation 
[122].  Moreover, unpublished data has (John Tranter and Wilna Oosthuyzen) identified 
that the CD11b+ macrophages in the spleen and the LTL+ tubular cells of the kidney 
are involved in the uptake of miR-122 following paracetamol-induced liver injury. 
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Therefore, it would be interesting to explore which cell subpopulations of the kidney 
and leucocytes are involved in the uptake of miR-122, and whether this impacts gene 
expression.  
 I would suggest carrying out single cell RNA-seq to assess the similarities and 
differences in transcriptome within a cell population. To achieve this, single cell RNA 
seq could be performed on the miR-122flox/flox mice at the early and later stages of 
miR-122 knockdown induced by the Cre-AAV8 treatment. In addition to investigating 
changes in the transcriptome of kidney cells and leucocytes during health, the mice 
could also be assessed after ALI (paracetamol-induced, Section 6.2.1) or AKI 
(nephrotoxicity or ischemia-reperfusion, Section 6.2.2 
6.3 Final conclusions 
The studies in this thesis aimed to better understand the role of hepatocyte enriched 
miR-122, following its release from the liver. Hepatic miR-122 was shown to be 
transferred from the liver to the kidney and spleen, before and after liver injury in 
vivo. Furthermore, liver derived miRNA was observed to negatively regulate the 
expression and activity of the miR-122 mRNA target, cyp2e1, in the kidney during 
paracetamol DILI. If translated into an in vivo model of hepatic miR-122 knockdown, 
this could represent a novel signalling mechanism available for therapeutic 
intervention to protect against kidney injury during ALF.  
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I.1 Dicer mRNA analysis 
I.1.1 Dicer mRNA expression in the liver 
Expression of Dicer mRNA was determined using RT-qPCR. Dicer was measured in the 
livers of the baseline, Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox mice (Figure 6.1). 
Figure 6.1, shows both the Null-AAV8 and Cre-AAV8 mice have comparable 
expression to the baseline mice (week 0, dotted line). Statistical comparisions 
determined the Cre-AAV8 expression was not statistically different when compared 
to the Null-AAV8 mice (Linear regression: Cre Slope= 3.7 week-1; Cre slope vs zero, 





Figure 6.1 Dicer mRNA expression in the liver of the Dicer1flox/flox mice 
Liver Dicer mRNA expression quantified by RT-qPCR. Dicer mRNA expression was 
measured in the baseline (untreated, week 0, dotted line), Null-AAV8 treated (white 
squares) and Cre-AAV8 treated (black squares) Dicer flox/flox mice. MRNA 
measurements were carried out from week 1 to 4 in the Null and Cre-AAV8 treated 
mice. Each point was normalised to Hprt and then represented as a percentage in 
relation to the baseline mice. Error bars represent mean ±SD, n=5 (W0, Null W3, Cre 
W1 n=4). Linear regression was used to determine whether Cre-AAV8 treated mice 
have significantly different expression to the Null-AAV8 treated mice (p=0.5).Dicer 
mRNA is unchanged in the spleen following Null and Cre-AAV8 injection 
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I.1.1 Dicer mRNA in the spleen 
Dicer mRNA was determined in the spleen using RT-qPCR. Dicer was measured in the 
spleen of the baseline, Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox mice (Figure 
6.2). Figure 6.2 shows both the Null-AAV8 and Cre-AAV8 mice have similar expression 
to the baseline mice (week 0, dotted line). Statistical comparisions determined the 
Cre-AAV8 expression was not statistically different when compared to the Null-AAV8 






Figure 6.2 Dicer mRNA expression in the spleen in the Null and Cre-AAV8 treated 
mice 
Dicer mRNA expression in the spleen was quantified through RT-qPCR. Dicer mRNA 
expression was measured in the baseline (untreated, week 0, dotted line), Null-AAV8 
treated (white squares) and Cre-AAV8 treated (black squares) Dicer1flox/flox mice. 
MRNA measurements were carried out from week 1 to 4 in the Null and Cre-AAV8 
treated mice. Each point was normalised to β-actin and then represented as a 
percentage in relation to the baseline mice. Error bars represent mean ±SD, n=5. 
Linear regression was used to determine whether Cre-AAV8 treated mice have 
significantly different expression to the Null-AAV8 treated mice (p=0.9)
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I.2 Dicer mRNA in the kidney following AAV8 treatment 
Dicer mRNA was measured in the kidney cortex and medulla of the baseline, Null-
AAV8 and Cre-AAV8 treated Dicer1flox/flox mice (Figure 6.3A and B respectively). In the 
cortex, the Cre-AAV8 treated mice displayed a significantly lower mRNA expression 
than the Null-AAV8 (Linear regression: Cre Slope= -13.8 week-1; Cre slope vs zero, 
p=0.003; Null vs Cre slope, p=0.005) (Figure 6.3A).  
In contrast, the medulla of the Cre-AAV8 treated mice had comparable expression to 
the baseline (untreated) and Null-AAV8 treated mice (Linear regression: Cre Slope=-




Figure 6.3 mRNA Dicer expression in the kidney following Null and Cre-AAV8 
injection 
Dicer mRNA expression in the kidney cortex (A) and medulla (B) quantified through 
RT-qPCR. Dicer mRNA expression was measured in the baseline (untreated, week 0, 
dotted line), Null-AAV8 treated (white squares) and Cre-AAV8 treated (black squares) 
Dicer1flox/flox mice. MRNA measurements were carried out from week 1 to 4 in the Null 
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and Cre-AAV8 treated mice. Each point was normalised to β-actin and then 
represented as a percentage in relation to the baseline mice. Error bars represent 
mean ±SD, n=5. Linear regression was used to determine whether Cre-AAV8 treated 
mice have significantly different expression to the Null-AAV8 treated mice (A: 
p=0.005; B: p=0.9).
 
I.3 Dicer mRNA expression in the brain, heart and lung  
As before, Dicer mRNA expression was measured in the heart, lung and brain of the 
Null and Cre-AAV8 treated mice (Figure 6.4A, B and C respectively). In all three 
tissues, the Cre-AAV8 mice displayed a non-significant difference in Dicer mRNA 
expression, compared to the Null-AAV8 mice (Heart; linear regression: Cre Slope= 2.6 
week-1; Cre slope vs zero, p=0.4; Null vs Cre slope, p=0.5) (Lung; linear regression: Cre 
Slope=-12 week-1; Cre slope vs zero, p=0.01; Null vs Cre slope, p=0.86) (Brain: Linear 
regression: Cre Slope=-16.39 week-1; Cre slope vs zero, p=0<0.0001; Null vs Cre slope, 





Figure 6.4 Dicer mRNA expression in the heart, lung and brain
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Dicer mRNA expression in the heart (A), lung (B) and brain (C) quantified through RT-
qPCR. Dicer mRNA expression was measured in the baseline (untreated, week 0, 
dotted line), Null-AAV8 treated (white squares) and Cre-AAV8 treated (black squares) 
Dicer1flox/flox mice. MRNA measurements were carried out from week 1 to 4 in the Null 
and Cre-AAV8 treated mice. In the heart, each point was normalised to GAPDH. In the 
lung and brain, each point was normalised to β-actin. Once normalised by the 
housekeeping gene, the data was then represented as a percentage in relation to the 
baseline mice. Error bars represent mean ±SD, n=5. Linear regression was used to 
determine whether Cre-AAV8 treated mice have significantly different expression to 
the Null-AAV8 treated mice (A: p=0.005; B: p=0.9, C: p=0.07).
 
I.4 MiR-122 is expression in all seven tissues analysed 
Using RT-qPCR, Ct values of miRNA were measured in the liver (Table 6.1), spleen 
(Table 6.2), kidney cortex (Table 6.3) and medulla (Table 6.4), heart (Table 6.5), lung 
(Table 6.6) and brain (Table 6.7). For each tissue, miR-122-5p and its own tissue 
enriched miRNA were measured and assessed. 
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Table 6.1 Raw Ct miRNA values in the liver 
 
 
miR-122-5p miR-192-5p miR-151-3p 
W0 Baseline 12.21 12.12 12.425 11.89 12.31 17.3 17.03 17.57 17.455 17.675 22.885 22.81 22.875 22.825 23.265 
W1 
Null 11.89 12.235 12.46 11.785 11.64 17.635 17.73 17.97 17.54 17.035 22.99 22.85 23.065 22.58 22.57 
Cre 12.625 12.445 12.075 11.62 11.73 17.915 17.66 17.665 17.195 17.225 23.39 23.855 23.795 22.495 22.79 
W2 
Null 11.655 11.925 12.255 11.7 11.51 16.805 17.495 17.085 16.885 16.895 23.195 22.605 22.71 22.115 22.505 
Cre 13.045 12.88 12.945 13.105 13.135 18.595 18.935 19.135 18.92 18.69 23.78 23.06 22.975 23.135 22.87 
W3 
Null 13.215 11.805 12.24 11.635 11.64 17.47 18.635 17.675 16.96 16.995 22.655 23.79 23.05 22.345 22.57 
Cre 14.535 14.475 14.5 14.82 13.7 20.385 20.455 20.58 20.85 19.695 23.015 23.115 23.055 23.255 23.025 
W4 
Null 11.825 11.945 11.84 11.655 12.705 18.64 17.205 17.53 17.085 18.225 22.795 22.73 22.72 22.545 23.16 
Cre 15.875 15.8 16.875 14.93 15.53 22.09 21.99 22.835 21.135 20.93 23.045 23.25 23.45 22.985 22.89 
 
MiRNA expression (miR-122-5p, miR-192-5p and miR-151-3p) in the liver of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated 
Dicer1flox/flox mice. Measurements were taken from week 0-4 post AAV8 treatment. Each value represent an n=1 which is an average of 
the RT-qPCR duplicate reading.
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Table 6.2 Raw Ct miRNA values in the spleen 
  
miR-122-5p miR-146a-5p 
W0 Baseline 17.085 18.305 16.985 20.465 19.265 15.04 14.665 15.56 17.665 15.95 
W1 
Null 21.495 20.785 20.2 20.29 22.105 15.245 15.64 15.81 16.275 16.305 
Cre 23.565 21.045 21.725 23.075 20.725 16.75 16.885 16.345 16.24 15.76 
W2 
Null 21.89 20.835 20.44 21.355 22.25 16.09 16.09 15.955 14.97 14.775 
Cre 24.685 24.08 24.105 25.955 23.45 17.025 16.98 18.095 17.44 17.925 
W3 
Null 21.06 19.545 19.655 21.74 22.06 15.915 15.675 15.525 15.72 15.67 
Cre 24.67 24.395 25.39 25.49 23.815 15.665 15.605 15.69 15.8 14.77 
W4 
Null 22.59 18.965 22.095 22.385 22.22 15.795 15.62 15.12 15.52 14.93 
Cre 26.905 26.095 26.84 26.285 25.925 16.64 16.45 16.4 16.675 16.89 
MiRNA expression (miR-122-5p and miR-146a-5p) in the spleen of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox 




Table 6.3 Raw Ct miRNA values in the kidney cortex 
  
miR-122-5p miR-192-5p miR-196a-5p 
W0 Baseline 21.12 20.06 20.135 19.42 20.745 17.265 17.51 17.885 17.975 18.27 21.425 20.915 21.295 20.775 20.375 
W1 
Null 22.595 21.57 20.67 19.465 21.61 17.235 16.97 17.385 16.755 17.47 23.435 21.885 22.25 22.03 23.915 
Cre 21.835 22.49 21.085 20.125 21.64 16.98 16.905 16.325 16.035 17.15 22.475 22.265 22.31 22.025 22.745 
W2 
Null 20.125 21.04 18.955 21.79 19.115 16.895 17.79 17.815 17.525 16.73 23.34 21.855 22.01 21.59 22.89 
Cre 21.315 22.005 22.115 21.85 23.025 16.285 16.275 15.815 16.585 16.115 22.09 22.775 21.25 21.31 21.59 
W3 
Null 19.49 21.665 20.955 19.14 20.51 16.12 16.51 16.98 16.28 16.745 23.57 21.675 21.855 21.855 23.345 
Cre 22.99 23.155 22.935 23.695 22.465 16.86 16.405 16.495 16.87 16.355 22.375 22.01 21.905 21.72 20.935 
W4 
Null 19 20.39 22.02 20.565 19.57 16.43 16.83 16.875 16.685 16.835 21.785 22.17 21.13 21.7 21.37 
Cre 23.635 23.67 24.705 25.815 24.25 16.61 16.605 17.02 16.745 16.825 20.625 20.61 20.83 20.815 20.4 
MiRNA expression (miR-122-5p, miR-192-5p and miR-196a-5p) in the kidney cortex of the baseline (untreated), Null-AAV8 and Cre-AAV8 
treated Dicer1flox/flox mice. Measurements were taken from week 0-4 post AAV8 treatment. Each value represent an n=1 which is an 
average of the RT-qPCR duplicate reading.
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Table 6.4 Raw Ct miRNA values in the kidney medulla 
  
miR-122-5p miR-192-5p miR-196a-5p 
W0 Baseline 20.21 20.68 18.7 19.6 18.79 17.425 17.31 17.32 17.93 17.965 21.925 21.68 22.07 21.915 21.875 
W1 
Null 20.555 22.095 20.715 17.605 20.525 17.105 17.135 17.305 16.83 16.95 22.415 23.115 23.145 22.245 22.49 
Cre 20.02 21.93 21.1 20.11 19.84 17.95 16.93 17.32 17.85 16.91 22.9 22.4 22.545 22.695 21.995 
W2 
Null 20.815 18.865 22.42 22.91 21.59 17.47 17.08 17.76 18.39 17.31 24.465 22.555 22.425 23.065 22.81 
Cre 24.495 23.715 22.38 23.09 21.93 17.21 17.775 17.76 17.53 17.47 22.85 22.69 22.395 22.38 22.925 
W3 
Null 19.135 20.88 20.875 17.965 18.95 17.105 17.995 17.55 17.41 17.26 22.175 21.96 22.5 22.14 21.75 
Cre 23.845 24.905 25.335 23.97 23.38 16.11 16.415 16.46 16.735 16.44 21.975 22.655 21.96 21.7 21.65 
W4 
Null 21.24 20.715 20.78 18.81 20.01 17.295 17.205 17.455 16.955 16.74 22.05 22.83 22.755 22.15 22.08 
Cre 24.37 22.675 23.59 24.865 22.705 19.245 16.51 17.09 16.565 16.255 23.755 21.88 21.75 21.46 21.365 
MiRNA expression (miR-122-5p, miR-192-5p and miR-196-5p) in the kidney medulla of the baseline (untreated), Null-AAV8 and Cre-AAV8 
treated Dicer1flox/flox mice. Measurements were taken from week 0-4 post AAV8 treatment. Each value represent an n=1 which is an 
average of the RT-qPCR duplicate reading.
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Table 6.5 Raw Ct miRNA values in the heart 
  
miR-122-5p miR-1-3p 
W0 Baseline 23.48 25.37 24.93 25.555 25.395 12.365 11.985 12.6 11.895 12.685 
W1 
Null 25.06 25.635 24.09 24.295 25.26 15.665 14.31 12.995 15.045 14.715 
Cre 27.195 25.025 26.735 25.14 26.75 14.555 13.19 12.63 14.835 12.2 
W2 
Null 25.94 25.825 26.01 25.725 25.92 14.42 13.65 13.685 13.925 14.08 
Cre 26.54 26.365 26.085 26.555 26.39 14.925 13.885 13.215 13.13 14.985 
W3 
Null 24.69 25.95 24.685 25.905 25.66 15.195 15.515 15.68 16.14 14.795 
Cre 26.155 27 26.625 26.455 26.65 13.915 13.66 13.455 11.835 13.725 
W4 
Null 25.6 26.195 24.62 26.135 24.7 14.36 14.34 14.415 14.74 14.29 
Cre 26.535 26.32 26.46 25.935 26.685 13.975 14.31 13.465 14 13.575 
MiRNA expression (miR-122-5p and miR-1-3p) in the heart of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox 




Table 6.6 Raw Ct miRNA values in the lung 
  
miR-122-5p miR-195a-5p 
W0 Baseline 23.305 24.085 23.72 24.18 24.725 14.415 13.715 13.985 13.9 14.16 
W1 
Null 24.62 22.615 25.335 24.72 26.17 15.53 15.555 15.56 15.735 15.9 
Cre 23.755 23.62 24.14 24.04 24.76 13.555 14.4 14 14.135 14.185 
W2 
Null 25.2 24.64 25.34 24.81   14.605 14.67 14.9 14.745   
Cre 25.015 24.7 24.55 24.37 24.585 14.385 14.555 14.575 14.005 14.075 
W3 
Null 22.55 24.4 24.025 24.555 24.225 13.935 14.415 14.1 14.28 14.07 
Cre 27.115 24.6 24.505 24.385 24.34 14.81 14.445 13.49 15.015 14.61 
W4 
Null 24.005 24.825 22.525 25.125 22.725 14.28 14.25 14.71 14.85 14.88 
Cre 24.935 25.175 25.73 25.425 26.245 13.61 14.475 15.475 15.415 15.65 
MiRNA expression (miR-122-5p and miR-195a-5p) in the lung of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox 




Table 6.7 Raw Ct miRNA values in the Brain 
  
miR-122-5p miR-124-3p 
W0 Baseline 25.25 25.045 25.09 25.55   13.62 12.895 12.24 12.67   
W1 
Null 25.935 25.385 25.62 25.58 25.6 14.52 14.015 13.47 13.775 14.505 
Cre 25.9 26.875 25.68 25.67 26.01 14.96 14.45 14.295 14.12 13.735 
W2 
Null 26.305 25.455 25.29 25.555 25.065 13.18 13.535 13.95 12.995 13.01 
Cre 25.99 25.805 25.8 25.995 26.03 14.26 14.305 14.11 14.575 13.875 
W3 
Null 25.855 25.57 26.295 25.675 25.315 14.395 14.58 14.965 13.985 14.865 
Cre 26.81 26.295 26.155 26.255 26.265 15.19 14.995 15.37 15.295 15.26 
W4 
Null 25.78 25.2 25.825 25.775 25.49 14.145 13.51 13.475 13.68 13.29 
Cre 26.015 26.805 25.755 26.165 25.97 14.98 15.03 13.43 14.08 13.64 
MiRNA expression (miR-122-5p and miR-124-3p) in the brain of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox 




Table 6.8 Raw Ct pri-miR-122 values of the liver and spleen 
  
Liver Spleen 
W0 Baseline 25.24 25.765 26.84 26.105 27.205 35 35 35 35 35 
W1 Null 25.125 26.495 26.335 26.765 27.405 35 35 35 35 35 
  Cre 23.77 25.54 25.31 25.5 25.5 35 35 35 35 35 
W2 Null 24.515 24.945 25.195 24.08 24.625 35 35 35 35 35 
  Cre 24.135 24.32 24.135 25.395 24.62 35 35 35 35 35 
W3 Null 23.165 23.25 23.335 23.36 23.86 35 35 35 35 35 
  Cre 23.735 25.8 23.68 23.92 24.575 35 35 35 35 35 
W4 Null 24.995 24.295 26.09 23.78 25.125 35 35 35 35 35 
  Cre 26.835 23.05 24.52 22.855 24.845 35 35 35 35 35 
Pri-miR-122 expression in the liver and spleen of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox mice. 




Table 6.9 Raw Ct pri-miR-122 values in the Kidney cortex and medulla 
  
Kidney cortex Kidney medulla 
W0 Baseline 35 35 35 34.72 35 35 36.165 34.035 33.425 35 
W1 Null 35 35 35 34.45 35 35 37.5 35 32.82 35 
  Cre 37.5 37.5 40 35 35 35 35 35 35 35 
W2 Null 35 35 35 35 35 35 35 35 35 35 
  Cre 35 35 35 35 35 35 35 35 35 35 
W3 Null 35 35 35 35 35 35 35 35 32.455 33.37 
  Cre 35 35 35 35 35 35 35 35 34.23 33.875 
W4 Null 35 35 35 35 35 35 35 40 37.15 35 
  Cre 35 35 35 35 35 35 35 35 35 35 
Pri-miR-122 expression in the kidney cortex and medulla of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox mice. 




Table 6.10 Raw Ct miRNA values in the plasma 
  
miR-122-5p miR-192-5p miR-196-5p 
W0 Baseline 26.17 26.44 26.53 25.5 26.07 26.91 26.67 27.76 27.26 26.54 29 30.07 30.095 29.625 28.975 
W1 
Null 16.89 23.145 18.57 26.245 26.075 20.83 24.755 22.21 26.315 27.065 27.065 27.12 27.41 28.65 29.095 
Cre 20.27 19.33 19.55 20.135  23.39 23.765 23.33 25.03   30.535 28.09 29.07 29.11  
W2 
Null 24.81 23.825 21.14 23.25  24.205 28.865 25.22 25.53   27.5 29.4 29.34 28.505  
Cre 23.515 26.115 19.91 25.14 21.84 26.975 25.075 23.46 26.62 24.55 30.06 29.155 28.095 30.74 29.195 
W3 
Null 17.38 15.635 19.92 19.255  22.21 20.06 22.83 23.675   27.69 28.605 28.31 28.005  
Cre 19.97 23.76 25.41 22.035 20.34 22.59 22.715 23.96 23.74 24.56 28.06 27.795 27.425 28.34 27.555 
W4 
Null 19.925 25.65 15.34 23.425 16.43 23.665 26.43 19.41 26.315 20.565 29.94 30.07 26.185 30.605 27.28 
Cre 26.175 24.615 23.93 21.235 26.195 25.07 25 24.57 25.41 26.9 29.06 27.755 28.265 27.96 29.645 
MiRNA expression (miR-122-5p, miR-192-5p and miR-151-3p) in the plasma of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated 
Dicer1flox/flox mice. Measurements were taken from week 0-4 post AAV8 treatment. Each value represent an n=1 which is an average of 
the RT-qPCR duplicate reading.
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I.5 Dicer mRNA expression is significantly lower following Cre-AAV8 
treatment 
To determine whether a lower dose of the Cre-AAV8 was effective at knocking down 
hepatic Dicer1, Dicer mRNA was assessed in the liver. The Cre-AAV8 treated Dicer1 
flox/flox mice displayed a significant loss of Dicer mRNA expression, compared to the 
Null-AAV8 treated group (ANOVA: saline Null vs Cre, p=0.0003)(Figure 6.5). With 
increasing doses of paracetamol, the expression of Dicer mRNA displays a non-





Figure 6.5 Dicer mRNA in the liver of the Dicer flox/flox mice following AAV8 injection 
Dicer mRNA expression measured following saline, 150mg/kg paracetamol and 
300mg/kg paracetamol in the liver of the baseline (untreated, white squares), Null-
AAV8 (light grey triangles) and Cre-AAV8 (dark grey circles) treated Dicer1 flox/flox mice. 
MRNA measurements were taken 3 weeks post AAV8 treatment and 6 hours following 
paracetamol dosing. Each point was normalised to β-actin, error bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine if expression 
was significant across all 9 sub-treatment groups. Dicer mRNA expression did not 
decrease in the spleen and kidney following Cre-AAV8 treatment.
 
Dicer mRNA was measured in the spleen, kidney cortex and medulla of the baseline, 
Null-AAV8 and Cre-AAV8 mice treated with saline, 150mg/kg paracetamol and 
300mg/kg paracetamol (Figure 6.6). In all three tissues, Dicer mRNA expression did 
not significantly decrease following Cre-AAV8 injection in comparison to the baseline 




Figure 6.6 Dicer expression does not decrease in the spleen, kidney cortex and 
kidney medulla following Cre-AAV8 injection 
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Dicer mRNA was measured in the (A) spleen, (B) kidney cortex and (C) kidney medulla 
of the male Dicer-floxed mice. MRNA measurements were carried out via RT-qPCR 3 
weeks following baseline (white squares), Null (light grey triangles) and Cre-AAV8 
(dark grey circles) treatment and 6 hours after saline, 150mg/kg and 300mg/kg of 
paracetamol. In the spleen and kidney medulla, the data were normalised to GAPDH. 
In the kidney cortex, each point was normalised to β-actin, error bars represent mean 
±SD, n=5. A multiple comparison two-way ANOVA was used to determine if the 
expression is significantly different between treatment groups.
 
I.6 Dicer mRNA expression in the heart, lung and brain  
Again, Dicer mRNA was measured in baseline, Null-AAV8 and Cre-AAV8 mice treated 
with saline, 150mg/kg and 300mg/kg paracetamol. In the heart, lung and brain, Dicer 
mRNA expression did not significantly decrease following Null-AAV8 or Cre-AAV8 








Dicer mRNA was measured in the (A) heart, (B) lung and (C) brain of the male Dicer1 
flox/flox mice. MiRNA measurements were carried out via RT-qPCR 3 weeks following 
baseline (white squares), Null-AAV8 (light grey triangles) and Cre-AAV8 (dark grey 
circles) treatment and 6 hours after saline, 150mg/kg and 300mg/kg of paracetamol. 
Data were normalised to β-actin in the lung and brain and in the heart, data were 
normalised to GAPDH. Error bars represent mean ±SD, n=5 (lung: Null saline, 
150mg/kg and 300mg/kg and Cre 300mg/kg, n=4). Multiple comparison two-way 
ANOVA was used to determine if the expression is significantly different between 
treatment groups 
I.6.1 Expression of cyp1a2 and cyp2e1 in the liver and kidney 
Using RT-qPCR, Ct values of cyp1a2 and cyp2e1 mRNA were measured in the liver 
(Table 6.11), kidney cortex (Table 6.12) and medulla (Table 6.13). It was noted that 
both sections of the kidney had lower levels of cyp1a2 and cyp2e1 mRNA expression, 




Table 6.11 Raw Ct values of CYP450 enzymes in the liver of the healthy Dicer1 flox/flox mice 
 
MRNA expression (cyp1a2 and cyp2e1) in the liver of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox mice. 




Table 6.12 Raw Ct values of CYP450 enzymes in the kidney cortex of the healthy Dicer1 flox/flox mice 
 
MRNA expression (cyp1a2 and cyp2e1) in the kidney cortex of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox 




Table 6.13 Raw Ct values of CYP450 enzymes in the kidney medulla of the healthy Dicer1 flox/flox mice 
 
MRNA expression (cyp1a2 and cyp2e1) in the kidney cortex of the baseline (untreated), Null-AAV8 and Cre-AAV8 treated Dicer1flox/flox 
mice. Measurements were taken from week 0-4 post AAV8 treatment. Each value represents an n=1 which is an average of the RT-qPCR 
duplicate reading. 
 
 
